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Abstract	  
Identification	  of	  Multiple	  Levels	  of	  Trauma	  Induced	  Coagulopathy	  By	  Jason	  Charles	  Newton,	  Ph.D.	  A	  dissertation	  submitted	  in	  partial	  fulfillment	  of	  the	  requirements	  for	  the	  degree	  of	  Doctor	  of	  Philosophy	  at	  Virginia	  Commonwealth	  University	  Virginia	  Commonwealth	  University	  2013	  Major	  Directors:	  	  Directors:	  Donald	  F.	  Brophy,	  Pharm.D.	  Chairman	  Department	  of	  Pharmacotherapy	  &	  Outcomes	  Science	  	  	  Robert	  F.	  Diegelmann,	  Ph.D.	  Professor	  of	  Biochemistry	  &	  Molecular	  Biology	  	  	   Trauma	  continues	  to	  be	  a	  major	  cause	  of	  death	  across	  the	  globe.	  	  While	  the	  exact	  causes	  of	  trauma	  differ	  greatly	  between	  the	  military	  and	  civilian	  lifestyles,	  the	  ability	  to	  stop	  bleeding	  after	  trauma	  is	  paramount	  for	  survival.	  	  Over	  the	  past	  decade	  coagulation	  research	  has	  transitioned	  from	  a	  classical	  understanding	  of	  plasma	  based	  protein	  coagulation	  to	  the	  current	  cell	  focused	  research.	  	  As	  part	  of	  this	  shift,	  platelets	  have	  become	  a	  central	  player	  in	  hemostasis.	  	  Unfortunately	  little	  is	  currently	  understood	  about	  how	  platelet	  function	  is	  affected	  by	  trauma.	  	   In	  an	  effort	  to	  better	  define	  platelet	  function	  during	  trauma	  and	  the	  resulting	  shock	  from	  exsanguination,	  a	  multipronged	  approach	  was	  developed.	  	  The	  hypothesis	  that	  the	  introduction	  of	  a	  state	  of	  clinical	  shock	  in	  a	  controlled	  environment	  would	  allow	  for	  an	  in-­‐depth	  assessment	  of	  trauma-­‐induced	  coagulopathy	  led	  to	  the	  development	  of	  a	  swine	  based	  model	  of	  hemorrhagic	  shock.	  	  	   In	  this	  model	  a	  composite	  injury	  consisting	  of	  soft	  tissue	  damage,	  long	  bone	  fracture,	  and	  controlled	  hemorrhage	  was	  used	  to	  induce	  a	  moderate	  state	  of	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1.1	  Significance	  of	  Hemostasis	  in	  Traumatic	  Injury	  	  	  	  	  	  	   Trauma	  is	  a	  major	  cause	  of	  death	  across	  the	  world,	  both	  in	  the	  civilian	  world	  as	  well	  as	  during	  military	  conflicts.1,2	  Uncontrolled	  hemorrhage	  accounts	  for	  40%	  of	  civilian	  trauma	  deaths,	  and	  in	  conjunction	  with	  the	  resulting	  shock	  represents	  the	  major	  causes	  of	  preventable	  deaths	  on	  the	  battlefield.2–4	  These	  facts	  highlight	  that	  hemostasis	  is	  a	  critical	  physiological	  response	  to	  trauma.	  	  The	  ability	  for	  blood	  to	  clot	  is	  paramount	  to	  avoid	  exsanguination	  once	  the	  vasculature	  is	  disturbed.	  	  Our	  understanding	  of	  the	  biological	  coagulation	  response	  has	  evolved	  over	  the	  years,	  with	  initial	  theories	  revolving	  around	  a	  cascading	  series	  of	  enzymatic	  reactions	  of	  plasma	  based	  proteins	  and	  current	  models	  integrating	  the	  cellular	  aspect	  of	  clot	  propagation.	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   Currently	  there	  is	  little	  agreement	  on	  the	  actual	  specifics	  related	  to	  the	  coagulation	  changes	  that	  occur	  early	  after	  trauma.	  	  Recent	  work	  by	  Gando	  performed	  on	  behalf	  of	  the	  Scientific	  and	  Standardization	  Committee	  on	  DIC	  of	  the	  International	  Society	  on	  Thrombosis	  and	  Hemostasis	  (ISTH)	  highlights	  the	  current	  gaps	  in	  understanding	  around	  trauma	  related	  coagulopathies.	  	  While	  this	  work	  focused	  mainly	  on	  the	  distinction	  between	  coagulopathy	  of	  trauma	  (COT),	  acute	  coagulopathy	  of	  trauma-­‐shock	  (ACoT),	  and	  disseminated	  intravascular	  coagulation	  (DIC),	  it	  highlights	  the	  need	  for	  better	  understanding	  of	  the	  mechanisms	  behind	  the	  pathologies.	  	  	  	   To	  further	  add	  to	  the	  complexity,	  the	  observation	  of	  hypercoagulopathy	  (HC)	  in	  recent	  studies	  performed	  on	  whole	  blood	  show	  that	  the	  current	  methods	  of	  defining	  and	  treating	  pathologies	  based	  on	  plasma	  tests	  may	  not	  be	  sufficient	  to	  truly	  discriminate	  between	  the	  subtle	  changes	  that	  occur	  to	  hemostasis	  in	  response	  to	  trauma.5	  An	  increased	  understanding	  of	  whole	  blood	  coagulation	  in	  response	  to	  trauma	  may	  lead	  to	  both	  improved	  diagnosis	  of	  coagulopathies	  and	  more	  effective	  treatment	  strategies	  to	  treat	  or	  even	  prevent	  trauma	  related	  coagulation	  disorders.	  
1.2	  Literature	  Review	  
Plasma	  Proteins	  and	  the	  Coagulation	  Cascade	  	  	  	  	  	  The	  first	  published	  mention	  of	  the	  coagulation	  cascade	  came	  in	  1964,	  as	  a	  theory	  to	  describe	  the	  newly	  standardized	  terminology	  of	  blood	  clotting	  factors.	  	  The	  International	  Committee	  on	  Blood	  Clotting	  Factors	  adopted	  a	  roman	  numeral	  terminology	  scheme	  clearing	  up	  the	  confusion	  caused	  by	  synonyms	  generated	  through	  separate	  lines	  of	  research.6	  This	  initial	  system	  (Figure	  1.1)	  is	  essentially	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Figure	  1.1	  Original	  Coagulation	  Cascade.	  Adapted	  from	  MacFarlane	  1964.6	  
	  
Figure	   1.2:	   Currently	   Accepted	   Coagulation	   Cascade.	   	   Adapted	   from	   Hayne	  1976.7	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correct	  in	  the	  stepwise	  activation	  of	  coagulation	  due	  to	  surface	  contact,	  but	  completely	  ignores	  Factor	  VII	  (FVII)	  as	  well	  as	  Factor	  XIII	  (FXIII).	  	  Interestingly	  enough	  the	  requirement	  of	  phospholipid	  was	  also	  discussed	  even	  in	  these	  early	  stages,	  almost	  foreshadowing	  the	  development	  of	  the	  cell	  based	  model	  of	  coagulation.	  	  The	  identification	  of	  the	  extrinsic	  pathway	  and	  the	  interaction	  of	  FVII	  with	  membrane	  bound	  tissue	  factor	  (TF)	  was	  soon	  to	  follow.8	  While	  not	  always	  shown	  as	  part	  of	  the	  coagulation	  cascade	  it	  has	  been	  know	  since	  the	  mid	  1960s	  that	  Factor	  XIII	  (FXIII)	  was	  required	  to	  stabilize	  the	  fibrin	  network	  generated	  by	  the	  cascade,	  as	  well	  as	  the	  fact	  that	  thrombin	  activates	  FXIII	  activity.9	  	  	  	  	  	  	  	  	   By	  the	  1970s	  the	  coagulation	  cascade	  included	  FVII	  in	  most	  printed	  articles	  (Figure	  1.2).7	  During	  the	  development	  of	  the	  understanding	  of	  the	  coagulation	  proteins,	  various	  tests	  were	  developed	  to	  test	  the	  effectiveness	  coagulation	  and	  some	  even	  resulted	  in	  diagnostically	  relevant	  tests.	  	  	  Publications	  all	  the	  way	  back	  to	  1916	  refer	  to	  the	  re-­‐calcification	  of	  plasma	  as	  testing	  the	  prothrombin	  time	  (PT).	  	  In	  1935	  Dr.	  Armand	  Quick	  published	  the	  version	  of	  the	  PT	  test	  that’s	  is	  still	  used	  today,	  albeit	  with	  some	  minor	  modifications.10	  	  	  	  	  	   The	  activated	  partial	  thromboplastin	  time	  (PTT)	  test	  developed	  in	  the	  late	  1950s,	  but	  the	  use	  of	  cephalin	  didn’t	  appear	  in	  literature	  until	  1962.11	  Each	  test	  was	  developed	  to	  test	  what	  was	  thought	  as	  independent	  methods	  of	  coagulation	  cascade	  activation.7	  	  	  	  	  	  	  	  	   PT	  is	  designed	  to	  test	  the	  extrinsic	  pathway,	  also	  known	  as	  the	  tissue	  factor	  (TF)	  pathway.	  	  The	  pathway	  moves	  stepwise	  with	  TF	  activating	  FVII,	  FVIIa	  (“a”	  was	  adopted	  to	  denote	  activated	  factors	  when	  the	  roman	  numeral	  system	  was	  adopted)	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then	  moves	  to	  activate	  Factor	  X	  (FX).	  	  FXa	  begins	  what	  is	  called	  the	  common	  pathway	  in	  the	  cascade.	  	  FXa	  combines	  with	  activated	  Factor	  V	  (FVa)	  to	  activate	  Factor	  II	  (FII).	  	  Factor	  II	  is	  also	  called	  prothrombin,	  and	  FIIa	  thrombin.	  	  Thrombin	  then	  cleaves	  fibrinogen	  to	  fibrin,	  ending	  what	  is	  typically	  considered	  the	  coagulation	  cascade	  (Figure	  1.3).7	  While	  still	  used	  diagnostically	  today,	  the	  fact	  that	  PT	  measures	  the	  activity	  of	  FVII,	  FX,	  FV,	  thrombin,	  and	  fibrinogen	  as	  a	  system.7	  	  This	  limits	  the	  usefullness	  of	  the	  test	  to	  determine	  the	  actual	  cause	  of	  a	  perturbance	  of	  clotting.	  	  The	  same	  can	  be	  said	  of	  PTT	  testing.	  	  	  	  	  	  	  	  	   PTT	  is	  designed	  to	  test	  the	  activity	  of	  the	  intrinsic	  pathway	  as	  a	  whole.	  	  The	  intrinsic	  pathway	  depends	  on	  the	  exposure	  of	  Factor	  XII	  (FXII)	  to	  a	  charged	  surface.	  	  Once	  activated	  FXIIa	  activates	  Factor	  XI	  (FXI),	  FXIa	  activates	  Factor	  IX	  (FIX),	  FIXa	  activates	  Factor	  VIII	  (FVIII),	  and	  FVIII	  then	  activates	  FX,	  then	  following	  the	  same	  common	  patway	  mentioned	  above	  (Figure	  1.4).	  	  	  PTT	  evaluates	  the	  activity	  of	  all	  of	  the	  proteins	  in	  the	  coagulation	  cascade	  except	  for	  FVII.7	  	  While	  both	  of	  these	  tests	  can	  identify	  problems	  in	  the	  respective	  pathways,	  additional	  testing	  must	  be	  performed	  to	  determine	  individual	  factor	  concentrations	  and	  activities	  to	  determine	  the	  actual	  underlying	  problem.	  	  Also	  there	  are	  multiple	  amplification	  loops,	  requirements	  for	  Calcium	  ions	  (Ca2+)	  once	  called	  Factor	  IV,	  and	  phospholipid	  associations	  that	  makes	  the	  pathway	  far	  more	  complicated	  (Figure	  1.5).12	  
Cell	  Based	  Model	  of	  Coagulation	  While	  the	  coagulation	  cascade	  provided	  an	  easily	  followed	  waterfall	  model	  of	  blood	  clotting,	  it	  was	  unable	  to	  account	  for	  the	  phospholipid	  membrane	  requirements	  or	  the	  emerging	  idea	  of	  platelets	  being	  the	  main	  mediators	  of	  the	  
	   6	  
	  
Figure	  1.3:	  Extrinsic	  Pathway	  of	  the	  Coagulation	  Cascade.	  	  Adapted	  from	  Hayne	  1976.7	  
	  
	  
Figure	  1.4:	  	  Intrinsic	  Pathway	  of	  the	  Coagulation	  Cascade.	  	  Adapted	  from	  Hayne	  1976.7	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Figure	  1.5:	  Coagulation	  Cascade	  with	  Amplification	  Loops	  and	  Cofactors.	   	  PL;	  phospholipid.	  	  Adapted	  from	  Davie	  1991.12	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physiological	  coagulation	  response.	  	  The	  cell	  based	  model	  of	  coagulation	  was	  introduced	  to	  address	  these	  issues	  in	  2003	  by	  Maureane	  Hoffman.13	  This	  model	  highlighted	  the	  need	  for	  cell	  membrane	  surfaces	  to	  provide	  the	  required	  phospholipid	  requirement	  to	  optimize	  enzymatic	  reactions	  (Figure	  1.6).	  The	  model	  was	  based	  on	  the	  theory	  that	  coagulation	  occurs	  in	  three	  overlapping	  steps	  (initiation,	  amplification,	  propagation)	  that	  take	  place	  on	  different	  cell	  surfaces	  (Figure	  1.7).	  	  	  The	  model	  emphasizes	  the	  assembly	  of	  membrane	  phosphatidylserine	  (PS)	  bound	  factor	  complexes	  in	  activation	  of	  the	  coagulation	  proteins.	  	  PS	  is	  an	  integral	  component	  of	  the	  platelet	  membrane	  inner	  leaflet.	  The	  tenase	  complex	  (sometimes	  referred	  to	  as	  the	  intrinsic	  tenase	  complex)	  is	  composed	  of	  FVIIIa	  and	  FIXa	  and	  is	  responsible	  for	  the	  generation	  of	  FXa.14	  The	  prothrombinase	  complex	  consists	  of	  FXa	  and	  FVa	  bound	  together	  through	  a	  linkage	  in	  FVa	  to	  PS.	  	  The	  prothrombinase	  complex	  is	  responsible	  for	  generation	  of	  large	  amounts	  of	  thrombin	  from	  prothrombin.14	  Assembly	  of	  both	  these	  complexes	  is	  dependent	  on	  the	  expression	  of	  a	  PS	  rich	  pro-­‐coagulant	  surface	  on	  activated	  platelets	  (Figure	  1.8).	  	  	  
Initiation	  
	  	  	  	  	  	   Initiation	  occurs	  when	  circulating	  FVIIa	  encounters	  a	  TF	  bearing	  cell	  in	  the	  presence	  of	  Ca2+	  and	  activates	  factor	  X.	  	  TF	  is	  normally	  not	  in	  contact	  with	  blood	  until	  injury	  or	  inflammation.13	  There	  is	  circulating	  tissue	  factor	  in	  the	  blood	  but	  it	  is	  unable	  to	  activate	  FX.	  	  It	  is	  thought	  that	  either	  the	  circulating	  TF	  requires	  cleavage	  to	  become	  activated,	  or	  if	  its	  lack	  of	  PS	  binding	  prevents	  proper	  tenase	  assembly.15	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Figure	  1.6:	  Cell	  Surface	  Assembly	  of	  Coagulation	  Factors.	  TF;	  tissue	  factor,	  vWF;	  Von	  Willebrand	  factor.	  Adapted	  from	  Hoffman	  2003.13	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Figure	   1.7:	   Cell	   Based	   Model	   of	   Coagulation.	   A)	   Initiation.	   	   B)	  	  Amplification.	  	  C)	  Propagation.	  	  TF;	  tissue	  factor,	  vWF;	  Von	  Willebrand	  factor.	  	  Adapted	  from	  Hoffman	  2003.12	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Figure	   1.8:	   Coagulation	   Enzyme	   Complexes.	   	   PS;	   phosphatidylserine.	   	   Adapted	  from	  Zwaal	  2004.16	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FVII	  is	  the	  only	  factor	  that	  circulates	  in	  an	  active	  form,	  with	  basal	  levels	  of	  FVIIa	  around	  1%.15	  The	  fact	  that	  TF,	  FVII,	  and	  FX	  all	  are	  expressed	  in	  tissues	  outside	  the	  vasculature	  suggests	  that	  there	  is	  initiation	  occurring	  in	  an	  idling	  fashion,	  increasing	  the	  ability	  for	  the	  body	  to	  respond	  rapidly	  at	  the	  site	  of	  injury.13	  	  	  	  	  	  	   There	  are	  a	  couple	  of	  different	  regulatory	  pathways	  that	  regulate	  the	  initiation	  phase.	  	  First	  the	  TF-­‐FVII	  complex	  is	  rapidly	  shut	  off	  by	  both	  TFPI	  and	  AT.	  	  This	  rapid	  shut	  off	  only	  generates	  trace	  amounts	  of	  thrombin.17	  This	  fits	  well	  with	  the	  second	  following	  amplification	  step.	  	  The	  other	  method	  can	  be	  looked	  at	  like	  a	  tenase	  /	  prothrombinase	  switch.	  	  FX	  and	  FXa	  have	  the	  same	  affinity	  for	  binding	  with	  PS.	  	  As	  FXa	  is	  generated	  it	  can	  displace	  FX	  from	  the	  platelet	  membrane	  by	  competing	  for	  the	  PS	  binding	  sites.	  	  This	  allows	  for	  the	  assembly	  of	  the	  prothrombinase	  complex	  and	  the	  progression	  into	  the	  later	  steps	  in	  the	  model	  (Figure	  1.7).18	  
Amplification	  
	  	  	  	  	   During	  the	  amplification	  step	  the	  platelets	  begin	  to	  ramp	  up	  their	  pro-­‐thrombotic	  response.	  	  Small	  levels	  of	  thrombin	  generated	  through	  initiation	  diffuse	  away	  from	  the	  initiation	  site.	  	  This	  diffused	  thrombin	  has	  multiple	  effects	  to	  the	  surrounding	  platelets.	  	  It	  activates	  platelets	  through	  the	  protease-­‐activated	  receptors	  1	  and	  4	  (PAR1,	  PAR4)	  in	  humans	  causing	  the	  secretion	  of	  α	  and	  dense	  granules	  that	  contain	  many	  autocrine	  and	  paracrine	  factors.13	  It	  also	  causes	  the	  exposure	  of	  PS	  on	  the	  surface	  of	  the	  platelet	  creating	  a	  pro-­‐coagulant	  surface	  for	  complex	  assembly.15	  Thrombin	  also	  activates	  FXI,	  FV,	  and	  cleaves	  vWF	  from	  FVIII.17	  At	  the	  end	  of	  the	  amplification	  phase	  platelets	  activated	  by	  the	  limited	  release	  of	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thrombin	  from	  the	  amplification	  phase	  are	  clad	  in	  activated	  factors	  on	  their	  surface	  (Figure	  1.7).13	  
Propagation	  
	  	  	  	  	  	   Propagation	  is	  the	  step	  of	  clotting	  progression	  where	  the	  thrombin	  burst	  occurs.17	  During	  this	  phase	  the	  assembly	  of	  the	  tenase	  complex	  continues	  to	  occur	  on	  adjacent	  platelets,	  as	  well	  the	  assembly	  of	  the	  prothrombinase	  complex.	  	  The	  tenase	  complex	  continues	  to	  generate	  FXa,	  which	  allows	  for	  large-­‐scale	  assembly	  of	  the	  prothrombinase	  complex,	  generating	  large	  amounts	  of	  thrombin.	  	  Along	  with	  platelet	  stimulation	  by	  thrombin,	  this	  large	  local	  concentration	  of	  thrombin	  promotes	  the	  cleavage	  of	  fibrinogen	  to	  fibrin.13	  	  Thrombin	  is	  also	  responsible	  for	  the	  activation	  of	  FXIII,	  crosslinking	  and	  stabilizing	  the	  thrombin	  clot.	  	  It	  is	  during	  this	  step	  that	  hemophilia	  patients	  begin	  to	  show	  dysfunction.	  	  Both	  hemophilia	  A	  (FVIII	  deficiency)	  and	  hemophilia	  B	  (FIX	  deficiency)	  cause	  issues	  with	  complex	  assembly	  and	  propagation	  of	  thrombin	  signaling	  through	  complex	  assembly.17	  Phospholipid	  scrambling	  due	  to	  Scott	  syndrome	  also	  causes	  inhibition	  of	  complex	  formation	  to	  lack	  of	  PS	  exposure.	  16	  	  
Coagulation	  Factors	  	  	  	  	  	  	   Although	  the	  cell	  based	  model	  stresses	  the	  importance	  of	  cellular	  response	  in	  the	  coagulation	  process,	  an	  understanding	  of	  the	  coagulation	  factors	  is	  required	  to	  understand	  the	  final	  fibrin	  clot	  formation	  that	  is	  required	  for	  hemostasis.	  	  There	  are	  14	  proteins	  involved	  in	  the	  pro-­‐coagulant	  response	  (Table	  1.1).	  	  When	  examining	  the	  individual	  proteins	  in	  the	  context	  of	  coagulation	  they	  can	  be	  divided	  into	  three	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  *	   atomic	  mass	  units,	   **	   there	   is	  no	  Factor	  VI,	   ***	  no	   factor	  number	  assigned,	  MW;	  molecular	  weight.	  	  	  Adapted	  from	  Lefkowitz	  2008.9	  	   	  
Table&1.1:&Plasma&Coagulation&Proteins
Factor&Name Common&Name MW&(kDa) Description
Factor'I Fibrinogen 340 Adhesive'glycoprotein'that'forms'the'basis'of'a'fibrin'clot




Factor'IV Ca++'ion 40.078* Divalent'cation'required'for'multiple'coagulation'reactions
Factor'V Labile'Factor 330 Cofactor'for'activation'of'thrombin'from'prothrombin




























Prekallikrein*** Fletcher'Factor 85 Serine'protease,'initiator'of'the'intrinsic'pathway'with'Factor'XII
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separate	  pathways.	  	  Traditionally	  these	  pathways	  are	  referred	  to	  as	  the	  intrinsic,	  extrinsic,	  and	  common	  pathways.	  
Extrinsic	  Pathway	  
Tissue	  Factor	  (Factor	  III)	  Tissue	  factor	  (TF)	  is	  typically	  referred	  to	  by	  its	  common	  name	  rather	  than	  by	  its	  factor	  number.	  	  TF	  is	  a	  37,000	  Da	  lipoprotein	  that	  is	  the	  main	  initiator	  of	  the	  extrinsic	  pathway.10	  TF	  is	  expressed	  constitutively	  on	  the	  cell	  membrane	  of	  subendothelial	  fibroblasts,	  epithelial	  cells	  of	  the	  skin	  and	  mucosa,	  stroma	  cells	  in	  the	  endometrium,	  and	  astrocytes	  in	  the	  brain.19–21	  TF	  combines	  with	  Factor	  VII	  (FVII)	  to	  activate	  the	  initiation	  phase	  of	  the	  cell-­‐based	  model	  of	  coagulation.	  	  TF	  serves	  as	  the	  cell	  based	  receptor	  of	  circulating	  F	  VII.22	  Once	  bound	  to	  circulating	  FVII	  TF	  activates	  FVII	  (FVIIa)	  and	  accelerates	  the	  activation	  of	  circulating	  FVII.22	  Tissue	  factor	  is	  also	  referred	  to	  as	  CD142	  and	  thromboplastin.	  	  
Proconvertin	  (Factor	  VII)	  Proconvertin	  is	  typically	  referred	  to	  as	  Factor	  VII	  (FVII).	  	  FVII	  is	  a	  50,000	  Da	  vitamin	  K	  dependent	  serine	  protease.	  	  It	  combines	  with	  TF	  on	  the	  membrane	  of	  TF	  bearing	  cells	  and	  becomes	  activated	  (FVIIa).23,24	  FVIIa	  activates	  two	  separate	  clotting	  factors	  (Factor	  X	  and	  Factor	  IX)	  via	  proteolytic	  mechanisms	  that	  cleave	  an	  activation	  peptide.22	  As	  discussed	  above	  it	  should	  also	  be	  noted	  that	  small	  amounts	  of	  FVII	  circulate	  in	  the	  active	  form.	  	  It	  is	  the	  only	  clotting	  factor	  to	  do	  so.20	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Intrinsic	  Pathway	  
Prekallikrein	  (Fletcher	  Factor)	  Prekallikrein	  is	  an	  80,000	  Da	  serine	  protease	  that	  is	  involved	  in	  the	  initiation	  of	  the	  intrinsic	  pathway	  in	  conjunction	  with	  Factor	  XII.10	  Deficiency	  in	  Prekallikrein	  causes	  increased	  PTT	  measurements,	  but	  has	  no	  thrombotic	  or	  bleeding	  phenotype.10	  Once	  activated,	  kallikrein	  is	  able	  to	  activate	  plasminogen	  through	  the	  urokinase	  type	  plasminogen	  activator	  (u-­‐PA).25	  
Hageman	  Factor	  (Factor	  XII)	  
	   Hageman	  factor	  is	  commonly	  referred	  to	  as	  Factor	  XII.	  	  It	  is	  an	  80,000	  Da	  serine	  protease	  that	  is	  commonly	  considered	  the	  start	  of	  the	  intrinsic	  pathway.10	  Deficiency	  in	  FXII	  does	  not	  result	  in	  either	  a	  bleeding	  or	  thrombotic	  phenotype.9	  Factor	  XII	  can	  be	  activated	  by	  either	  the	  serine	  protease	  kallikrein	  or	  spontaneously	  when	  the	  blood	  is	  exposed	  to	  a	  negatively	  charged	  surface.	  	  In	  a	  positive	  feedback	  loop	  FXIIa	  can	  act	  on	  Prekallikrein	  cleaving	  it	  to	  kallikrein,	  which	  in	  turn	  can	  activate	  more	  factor	  XII.	  	  FXIIa	  is	  also	  responsible	  for	  the	  activation	  of	  Factor	  XI	  as	  well	  as	  its	  disassociation	  from	  high	  molecular	  weight	  kininogen	  (HK).9	  	  
Plasma	  Thromboplastin	  Antecedent	  (Factor	  XI)	  	   Plasma	  thromboplastin	  antecedent	  is	  commonly	  referred	  to	  as	  Factor	  XI	  (FXI).	  	  It	  is	  a	  160,000	  Da	  serine	  protease	  that	  is	  involved	  in	  the	  intrinsic	  activation	  of	  Factor	  IX.9	  FXI	  binds	  both	  specifically	  and	  reversibly	  to	  GP	  Ibα	  in	  the	  presence	  of	  either	  high	  molecular	  weight	  kininogen	  and	  Zn2+	  or	  prothrombin	  and	  Ca2+.26	  This	  binding	  appears	  to	  occur	  only	  on	  activated	  platelets	  and	  is	  localized	  to	  lipid	  rafts	  on	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the	  membrane	  surface.27	  This	  binding	  then	  serves	  to	  promote	  activation	  of	  FXI	  by	  thrombin.26,27	  
Christmas	  Factor	  (Factor	  IX)	  	   Christmas	  factor	  is	  traditionally	  referred	  to	  as	  Factor	  IX	  (FIX).	  FIX	  is	  a	  55,000	  Da	  vitamin	  K	  dependent	  serine	  protease	  and	  a	  component	  of	  the	  intrinsic	  tenase	  complex.9	  Factor	  IX	  can	  be	  activated	  by	  both	  the	  intrinsic	  and	  extrinsic	  pathways	  via	  FXIa	  and	  FVIIa	  respectively.28	  FIX	  binding	  to	  the	  phospholipid	  surface	  of	  the	  platelet	  is	  Ca2+	  dependent.	  	  22,29	  FIXa	  assembles	  on	  the	  lipid	  membrane	  along	  with	  FVIIIa	  and	  FX	  to	  form	  the	  tenase	  complex,	  which	  also	  requires	  Ca2+	  for	  full	  activity.30	  
Antihemophillic	  Factor	  (Factor	  VIII)	  
	   Antihemophillic	  factor	  is	  commonly	  referred	  to	  as	  Factor	  VIII	  (FVIII).	  	  It	  is	  a	  330,000	  Da	  protein	  that	  is	  a	  cofactor	  for	  the	  intrinsic	  activation	  of	  Factor	  X.10	  FVIII	  binds	  to	  and	  circulates	  with	  Von	  Willebrand	  Factor	  (vWF)	  as	  an	  inactive	  precursor.31	  FVIII	  can	  be	  activated	  either	  by	  thrombin	  or	  activated	  factor	  X	  (FXa)	  via	  a	  cleavage	  event,	  and	  following	  disassociation	  with	  vWF	  is	  concentrated	  via	  phospholipid	  binding	  to	  cellular	  membranes.32,33	  Once	  bound	  to	  the	  membrane	  surface	  the	  FIXa/FVIIIa/FX	  complex	  (intrinsic	  tenase	  complex)	  enhances	  the	  catalysis	  of	  FXa	  100,000	  times	  the	  normal	  rate.28,34	  Thrombin	  mediated	  cleavage	  of	  FVIII	  does	  not	  require	  the	  presence	  of	  Ca2+,	  but	  once	  activated	  Ca2+	  is	  required	  for	  proper	  functioning	  of	  the	  tenase	  complex.35	  Hemophilia	  is	  the	  result	  of	  either	  qualitative	  or	  quantitative	  deficiencies	  of	  FVIII.31	  
Common	  Pathway	  
Stuart-­‐Prower	  Factor	  (Factor	  X)	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   Stuart-­‐Prower	  factor	  is	  commonly	  referred	  to	  as	  Factor	  X	  (FX).	  	  FX	  is	  a	  58,900	  Da	  vitamin	  K	  dependent	  serine	  protease.10	  Activated	  FX	  (FXa)	  is	  the	  initiator	  of	  the	  final	  common	  pathway	  and	  is	  the	  enzymatic	  force	  behind	  the	  activation	  of	  thrombin.9	  Due	  to	  the	  importance	  of	  FX’s	  role	  in	  the	  coagulation	  protein	  pathway,	  it	  is	  often	  considered	  central	  to	  the	  cascade.36	  FX	  is	  the	  only	  coagulation	  factor	  to	  be	  involved	  in	  the	  formation	  and	  function	  of	  both	  the	  tenase	  as	  well	  as	  the	  prothrombinase	  complexes,	  and	  its	  activity	  is	  highly	  dependent	  on	  its	  association	  with	  the	  plasma	  membrane.34	  	  	  	   FX	  can	  be	  activated	  by	  either	  the	  intrinsic	  or	  extrinsic	  pathway	  as	  a	  result	  of	  activation	  of	  the	  coagulation	  pathway,	  and	  has	  been	  shown	  to	  be	  activated	  in	  unrelated	  pathways	  as	  well.	  	  MAC-­‐1	  (CD11b/	  CD18)	  present	  on	  the	  surface	  of	  monocytic	  cells	  is	  capable	  of	  binding	  FX	  and	  be	  activated	  by	  cathepsin	  G	  secreted	  during	  periods	  of	  inflammation.37	  Various	  pathological	  agents	  have	  been	  shown	  to	  activate	  FX	  as	  well,	  which	  creates	  a	  link	  between	  infection,	  inflammation,	  and	  coagulation.	  	  Cytomegalovirus	  and	  herpes	  simplex	  virus	  (types	  1	  and	  2)	  express	  phospholipids	  on	  their	  surface	  that	  allow	  for	  the	  imitation	  of	  the	  FVII-­‐TF	  complex	  and	  subsequent	  activation	  of	  FX.38	  Bacterial	  proteinases	  have	  also	  been	  shown	  to	  activate	  FX,	  with	  the	  most	  commonly	  studied	  being	  gingipain-­‐Rs	  produced	  by	  
Porphyromonas	  gingivalis.39	  	   Regulation	  of	  FX	  is	  of	  upmost	  importance	  when	  maintaining	  homeostasis	  in	  the	  coagulation	  pathway.	  	  Because	  of	  the	  central	  role	  it	  plays,	  FX	  inhibition	  is	  the	  focus	  of	  multiple	  physiological	  coagulation	  inhibitors.	  	  TFPI	  binds	  strongly	  to	  the	  TF-­‐FVII	  complex	  in	  the	  presence	  of	  FX,	  creating	  a	  quaternary	  complex	  that	  prevents	  the	  
	   19	  
formation	  of	  FXa.40,41	  TFPI	  is	  the	  strongest	  endogenous	  inhibitor	  of	  the	  coagulation	  pathway	  due	  to	  it’s	  ability	  to	  stop	  the	  extrinsic	  pathway	  at	  the	  initiation	  phase,	  essentially	  stopping	  the	  TF	  response	  directly	  at	  the	  site	  of	  injury.36	  Antithrombin	  is	  also	  a	  direct	  inhibitor	  of	  FXa	  activity,	  binding	  to	  FXa	  and	  creating	  an	  inactive	  complex	  in	  the	  presence	  of	  heparin.42	  Both	  inhibitory	  FX	  complexes	  are	  quickly	  cleared	  from	  the	  blood	  and	  transported	  to	  the	  liver	  where	  they	  are	  degraded.36,43,44	  	   FXa	  also	  plays	  a	  significant	  role	  in	  cell	  signaling,	  as	  it	  is	  able	  to	  activate	  protease-­‐activated	  receptors	  (PARs)	  in	  various	  cell	  types.	  	  FXa	  has	  been	  shown	  to	  be	  able	  to	  activate	  protease	  activated	  receptors	  (PARs)	  1	  and	  2	  via	  proteolytic	  cleavage.45,46	  PARs	  are	  G	  protein	  coupled	  receptors,	  and	  will	  be	  discussed	  later	  in	  this	  work	  in	  detail.	  	  For	  current	  purposes	  however	  it	  should	  be	  mentioned	  that	  the	  main	  result	  of	  FX	  activation	  in	  the	  blood	  is	  the	  subsequent	  generation	  of	  thrombin	  from	  prothrombin.	  	  Thrombin	  is	  the	  most	  effective	  singular	  mediator	  of	  PAR	  activation,	  and	  widely	  accepted	  to	  be	  the	  receptor’s	  physiological	  agonist	  of	  choice.	  	  The	  fact	  that	  FXa	  is	  also	  able	  to	  activate	  the	  receptor	  provides	  a	  fall	  back	  mechanism	  that	  allows	  for	  the	  activation	  of	  the	  receptor	  in	  the	  absence	  of	  thrombin	  generation.36	  While	  the	  activation	  of	  PAR	  signaling	  by	  FXa	  alone	  is	  inefficient	  (requiring	  nM	  concentrations),	  when	  complexed	  with	  TF	  and	  FVII	  the	  ability	  to	  activate	  PAR-­‐1	  increases	  to	  that	  of	  thrombin.47,48	  	   As	  mentioned	  above,	  the	  main	  physiological	  role	  of	  FXa	  is	  the	  conversion	  of	  prothrombin	  to	  thrombin.	  	  FXa	  is	  relatively	  efficient	  alone	  in	  the	  conversion	  and	  activation	  of	  thrombin,	  requiring	  less	  than	  nM	  amounts	  in	  vitro	  to	  generate	  thrombin.48	  Thrombin	  generated	  at	  this	  stage	  activates	  factor	  V	  (FV),	  which	  then	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complexes	  on	  a	  lipid	  membrane	  surface	  with	  FXa	  creating	  what	  is	  known	  as	  the	  prothrombinase	  complex.	  	  The	  prothrombinase	  complex	  generates	  massive	  thrombin	  production,	  often	  termed	  the	  thrombin	  burst.22	  
Labile	  Factor	  (Factor	  V)	  
	   Labile	  factor	  is	  commonly	  referred	  to	  as	  factor	  V	  (FV).	  	  FV	  is	  a	  330,000	  Da	  protein	  that	  acts	  as	  a	  cofactor	  alongside	  FXa	  to	  generate	  thrombin.10	  FV’s	  main	  mechanism	  of	  action	  is	  through	  the	  assembly	  of	  the	  prothrombinase	  complex.	  	  FV	  is	  tightly	  regulated	  by	  protein	  C,	  providing	  an	  inhibitory	  feedback	  loop	  in	  the	  regulation	  of	  coagulation.49	  Factor	  V	  Leiden	  is	  caused	  by	  a	  mutation	  that	  inhibits	  the	  ability	  of	  protein	  C	  to	  inactivate	  FVa,	  and	  shows	  both	  a	  thrombotic	  phenotype	  as	  well	  as	  protective	  qualities	  in	  hemophilia.49	  	  
Prothrombin	  (Factor	  II)	  
	   Prothrombin	  is	  the	  precursor	  for	  thrombin,	  the	  central	  enzyme	  in	  the	  coagulation	  cascade.	  	  It	  is	  a	  72,000	  Da	  vitamin	  K-­‐dependent	  serine	  protease,	  and	  is	  normally	  referred	  to	  as	  prothrombin.9	  Thrombin	  conversion	  happens	  in	  two	  separate	  steps	  in	  the	  cell-­‐based	  model.	  	  Small	  amounts	  of	  thrombin	  are	  generated	  during	  the	  initiation	  phase,	  which	  diffuses	  away	  from	  the	  immediate	  site	  of	  injury.15	  	  Binding	  of	  small	  amounts	  of	  thrombin	  to	  PARs	  on	  the	  platelet	  surface	  induce	  the	  rearrangement	  of	  phospholipids	  on	  the	  membrane	  surface.16,50,51	  PAR	  signaling	  is	  capable	  of	  complete	  activation	  of	  the	  platelet	  response	  through	  G	  proteins	  as	  well,	  and	  both	  these	  responses	  will	  be	  discussed	  later	  in	  this	  work.	  	  Thrombin	  also	  activates	  positive	  feedback	  loops	  generating	  more	  FXIa	  and	  FVa	  (demonstrated	  in	  figure	  1.5).	  	  In	  addition,	  thrombin	  is	  able	  to	  cleave	  the	  FVIII-­‐vWF	  complex	  liberating	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FVIII.	  	  This	  FVIII	  is	  then	  also	  converted	  to	  FVIIIa	  by	  thrombin	  as	  well.	  	  Thrombin	  is	  central	  to	  the	  structure	  of	  a	  clot,	  as	  it	  cleaves	  soluble	  fibrinogen	  to	  a	  loosely	  associated	  fibrin	  network.	  	  To	  stabilize	  the	  clot	  thrombin	  is	  also	  responsible	  for	  the	  activation	  of	  the	  cross-­‐linking	  transamidase	  FXIIIa.15	  
Fibrinogen	  (Factor	  I)	  	   Fibrinogen	  is	  the	  final	  substrate	  in	  the	  protein	  clotting	  system.	  	  Fibrinogen	  is	  produced	  in	  the	  liver	  and	  circulates	  as	  a	  dimer	  composed	  of	  a	  pair	  of	  three	  individual	  protein	  chains.9	  The	  individual	  protein	  components	  of	  the	  monomers	  are	  called	  Aα, Ββ,	  and	  γ.	  	  These	  individual	  units	  are	  linked	  together	  at	  their	  N	  terminal	  ends	  by	  a	  disulfide	  linkage	  (Figure	  1.9).	  9	  Once	  activated	  thrombin	  cleaves	  two	  small	  peptides	  (Fibrinopeptides	  A	  and	  B)	  forming	  a	  fibrin	  monomer.	  	  The	  resulting	  fibrin	  monomers	  align	  by	  non-­‐covalent	  interactions	  into	  an	  unstable	  fibrin	  polymer,	  which	  requires	  FXIII	  for	  stabilization.9	  A	  schematic	  of	  this	  process	  can	  be	  found	  in	  Figure	  1.9.	  	  	  	  	   Fibrinogen	  is	  unique	  as	  it	  is	  active	  in	  the	  clotting	  process	  both	  in	  the	  fluid	  and	  the	  solid	  phase.	  	  Soluble	  fibrinogen	  is	  the	  mediator	  of	  platelet-­‐platelet	  aggregation.	  	  Once	  activated	  the	  platelet	  integrin	  GP	  IIb/IIIa	  binds	  to	  fibrinogen.52	  Platelet	  aggregation	  occurs	  when	  multiple	  platelets	  are	  linked	  through	  the	  fibrinogen	  molecule.53	  In	  comparison,	  the	  main	  structural	  component	  of	  the	  solid	  phase	  is	  fibrin	  generated	  from	  the	  thrombin	  mediated	  cleavage	  of	  fibrinogen.52,54	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Figure	  1.9:	  	  Schematic	  of	  Fibrinogen	  Structure	  and	  Fibrin	  Polymer	  Generation.	  	  FpA;	  fibrinopeptide	  A,	  FpB;	  fibrinopeptide	  B.	  	  Adapted	  from	  Lefkowitz	  2008.9	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Fibrin	  Stabilizing	  Factor	  (Factor	  XIII)	  
	   Fibrin	  stabilizing	  factor	  is	  more	  commonly	  referred	  to	  as	  Factor	  XIII	  (FXIII).	  	  It	  is	  a	  320,000	  Da	  transamidase	  that	  is	  activated	  by	  thrombin.9	  FXIII	  covalently	  cross-­‐links	  the	  fibrin	  network	  generated	  by	  thrombin	  by	  connecting	  the	  γ	  monomers	  by	  attacking	  glutamic	  acid	  and	  lysine	  in	  side	  chains.36	  	  	  	   FXIII	  also	  covalently	  attaches	  plasminogen,	  antiplasmin,	  and	  other	  materials	  to	  the	  growing	  clot.	  	  This	  action	  serves	  to	  alter	  the	  composition	  of	  the	  clot,	  and	  it	  is	  thought	  to	  increase	  wound	  healing	  and	  tissue	  repair	  activity	  inside	  the	  clot.10	  	  
High	  Molecular	  Weight	  Kininogen	  
	   High	  molecular	  weight	  kininogen	  (HMWK)	  is	  an	  110,000	  protein	  that	  has	  no	  enzyme	  activity.	  	  It	  acts	  as	  a	  cofactor	  for	  the	  conversion	  of	  kallikrein	  and	  FXII	  in	  the	  initiation	  of	  the	  intrinsic	  pathway.9	  It	  is	  also	  required	  for	  the	  activation	  of	  FXI	  by	  FXIIa.	  	  HMWK	  also	  serves	  a	  purpose	  in	  the	  binding	  and	  regulation	  of	  endothelial	  cells,	  and	  is	  a	  strong	  inhibitor	  of	  cysteine	  proteases.55	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Tissue	  Factor	  Pathway	  Inhibitor	  (TFPI)	  
	   TFPI	  is	  a	  33,000	  Da	  protein	  that	  is	  the	  main	  inhibitor	  in	  the	  extrinsic	  TF	  pathway.	  	  TFPI	  is	  secreted	  from	  the	  endothelium,	  and	  rapidly	  inactivates	  the	  TF/FVII	  complex.10	  	  
Antithrombin	  (AT)	  	  	  
	   Antithrombin	  is	  a	  58,000	  Da	  serpin	  that	  directly	  inhibits	  several	  serine	  proteases	  (FXa,	  FIXa,	  and	  FXIa)	  in	  the	  coagulation	  cascade.	  	  AT	  requires	  heparin	  as	  a	  cofactor	  for	  proper	  activity.9	  Heparin	  is	  often	  given	  as	  an	  anticoagulant	  during	  pharmacological	  therapy,	  but	  physiologically	  its	  role	  is	  somewhat	  less	  defined.	  	  It	  is	  known	  to	  be	  present	  on	  endothelial	  cells	  and	  to	  be	  released	  by	  mast	  cells	  at	  the	  site	  of	  injury.56	  Once	  bound	  to	  heparin	  AT	  undergoes	  a	  conformational	  change	  that	  increases	  the	  efficiency	  of	  the	  inhibitor	  1000	  fold.10	  
Protein	  C	  	  
	   Protein	  C	  is	  a	  62,000	  Da	  vitamin	  K	  dependent	  serine	  protease	  that	  is	  able	  to	  cleave	  and	  inactivate	  both	  FVa	  and	  FVIIIa.9	  Protein	  C	  is	  responsible	  for	  controlling	  thrombin	  formation	  in	  the	  physical	  area	  around	  the	  clot.57	  In	  the	  inactive	  state	  protein	  C	  is	  localized	  to	  the	  surface	  of	  the	  endothelium	  by	  the	  endothelial	  cell	  protein	  C	  receptor	  (EPCR).58	  Thrombin	  generated	  during	  the	  clotting	  process	  binds	  to	  thrombomodulin	  (TM)	  on	  the	  endothelial	  surface	  as	  well.	  	  This	  binding	  itself	  inhibits	  thrombin’s	  ability	  to	  interact	  with	  fibrinogen,	  but	  also	  brings	  it	  into	  proximity	  to	  protein	  C.59	  Thrombin	  cleaves	  protein	  C	  from	  the	  endothelium	  generating	  activated	  protein	  C	  (APC).	  	  APC	  then	  moves	  to	  act	  on	  its	  main	  targets,	  FVIIIa	  and	  FVa	  reducing	  generation	  of	  thrombin	  away	  from	  the	  site	  of	  endothelial	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injury.40	  Protein	  C’s	  inhibitory	  activity	  is	  greatly	  increased	  in	  the	  presence	  of	  the	  cofactor	  protein	  S.60	  	  	  
Protein	  S	  
	   Protein	  S	  is	  a	  75,000	  Da	  vitamin	  K-­‐dependent	  serine	  protease	  that	  acts	  as	  a	  cofactor	  for	  protein	  C.9	  It	  has	  been	  shown	  that	  activated	  protein	  S	  (APS)	  greatly	  increases	  the	  ability	  of	  activated	  protein	  C	  (APC)	  to	  inactivate	  FVa.60	  It	  has	  also	  been	  shown	  that	  APS	  increases	  the	  binding	  of	  APC	  to	  a	  negatively	  charged	  phospholipid	  surface	  as	  well	  as	  increase	  the	  interaction	  of	  APC	  with	  activated	  platelets.60–62	  APS	  also	  increases	  the	  inherent	  inactivation	  of	  FVIIIa	  by	  APC	  in	  a	  dose	  dependent	  manner.	  	  Interestingly,	  APS	  is	  also	  able	  to	  further	  cleave	  the	  breakdown	  products	  generated	  by	  the	  cleavage	  of	  FVIIIa	  by	  APC.33	  	  	  
1.3	  Fibrinolysis	  	   In	  comparison	  to	  the	  coagulation	  cascade,	  the	  fibrinolytic	  pathway	  is	  comprised	  of	  far	  less	  active	  participants.	  	  Fibrinolysis	  is	  accomplished	  through	  an	  inactive	  proenzyme	  (plasminogen)	  that	  is	  converted	  to	  the	  active	  serine	  protease	  plasmin	  by	  two	  separate	  activators	  (tissue-­‐type	  plasminogen	  activator,	  urokinase-­‐type	  plasminogen	  activator).	  	  Inhibition	  of	  the	  pathway	  is	  accomplished	  at	  two	  levels.	  	  α2-­‐antiplasmin	  inactivates	  plasmin,	  and	  plasminogen	  activator	  inhibitor	  specifically	  and	  thrombin-­‐activatable	  fibrinolytic	  inhibitor	  inhibit	  the	  activity	  of	  the	  plasminogen	  activators.63	  A	  schematic	  of	  the	  fibrinolytic	  pathway	  can	  be	  found	  in	  Figure	  1.10.64	  Each	  component	  is	  discussed	  further	  below.	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Figure	   1.10:	   	   Schematic	   Representation	   of	   Fibrinolytic	   Pathway.	   PAI-­‐1;	  plasminogen	   activator	   inhibitor	   1,	   t-­‐PA;	   tissue-­‐type	   plasminogen	   activator,	   u-­‐PA;	  urokinase-­‐type	   plasminogen	   activator,	   α2-­‐AP;	   α2-­‐antiplasmin,	   TAFI;	   thrombin-­‐activatable	   fibrinolysis	   inhibitor.	   	   Dashed	   lines	   indicate	   inhibition.	   	   Adapted	   from	  Thelwell	  2010.64	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Plasminogen	  
	   Plasminogen	  is	  a	  92,000	  Da	  glycoprotein	  proenzyme.	  	  It	  is	  converted	  by	  plasminogen	  activators	  by	  a	  cleavage	  mechanism	  that	  creates	  a	  two-­‐chain	  trypsin-­‐like	  serine	  protease	  named	  plasmin.65	  Plasmin	  digests	  and	  cleaves	  fibrin	  indiscriminately	  at	  different	  sites,	  resulting	  in	  the	  generation	  of	  various	  sized	  fibrin	  degradation	  products	  (FDPs).	  	  The	  half	  life	  of	  free	  plasminogen	  is	  extremely	  short	  (0.1	  seconds)	  due	  to	  inactivation	  by	  α2-­‐antiplasmin,	  but	  this	  reaction	  is	  much	  slower	  (10	  to	  100	  seconds)	  when	  plasmin	  is	  bound	  to	  fibrin.66	  This	  fact	  leads	  to	  the	  understanding	  that	  fibrinolysis	  occurs	  almost	  exclusively	  at	  the	  fibrin	  surface.	  
Plasminogen	  Activators	  (PAs)	  
	   There	  are	  two	  types	  of	  plasminogen	  activators.	  	  Tissue	  type	  plasminogen	  activator	  (t-­‐PA)	  is	  produced	  by	  endothelial	  cells,	  and	  is	  a	  70,000	  Da	  serine	  protease.63	  t-­‐PA	  is	  a	  very	  inefficient	  enzyme	  on	  its	  own,	  but	  upon	  binding	  to	  fibrin	  its	  efficiency	  increases	  by	  at	  least	  two	  orders	  of	  magnitude.	  	  The	  association	  with	  fibrin	  does	  not	  change	  the	  catalytic	  ability	  of	  the	  enzyme,	  but	  instead	  increases	  its	  rate	  of	  association	  with	  plasminogen.67	  In	  a	  similar	  fashion,	  the	  activation	  rate	  of	  t-­‐PA	  on	  cell	  bound	  plasminogen	  is	  approximately	  10	  times	  that	  of	  the	  activation	  rate	  in	  solution.63	  Plasmin	  generated	  by	  the	  reaction	  in	  turn	  inactivates	  t-­‐PA	  through	  a	  hydrolysis	  bond,	  providing	  feedback	  inhibition	  of	  this	  pathway.68	  Urokinase-­‐type	  plasminogen	  activator	  (u-­‐PA)	  is	  a	  54,000	  Da	  protease	  that	  circulates	  in	  a	  single	  chain	  (prourokinase).	  	  u-­‐PA	  can	  be	  activated	  by	  plasmin	  or	  kallikrein	  generating	  an	  active	  enzyme.	  Active	  u-­‐PA	  does	  not	  bind	  to	  fibrin,	  but	  does	  bind	  to	  a	  specific	  cell	  surface	  receptor	  (u-­‐PAR).63	  Inactive	  u-­‐PA	  does	  bind	  to	  the	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surface	  of	  fibrin	  however,	  where	  it	  is	  brought	  into	  close	  proximity	  to	  plasmin	  and	  subsequently	  activated.65	  u-­‐PA	  is	  inactivated	  by	  thrombin	  at	  a	  slow	  rate,	  but	  this	  reaction	  is	  strongly	  accelerated	  in	  the	  presence	  of	  thrombomodulin.25	  
α2-­‐Antiplasmin	  	   α2-­‐antiplasmin	  is	  a	  70,000	  Da	  serpin	  that	  has	  a	  high	  affinity	  for	  plasmin/plasminogen.	  	  This	  involves	  the	  formation	  of	  a	  1:1	  complex	  between	  the	  two	  molecules,	  and	  a	  fast	  initial	  reversible	  step,	  followed	  by	  a	  slower	  irreversible	  permanent	  inactivation	  of	  both	  molecules.63,65	  
Thrombin	  Activatable	  Fibrinolytic	  Inhibitor	  (TAFI)	  
	   TAFI	  is	  also	  referred	  to	  as	  plasma	  procarboxypeptidase	  B,	  and	  is	  a	  60,000	  Da	  proenzyme.	  	  TAFI	  can	  be	  activated	  by	  thrombin,	  but	  this	  reaction	  rate	  is	  increased	  1250	  fold	  in	  the	  presence	  of	  thrombomodulin.63	  TAFI	  is	  unique	  as	  it	  can	  be	  both	  activated	  as	  well	  as	  inactivated	  by	  plasmin.69	  TAFI	  acts	  by	  removing	  C-­‐terminal	  lysine	  and	  arginine	  residues	  on	  the	  surface	  of	  partially	  degraded	  fibrin,	  which	  decreases	  the	  ability	  of	  plasminogen	  to	  bind	  and	  become	  activated.70	  
Plasminogen	  Activator	  Inhibitor	  1	  (PAI-­‐1)	  
	   PAI-­‐1	   is	  a	  52,000	  Da	  member	  of	  the	  serpin	  superfamily.	  	  PAI-­‐1	  is	  the	  main	  inhibitor	  of	  both	  PAs,	  and	  is	  present	  in	  the	  circulation	  in	  low	  concentrations	  normally.63	  Platelets	  have	  been	  shown	  to	  contain	  relatively	  large	  amounts	  of	  inactive	  PAI-­‐1,	  and	  recent	  work	  also	  shows	  that	  they	  can	  convert	  this	  PAI-­‐1	  to	  its	  active	  form	  and	  release	  it.71	  PAI-­‐1	  can	  act	  on	  t-­‐PA	  and	  active	  u-­‐PA,	  but	  cannot	  bind	  to	  inactive	  u-­‐PA.	  	  It	  follows	  a	  similar	  mechanism	  of	  inhibition	  as	  TAFI,	  with	  the	  quick	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formation	  of	  a	  reversible	  1:1	  complex,	  followed	  by	  a	  slow	  covalent	  linkage	  that	  permanently	  inactivates	  the	  PA.63	   	  
Additional	  Plasma	  Proteins	  Involved	  In	  Hemostasis	  
Von	  Willebrand	  Factor	  (vWF)	  Von	  Willebrand	  Factor	  (vWF)	  is	  present	  in	  a	  soluble	  form	  in	  the	  plasma,	  but	  is	  also	  present	  as	  a	  component	  of	  the	  subendothelial	  matrix.	  	  In	  the	  plasma	  it	  circulates	  in	  complex	  with	  FVIII,	  which	  protects	  it	  from	  catalysis	  by	  APC.	  	  Once	  thrombin	  activates	  FVIII	  the	  two	  molecules	  separate	  and	  vWF	  and	  FVIIIa	  move	  on	  to	  promote	  coagulation.72	  Matrix	  vWF	  is	  recognized	  by	  the	  platelet	  integrin	  GP	  Ib,	  and	  this	  interaction	  is	  the	  only	  adhesion	  reaction	  that	  works	  under	  high	  shear	  situations	  found	  in	  the	  arteries	  and	  arterioles.73	  Additionally	  vWF	  is	  able	  to	  fully	  support	  platelet	  aggregation	  through	  GPIIb/IIIa	  in	  the	  absence	  of	  fibrinogen.	  	  vWF	  shares	  a	  binding	  domain	  with	  fibrinogen	  (RGD	  domain)	  so	  they	  compete	  for	  binding.	  	  The	  concentration	  of	  fibrinogen	  is	  two	  orders	  of	  magnitude	  higher	  than	  vWF	  however,	  which	  causes	  most	  activated	  platelets	  to	  bind	  to	  fibrinogen	  and	  eventually	  end	  up	  incorporated	  to	  the	  fibrin	  clot.74,75	  Soluble	  vWF	  in	  the	  plasma	  also	  recognizes	  and	  binds	  to	  exposed	  components	  of	  the	  extracellular	  matrix,	  most	  notably	  collagen.76,77	  This	  allows	  for	  proper	  platelet	  recognition	  and	  attachment	  to	  any	  break	  or	  irregularity	  in	  the	  vasculature,	  regardless	  of	  the	  presence	  of	  subendothelial	  vWF.	  	  The	  platelet	  vWF	  interaction	  will	  be	  discussed	  more	  in	  depth	  later	  in	  this	  work.	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Thrombospondin	  
	   Thrombospondin	  (TSP)	  is	  an	  150,000	  Da	  adhesive	  glycoprotein	  that	  comprises	  a	  large	  portion	  of	  the	  platelet	  α-­‐granule.78	  TSP	  has	  been	  shown	  to	  bind	  to	  multiple	  platelet	  integrin	  receptors,	  vWF,	  collagen,	  plasminogen,	  fibrinogen,	  thrombin,	  fibrinectin,	  and	  multiple	  other	  molecules.72	  Both	  adhesive	  and	  anti-­‐adhesive	  properties	  have	  been	  reported,	  and	  it	  is	  also	  able	  to	  mediate	  cell	  apoptosis,	  angiogenesis,	  cell	  migration	  and	  tumor	  progression.79	  TSPs	  diverse	  array	  of	  biological	  functions	  may	  be	  attributed	  to	  its	  ability	  to	  bind	  multiple	  receptors	  simultaneously.78	  TSP	  also	  directly	  activates	  the	  platelet	  scavenger	  receptor	  CD36	  (GPIV).72	  
Vitronectin	  
	   Vitronectin	  is	  a	  75,000	  Da	  adhesive	  glycoprotein	  that	  participates	  in	  cell	  differentiation,	  complement	  assembly,	  and	  cell	  proliferation	  in	  addition	  to	  its	  role	  in	  platelet	  aggregation	  and	  adhesion.80,81	  Perhaps	  the	  most	  important	  role	  it	  plays	  in	  thrombosis	  is	  its	  ability	  to	  prevent	  fibrinolysis	  by	  binding	  to	  PAI-­‐1	  and	  allowing	  it	  to	  become	  incorporated	  into	  the	  platelet	  plug	  at	  the	  site	  of	  injury.72	  
Collagen	  
	   Collagen	  is	  not	  technically	  a	  plasma	  protein,	  but	  its	  effects	  on	  platelet	  activity	  and	  interactions	  with	  vWF	  warrant	  visitation	  of	  this	  protein	  further.	  	  There	  are	  25	  different	  types	  of	  collagen,	  representing	  up	  to	  40%	  of	  the	  total	  protein	  in	  the	  vessel	  wall.	  	  Collagen	  provides	  an	  attachment	  surface	  for	  the	  adhesion	  of	  vascular	  cells	  and	  attachment	  of	  matrix	  proteins.76	  Platelets	  are	  directly	  able	  to	  adhere	  to	  collagen	  types	  I,	  III,	  IV,	  V,	  and	  VI	  which	  comprise	  the	  majority	  of	  collagen	  in	  the	  vessel	  walls.82	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This	  adhesion	  is	  accomplished	  through	  a	  variety	  of	  integrin	  moieties,	  but	  is	  mainly	  accomplished	  through	  GPVI	  and	  the	  GPIb-­‐vWF	  complex.82,83	  	   Every	  form	  of	  collagen	  tested	  has	  been	  able	  to	  induce	  aggregation	  of	  stirred	  platelets	  in-­‐vitro,	  suggesting	  that	  all	  forms	  of	  collagen	  can	  induce	  platelet	  activation	  under	  appropriate	  conditions.82	  This	  ability	  to	  serve	  as	  both	  an	  adhesion	  molecule	  as	  well	  as	  potent	  activator	  makes	  collagen	  unique	  among	  the	  plasma	  proteins.	  
Thrombomodulin	  
	   Like	  collagen,	  thrombomodulin	  is	  not	  typically	  considered	  a	  plasma	  protein.	  	  Thrombomodulin	  is	  an	  endothelial	  cell	  protein	  that	  binds	  to	  thrombin	  and	  acts	  like	  a	  molecular	  switch,	  changing	  the	  enzyme’s	  role	  from	  prothrombotic	  to	  antithrombotic.63,65,84	  The	  ability	  of	  thrombin	  to	  activate	  protein	  C	  and	  other	  anticoagulant	  and	  fibrinolytic	  proteins	  when	  bound	  to	  thrombomodulin	  is	  approximately	  equal	  to	  that	  of	  unbound	  thrombin’s	  ability	  to	  cleave	  coagulant	  proteins.84	  
1.4	  Platelet	  Literature	  
Introduction	  The	  cell	  based	  model	  stresses	  the	  importance	  of	  platelet	  function	  in	  the	  clot	  formation.	  	  Platelets	  do	  more	  than	  just	  provide	  a	  surface	  for	  the	  assembly	  of	  enzymatic	  complexes.	  	  Activation	  of	  the	  coagulation	  system	  causes	  distinct	  responses	  including	  aggregation,	  secretion,	  shape	  change,	  and	  membrane	  rearrangement.	  	  To	  understand	  the	  complex	  response	  of	  platelets	  to	  the	  surrounding	  environment	  a	  detailed	  look	  at	  platelet	  signaling	  is	  required.	  	  Platelet	  response	  is	  based	  on	  both	  traditional	  receptor	  interactions	  as	  well	  as	  integrin	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interaction	  with	  extracellular	  matrix	  components	  (Figure	  1.11).	  	  These	  pathways	  normally	  function	  together	  in	  the	  physiological	  platelet	  response,	  with	  crosstalk	  and	  autocrine	  amplification	  pathways	  providing	  redundancy	  ensuring	  a	  robust	  platelet	  response.	  	  The	  pathways	  will	  be	  examined	  individually	  first	  to	  allow	  for	  identification	  of	  each	  individual	  component,	  and	  then	  the	  crosstalk	  will	  be	  examined	  allowing	  for	  a	  better	  understanding	  of	  the	  concerted	  platelet	  response.	  
Platelet	  Response	  
	   Platelets	  are	  the	  main	  functional	  cells	  in	  the	  hemostasis	  system.	  	  Unlike	  the	  protein	  coagulation	  system	  mentioned	  above,	  platelets	  are	  able	  to	  adapt	  to	  their	  environment	  and	  thus	  differentiate	  their	  response	  based	  on	  the	  signals	  they	  receive.	  	  Platelets	  can	  be	  induced	  to	  produce	  a	  variety	  of	  responses	  including	  shape	  change,	  secretion	  of	  their	  granule	  contents,	  aggregation	  with	  other	  cell	  types,	  adhesion	  to	  extracellular	  matrix	  components,	  membrane	  rearrangement,	  and	  microvesiculation.	  	  These	  responses	  are	  required	  for	  proper	  hemostasis	  and	  will	  be	  discussed	  further	  below.	  	  
Shape	  Change	  
	   In	  a	  step	  wise	  analysis	  of	  platelet	  activation	  the	  first	  response	  of	  the	  platelet	  is	  shape	  change.	  	  The	  normally	  disc	  shaped	  anucleate	  cells	  undergo	  a	  cytoskeletal	  rearrangement	  that	  causes	  them	  to	  become	  spheres	  and	  extend	  filopodia.85,86	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Figure	   1.11:	   	   Common	   Platelet	   Signaling	   Pathways.	   	   Figure	   depicts	   agonist	  stimulation	   of	   both	   G	   protein	   coupled	   receptors	   (top)	   and	   integrin	   receptors	  (bottom)	  and	   their	   respective	  main	  effectors.	  5-­‐HT;	   serotonin,	  TxA2;	   thromboxane	  A2,	  AC;	  adenylyl	  cyclase,	  ATP;	  adenosine	  triphosphate,	  ADP;	  adenosine	  diphosphate,	  AMP;	   adenosine	   monophosphate,	   cAMP;	   cyclic	   AMP,	   PI-­‐3-­‐K;	   phospoinositide	   3-­‐kinase,	  PLCγ2,	  phospholipase	  Cγ2,	  PLCβ;	  phospholipase	  Cβ.	  LAT;	  linker	  of	  activated	  T-­‐cells,	   Rho-­‐GEF;	   Rho	   guanine	   nucleotide	   exchange	   factor,	   PKC;	   protein	   kinase	   C,	  DAG;	   diacylglycerol,	   PIP2;	   phosphatidylinositol	   4,5-­‐bisphosphate,	   PIP3;	  phosphatidylinositol	   (3,4,5)-­‐trisphosphate,	   vWF;	   Von	   Willebrand	   factor,	   GPVI;	  glycoprotein	  VI.	  	  Adapted	  from	  Jennings	  2009.110	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Studies	  have	  shown	  that	  phosphorylation	  of	  the	  regulatory	  myosin	  light	  chain	  is	  required	  to	  initiate	  shape	  change.87	  The	  small	  GTP-­‐binding	  protein	  families	  Rho,	  Rac,	  and	  Cdc42	  have	  been	  implicated	  in	  platelet	  shape	  change.88	  These	  reactions	  have	  been	  shown	  to	  occur	  with	  or	  without	  Ca++	  mobilization,	  which	  is	  recognized	  as	  the	  final	  common	  response	  to	  all	  strong	  platelet	  agonists.89	  The	  individual	  small	  GTP	  binding	  protein	  involved	  in	  the	  shape	  change	  is	  dependent	  on	  the	  agonist	  used	  to	  elicit	  the	  response,	  and	  will	  be	  discussed	  in	  detail	  when	  examining	  the	  individual	  signaling	  pathways.	  
Secretion	  
	   Platelets	  have	  been	  shown	  to	  contain	  three	  separate	  types	  of	  granules	  (α,	  dense,	  and	  lysosomal),	  which	  upon	  stimulation	  they	  can	  secrete	  into	  their	  environment.	  	  The	  exact	  mechanism	  of	  platelet	  secretion	  has	  not	  been	  identified	  as	  of	  yet,	  but	  it	  is	  understood	  that	  the	  cytoskeletal	  remodeling	  involved	  in	  shape	  change	  causes	  centralization	  of	  the	  granules.	  	  A	  fusion	  event	  then	  allows	  the	  contents	  of	  the	  granules	  to	  exocytose.90	  α-­‐granules	  are	  thought	  to	  release	  their	  contents	  into	  the	  open	  canicular	  system	  on	  the	  surface	  of	  the	  platelets,	  where	  as	  dense	  granules	  fuse	  directly	  with	  the	  plasma	  membrane	  and	  allow	  for	  exocytosis	  of	  their	  contents.91	  Lysosomes	  are	  membrane	  bound	  vesicles	  and	  their	  role	  in	  coagulation	  is	  still	  poorly	  understood.90	  Similar	  lysosomes	  in	  other	  cell	  types,	  they	  are	  believed	  to	  have	  a	  cellular	  degradation	  purpose,	  as	  well	  as	  possible	  an	  immune	  function	  inside	  platelets.92,93	  The	  contents	  in	  the	  individual	  granules	  can	  be	  found	  in	  Table	  1.2.94	  Secretion	  allows	  for	  autocrine	  and	  paracrine	  signaling	  by	  the	  platelets,	  as	  well	  as	  expression	  of	  new	  surface	  markers	  and	  adhesion	  molecules.	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Table	  1.2:	  Platelet	  Granule	  Contents	  
	  Adapted	  from	  McNicole	  and	  Israels	  1999.94	  	   	  
Table 1. Platelet granule contents
Alpha granulesa Dense granules Lysosomal granulesb
Albumin Serotonin Cathepsin D
Fibrinogen ATP Cathepsin E
Fibronectin ADP Carboxypeptidase A
Vitronectin Calcium Carboxypeptidase B
Osteonectin Pyrophosphate Proline carboxypeptidase
von Willebrand factor !-N-acetyl-d-hexosaminidase
von Willebrand antigen II !-d-glucuronidase
Thrombospondin !-d-galactosidase
Platelet factor 4 "-d-mannosidase
IgG, IgA, IgM "-l-arabinofuranosidase
C1 inhibitor "-d-galactosidase
Plasminogen "-l-fucosidase
Plasminogen activator inhibitor-1 !-d-fucosidase
Platelet-derived collagenase inhibitor !-d-glucosidase
High molecular weight kininogen "-d-glucosidase








Connective tissue-activating protein III
Neutrophil-activating protein II
Platelet-derived growth factor
Transforming growth factor !-
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Aggregation/	  Adhesion	  
	   Platelet	  aggregation	  and	  adhesion	  can	  be	  viewed	  together	  as	  they	  are	  similar	  processes.	  	  Both	  are	  mediated	  by	  integrin	  binding,	  but	  are	  spatially	  dependent.	  	  Aggregation	  occurs	  when	  platelets	  attach	  themselves	  to	  other	  circulating	  platelets	  or	  cell	  types.	  	  While	  platelet-­‐white	  blood	  cell	  aggregates	  have	  been	  identified,	  for	  the	  purpose	  of	  hemostasis	  the	  platelet-­‐platelet	  aggregation	  response	  is	  more	  physiologically	  involved.	  	  Adhesion	  is	  the	  process	  by	  which	  platelets	  become	  attached	  to	  an	  immobile	  surface,	  such	  as	  exposed	  collagen	  of	  vWF	  at	  the	  site	  of	  injury.	  	  As	  discussed	  previously	  platelet	  attachment	  to	  collagen	  and	  vWF	  is	  mediated	  mainly	  through	  the	  GP	  Ib-­‐IX-­‐V	  complex,	  and	  this	  complex	  will	  be	  reviewed	  in	  depth	  in	  the	  integrin	  section.82,83	  Platelet	  aggregation	  occurs	  through	  the	  activated	  GP	  IIb/IIIa	  integrin,	  and	  this	  interaction	  will	  be	  discussed	  in	  more	  detail	  during	  the	  integrin	  review	  as	  well.95,96	  
Exposure	  of	  Pro-­‐Coagulant	  Membrane	  Surfaces	  
	  	   The	  availability	  of	  a	  phospholipid	  surface	  to	  allow	  for	  the	  assembly	  of	  the	  tenase	  and	  prothrombinase	  complexes	  is	  a	  vital	  for	  proper	  hemostatic	  function.	  	  While	  this	  assembly	  can	  happen	  at	  the	  site	  of	  injury	  in	  TF	  bearing	  cells,	  this	  local	  extrinsic	  response	  is	  unable	  to	  provide	  an	  adequate	  response	  to	  allow	  for	  the	  propagation	  of	  a	  clot.	  	  The	  ability	  of	  platelets	  to	  rearrange	  their	  membranes	  to	  expose	  PS	  in	  response	  to	  activation	  allows	  them	  to	  act	  like	  a	  template	  for	  assembly	  of	  the	  coagulation	  complexes	  further	  away	  from	  the	  actual	  immediate	  site	  of	  injury.97	  The	  identification	  of	  a	  platelet	  population	  that	  exposes	  high	  amounts	  of	  PS	  after	  dual	  stimulation	  with	  thrombin	  and	  collagen	  have	  been	  termed	  COAT	  or	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coated	  platelets,	  and	  appear	  as	  a	  subpopulation	  of	  the	  entire	  platelet	  pool.97,98	  They	  show	  not	  only	  increased	  binding	  of	  Annexin	  V,	  but	  also	  binding	  of	  coagulation	  factors,	  serotonin,	  and	  fibrinogen.	  	  Interestingly	  these	  coated	  platelets	  will	  not	  bind	  to	  the	  PAC-­‐1	  antibody	  used	  to	  detect	  GP	  IIb/IIIa	  activation,	  although	  normally	  the	  binding	  affinity	  for	  PAC-­‐1	  is	  orders	  of	  magnitude	  higher	  for	  the	  integrin,	  allowing	  it	  to	  displace	  fibrinogen.98,99	  	  	  	  	  	  	   In	  platelets	  the	  rearrangement	  of	  the	  lipid	  membrane	  is	  accomplished	  in	  three	  separate	  systems	  (Figure	  1.12).	  Two	  of	  the	  systems	  are	  considered	  to	  be	  responsible	  for	  the	  steady	  state	  maintenance	  of	  the	  asymmetric	  phospholipid	  composure	  of	  resting	  platelets.	  	  A	  third	  system	  is	  responsible	  for	  the	  rapid	  breakdown	  of	  this	  symmetry	  and	  exposure	  of	  PS	  and	  PE	  on	  the	  platelet	  membrane	  in	  response	  to	  activation.14	  	  	  	  	  	  Steady	  state	  membrane	  maintenance	  is	  accomplished	  through	  two	  separate	  enzymes.	  	  Aminophospholipid	  translocase	  is	  a	  PS	  and	  PE	  specific	  translocase	  that	  transports	  these	  lipids	  against	  a	  gradient	  from	  the	  outer	  membrane	  to	  the	  inner	  membrane	  leaflet.	  	  This	  enzyme	  is	  ATP	  dependent	  and	  inhibited	  by	  Ca2+.51	  To	  balance	  the	  action	  of	  the	  translocase	  a	  slow	  acting	  and	  yet	  unidentified	  floppase	  is	  postulated	  to	  be	  responsible	  for	  the	  outward	  non-­‐specific	  transport	  of	  phospholipids	  to	  the	  outer	  membrane	  from	  the	  inner	  leaflet.	  51	  Due	  to	  the	  slow	  acting	  nature	  of	  both	  these	  processes	  it	  is	  unlikely	  they	  are	  able	  to	  respond	  to	  platelet	  activation,	  and	  elevated	  intracellular	  Ca2+	  levels	  associated	  with	  the	  activation	  response	  likely	  would	  inhibit	  their	  activity.	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Figure	   1.12:	   Enzymes	   Responsible	   for	   Platelet	   Membrane	   Rearrangement.	  	  Floppase	  is	  also	  commonly	  referred	  to	  as	  translocase.	  	  ATP;	  adenosine	  triphosphate.	  Adapted	  from	  Zwaal	  2004.16	  	  	  
	  
Figure	  1.13:	  	  Microvesicle	  Generation	  in	  Platelets.	  	  Translocase	  is	  often	  referred	  to	   as	   floppase.	   	   ATP;	   adenosine	   triphosphate,	   ADP;	   adenosine	   diphosphate,	   PS;	  phosphotidylserine.	  	  Adapted	  from	  Zwaal	  and	  Schroit	  1997.51	  	   	  
ZWAAL AND SCHROIT1122
Fig 1. The regulation and physiology of membrane phospholipid asymmetry. This model describes howmembrane phospholipid asymmetry
is generated, maintained, and perturbed as a prerequisite to various phosphatidylserine-related pathophysiologies. Membrane lipid asymmetry
is regulated by the cooperative activities of three transporters. The ATP-dependent aminophospholipid-specific translocase, which rapidly
transports PS and PE from the cell’s outer-to-inner leaflet; the ATP-dependent nonspecific lipid floppase, which slowly transports lipids from
the cell’s inner-to-outer leaflet; and the Ca2"-dependent nonspecific lipid scramblase, which allows lipids to move randomly between both
leaflets. The model predicts that the translocases are targets for Ca2" that directly regulates the transporter’s activities. The figure shows that
elevated intracellular Ca2" induces PS randomization across the cell’s plasma membrane by providing a stimulus that positively and negatively
regulates scramblase and translocase activities, respectively. At physiologic Ca2" concentrations, PS asymmetry is promoted because of an
active translocase and floppase but inactive scramblase. Depending on the type of cell, elevated intracellular Ca2" levels can be achieved by
cellular activation that generally results in the concomitant influx and accumulation of extracellular Ca2" and by its release from intracellular
stores. Increased cytosolic Ca2" can also result in calpain activation, which facilitates membrane blebbing and the release of PS-expressing
procoagulant microvesicles. Exposure of PS at the cell’s outer leaflet. The appearance of PS at the cell’s outer leaflet promotes coagulation
and thrombosis by providing a catalytic surface for the assembly of the prothrombinase and tenase (not shown) complexes and marks the
cell as a pathologic target for elimination by phagocytes. Recognition of the PS-expressing targets can occur by both antibody-dependent and
direct receptor-mediated pathways. (Aminophospholipids are shown with red polar headgroups and cholinephospholipids with blue polar
headgroups, see cover photo; b2-Gp, b2-glycoprotein-I; rec, receptor).
outer leaflet upon the addition of Mg2/-ATP, suggesting that sette (ABC) family of proteins to which the aminophospholipid
translocase might belong.41,42this ATPase is responsible for aminophospholipid translocation.
However, it was recently reported that, similar to previous Aminophospholipid translocase activity has been ob-
served in other membranes, including intracellular chromaf-purification strategies,33 the active fraction was not homogenous
and contained several proteins ranging from 35 kD to 120 kD.36 fin granule membranes43 and endoplasmatic reticulum.44 Ac-
tivity has also been shown in various cells,31,45-50 includingThese observations preclude assignment of the transporter to a
single protein and are not inconsistent with studies implicating endothelial cells, in which its expression is regulated by
basic fibroblast growth factor.51 Mutants defective in PSthe involvement of a 30-kD to 32-kD band 7 transmembrane
polypeptide in aminophospholipid transport.28,37,38 This protein, transport have been isolated.52
ATP-dependent floppase. Another ATP-dependent trans-which may be complexed to Rh polypeptides, was preferen-
tially labeled in erythrocyte membranes with a photoactivatable locating activity has been described that, in conjunction with
the aminophospholipid translocase, may regulate the differ-PS analog only under conditions conducive to PS trans-
port.25,39,40 Consistent with these observations, aminophospho- ential transbilayer orientation of phospholipids in complex
biologic membranes. A less specific ATP-requiring floppase,lipid transport activity was suggested to require the coordinated
and complimentary participation of a Mg2/-ATPase and a 32- first discovered in red blood cells, transports both amino-
phospholipids and cholinephospholipids from the inner tokD protein,16 a motif not uncommon for the ATP-binding cas-
AID Blood 0036 / 5h2e$$$701 01-16-97 17:35:39 blda WBS: Blood
 For personal use only. at VA COMM UNIV on April 14, 2013. bloodjournal.hematologylibrary.orgFrom 
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  The	  third	  system	  is	  fast	  acting,	  bi-­‐directional,	  and	  activated	  by	  Ca2+.50	  This	  system	  is	  regulated	  by	  the	  enzyme	  “scramblase”	  although	  the	  random	  nature	  of	  the	  term	  does	  not	  actually	  reflect	  a	  random	  system.100	  It	  is	  this	  system	  that	  is	  believed	  by	  many	  groups	  o	  be	  responsible	  for	  the	  rapid	  translocation	  of	  PS	  to	  the	  platelet	  outer	  membrane,	  allowing	  for	  assembly	  of	  the	  factor	  complexes.	  
Microvesiculation	  The	  formation	  of	  microparticles	  (MP)	  is	  also	  associated	  with	  the	  platelet	  activation	  response.	  	  These	  resulting	  small	  phospholipid	  microvesicles	  have	  a	  membrane	  skeleton	  and	  are	  capable	  of	  expressing	  cell	  surface	  receptors	  and	  antigens.101	  MPs	  are	  generally	  defined	  as	  having	  a	  general	  size	  range	  of	  0.1-­‐1.0	  μm	  in	  diameter,	  however	  can	  be	  found	  as	  large	  as	  1.5	  μm	  and	  as	  small	  as	  40-­‐80	  nm.102	  Many	  other	  cell	  types	  are	  also	  capable	  of	  producing	  MPs,	  however	  70-­‐90%	  of	  all	  circulating	  MPs	  (cMPs)	  originate	  from	  platelets	  (pMPs).103	  These	  pMPs	  have	  been	  shown	  to	  enhance	  platelet	  deposition	  and	  thrombus	  formation	  both	  in	  healthy	  individuals	  as	  well	  as	  those	  with	  cardiovascular	  atherothrombotic	  disease.104	  A	  diagram	  of	  this	  process	  can	  be	  found	  in	  Figure	  1.13.16	  
Platelet	  Signaling	  
Integrin	  signaling	  Adhesive	  proteins	  expressed	  on	  the	  platelet	  surface	  not	  only	  act	  as	  adhesion	  molecules	  for	  the	  physiological	  adhesion	  and	  aggregation	  response	  but	  can	  also	  participate	  in	  both	  outside-­‐in	  and	  inside-­‐out	  signaling.	  	  All	  integrins	  contain	  an	  α	  subunit	  and	  a	  β subunit.	  	  In	  platelets	  there	  are	  two	  β	  subunits	  expressed,	  β2	  and	  β3.	  	  These	  subunits	  are	  associated	  with	  various	  a	  subunits.105	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Each	  subunit	  protein	  has	  a	  large	  extracellular	  domain,	  single	  transmembrane	  domain,	  and	  intracellular	  domain.	  	  The	  ligand	  recognition	  and	  binding	  pocket	  is	  formed	  by	  the	  extracellular	  domains	  of	  both	  subunits.106 In	  most	  cases	  a	  divalent	  cation	  presence	  (either	  Mg2+	  or	  Ca2+)	  is	  required	  to	  maintain	  the	  ligand	  binding	  site.107  	  	   The	  arginine-­‐glycine-­‐aspartic	  acid	  motif	  (RGD)	  is	  the	  recognition	  site	  for	  ligand	  binding	  to	  integrins,	  and	  they	  bind	  a	  variety	  of	  soluble	  molecules	  as	  well	  as	  extracellular	  matrix	  proteins.74,108	  Integrins	  present	  on	  the	  platelet	  surface	  and	  their	  ligands	  can	  be	  found	  in	  Table	  1.3.	  
The	  αIIbβ3	  Integrin	  (GP	  IIb/IIIa)	  The	  αIIbβ3	  integrin	  (GP	  IIb/IIIa)	  is	  the	  most	  abundant	  protein	  expressed	  on	  the	  platelet	  surface,	  and	  accounts	  for	  roughly	  17%	  of	  the	  total	  protein	  composition	  of	  the	  platelet	  membrane.96	  This	  integrin	  is	  commonly	  referred	  to	  as	  the	  fibrinogen	  receptor,	  and	  is	  responsible	  for	  the	  platelet-­‐platelet	  aggregation	  response.	  	  This	  integrin	  can	  participate	  in	  both	  inside-­‐out	  as	  well	  as	  outside	  in	  signaling.109	  While	  fibrinogen	  is	  the	  main	  ligand	  for	  GP	  IIb/IIIa,	  the	  integrin	  has	  also	  been	  shown	  to	  recognize	  vWF,	  fibrinectin,	  vitronectin,	  thrombospondin,	  collagen,	  PECAM-­‐1,	  prothrombin,	  serum	  amyloid	  A,	  and	  CD40L.	  	  It	  should	  be	  noted	  that	  these	  ligands	  may	  be	  involved	  with	  the	  adhesion	  response,	  but	  are	  not	  able	  to	  support	  platelet-­‐	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Table	  1.3:	  Common	  Platelet	  Integrins,	  Their	  Ligands,	  and	  Function.	  
	  GP;	  glycoprotein.	  	  Adapted	  from	  Jennings	  2009.110	  	   	  
GP Receptor Ligand Biologic Function
GP Ia/IIa (!2"1, VL2-
A)
Collagen Adhesion
GP Ib/IX/V von Willebrand factor Adhesion
GP Ic/IIa (!5"1) Fibronectin Adhesion, stabilizing
GP Ia/IIa
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platelet	  aggregation.105	  In	  fact	  it	  has	  been	  shown	  that	  these	  alternate	  ligands	  may	  have	  an	  inhibitory	  effect	  on	  the	  platelet	  aggregation	  response.105	  	  	  	   Once	  bound	  to	  ligand	  GP	  IIb/IIIa	  undergoes	  a	  conformational	  change	  initiating	  outside-­‐in	  signaling.	  	  This	  conformational	  change	  allows	  the	  β3	  subunit	  to	  bind	  to	  the	  G	  protein	  α13	  subunit	  inside	  the	  cytoplasm.111	  This	  interaction	  activates	  Src	  family	  kinases	  (SFKs),	  with	  the	  main	  effector	  being	  c-­‐Src.112	  c-­‐Src	  moves	  forward	  to	  activate	  PLCγ resulting	  in	  the	  increase	  of	  IP3	  and	  resultant	  increase	  in	  intracellular	  calcium	  mobilization.110	  
The	  GP	  Ib-­‐IX-­‐V	  Complex	  The	  complex	  of	  GP	  Ib-­‐IX-­‐V	  complex	  serves	  as	  a	  major	  adhesive	  receptor	  on	  the	  platelet	  surface.	  	  It	  is	  composed	  of	  four	  separate	  glycoproteins,	  GP	  Ibα,	  GP	  Ibβ,	  GP	  IX,	  and	  GP	  V.	  113	  	  This	  receptor	  complex	  is	  vital	  to	  proper	  platelet	  function	  due	  to	  the	  fact	  it	  is	  able	  to	  mediate	  adhesion	  under	  high	  sheer	  via	  interactions	  with	  vWF.	  	  Sheer	  rates	  vary	  greatly	  between	  veins,	  large	  arteries,	  arterioles,	  and	  stenotic	  vessels	  (Table	  1.4).114	  	  The	  GP	  Ib-­‐IX-­‐V	  complex	  is	  constitutively	  expressed	  on	  the	  surface	  of	  the	  platelet	  at	  around	  25,000	  copies	  per	  cell.115	  Structurally	  it	  is	  composed	  of	  four	  distinct	  glycoprotein	  subunits.	  	  GP	  Ibα and	  GP	  Ibβ	  subunits	  are	  linked	  via	  a	  disulfide	  bond,	  and	  then	  non-­‐covalently	  associated	  with	  GP	  IX	  and	  GP	  V.	  	  These	  subunits	  maintain	  a	  stoichiometric	  ratio	  of	  2:2:2:1.116	  It	  has	  been	  shown	  that	  the	  GP	  Ib-­‐IX-­‐V	  complex	  is	  found	  to	  be	  enriched	  in	  lipid	  rafts	  on	  the	  platelet	  membrane,	  and	  that	  after	  stimulation	  more	  of	  the	  complex	  is	  recruited	  to	  the	  rafts	  to	  increase	  signaling	  potential.117	  Improper	  expression	  of	  the	  subunits	  GP	  Ibα,	  GP	  Ibβ,	  and	  GP	  IX	  have	  	  






	  	  	   	  
Table1.4:	  Typical	  Range	  of	  Wall	  Shear	  Rates.	  	  
Assuming	  a	  viscosity	  of	  0.038	  Poise.	  	  Adapted	  from	  Kroll	  1996.	  60	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  been	  found	  to	  cause	  the	  hereditary	  Bernard-­‐Soulier	  syndrome.118	  The	  process	  by	  which	  GP	  Ib-­‐IX-­‐V	  mediates	  adhesion	  under	  high	  shear	  rates	  involves	  engagement	  of	  GP	  Ibα	  to	  the	  A1	  binding	  sites	  on	  vWF.	  	  vWF	  is	  bound	  to	  collagen	  at	  the	  site	  of	  vascular	  injury	  through	  its	  A3	  binding	  sites.	  	  The	  binding	  of	  vWF	  to	  collagen	  at	  high	  shear	  causes	  a	  stretching	  of	  the	  vWF	  protein,	  this	  exposing	  the	  A1	  binding	  sites.119	  The	  interaction	  with	  vWF	  has	  a	  high	  disassociation	  rate	  but	  causes	  a	  significant	  slowing	  of	  platelet	  movement	  allowing	  for	  the	  engagement	  of	  the	  GP	  IIb/IIIa	  receptor	  to	  the	  RGD	  domain	  of	  vWF.120	  After	  receptor	  engagement	  with	  vWF	  a	  number	  of	  intracellular	  events	  mediate	  the	  outside-­‐in	  signaling	  (Figure	  1.14).	  	  The	  cytoplasmic	  tails	  of	  the	  complex	  interact	  with	  a	  number	  of	  intracellular	  proteins	  in	  a	  resting	  state	  including	  actin	  binding	  protein	  (ABP),	  filamin	  A,	  14-­‐3-­‐3ζ,	  and	  calmodulin.113,121–123	  ABP	  has	  been	  shown	  to	  be	  required	  for	  maintaining	  the	  binding	  of	  the	  receptor	  complex	  under	  high	  shear	  as	  well	  as	  platelet	  slowing	  and	  rolling	  along	  vWF.124–126	  Filamin	  A	  interactions	  also	  help	  link	  the	  adhesion	  receptor	  complex	  to	  the	  cytoskeleton.127	  Loss	  of	  any	  of	  these	  cytoskeletal-­‐binding	  proteins	  negatively	  impacts	  the	  platelet’s	  ability	  to	  bind	  to	  vWF	  under	  high	  shear	  and	  loss	  of	  intracellular	  signaling.	  14-­‐3-­‐3ζ	  protein	  is	  associated	  with	  the	  cytoplasmic	  region	  of	  the	  receptor,	  but	  its	  activation	  causes	  different	  effects	  depending	  on	  its	  spatial	  location	  on	  the	  intracellular	  domain	  (Figure	  1.14).	  	  14-­‐3-­‐3ζ	  can	  associate	  with	  GP	  Ibα,	  GP	  Ibβ,	  and	  GP	  V.113	  Binding	  of	  14-­‐3-­‐3ζ to	  the	  GP	  Ib	  integrins	  is	  cooperative,	  with	  association	  of	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Figure	  1.14:	  The	  Platelet	  GP	  Ib-­‐IX-­‐V	  complex	  A)	  Model	  of	  GP	  Ib-­‐IX	  Complex.	  B)	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the	  protein	  with	  one	  subunit	  increasing	  the	  association	  of	  the	  protein	  with	  the	  other	  subunit.129	  This	  association	  has	  been	  shown	  to	  be	  a	  result	  of	  phosphorylation	  of	  14-­‐3-­‐3ζ	  by	  protein	  kinase	  A	  (PKA)	  and	  negatively	  regulates	  the	  ability	  of	  the	  receptor	  to	  bind	  to	  vWF.121	  Alternately	  14-­‐3-­‐3ζ	  can	  also	  associate	  with	  the	  cytoplasmic	  domain	  of	  GP	  V	  in	  resting	  platelets.113	  This	  association	  level	  increases	  when	  the	  platelets	  are	  stimulated	  with	  vWF.	  	  Signal	  transduction	  through	  14-­‐3-­‐3ζ	  is	  accomplished	  via	  activation	  of	  tyrosine	  kinases	  Syk,	  FAK,	  and	  Pyk2	  as	  well	  as	  activation	  of	  PI3K	  and	  subsequently	  PLCγ.130–133	  It	  has	  also	  been	  found	  that	  vWF	  interaction	  with	  GP	  Ib-­‐IX-­‐V	  induces	  phosphorylation	  of	  the	  immunoreceptor	  tyrosine-­‐based	  activation	  motif	  (ITAM)	  containing	  receptors	  FcγRIIA	  and	  FcR	  γ-­‐chain.128,134,135	  ITAM	  signaling	  proceeds	  through	  Syk	  to	  initiate	  an	  intracellular	  tyrosine	  kinase	  cascade	  that	  will	  be	  addressed	  when	  the	  receptors	  are	  looked	  at	  individually.	  	  These	  ITAM	  receptors	  are	  most	  commonly	  known	  for	  their	  requirement	  for	  competent	  GP	  VI	  –	  collagen	  signaling,	  but	  it	  has	  been	  demonstrated	  that	  vWF	  alone	  is	  able	  to	  initiate	  this	  signaling	  pathway	  in	  platelets.128	  The	  final	  outcome	  from	  ITAM	  mediated	  signaling	  is	  TXA2	  generation	  and	  GP	  IIb/IIIa	  activation	  (Figure	  1.14).113	  While	  vWF	  is	  the	  main	  physiological	  ligand	  for	  the	  GP	  Ib-­‐IX-­‐V	  complex,	  it	  also	  interacts	  with	  multiple	  other	  ligands.	  	  Thrombin,	  thrombospondin-­‐1,	  factors	  XI	  and	  XII,	  high	  molecular	  weight	  kininogen,	  MAC-­‐1,	  and	  P-­‐selectin	  all	  have	  been	  shown	  to	  interact	  with	  the	  extracellular	  N-­‐terminal	  domain	  of	  GP	  Ibα.113	  Thrombospondin-­‐1,	  and	  P-­‐selectin	  binding	  are	  implicated	  in	  the	  platelet	  adhesion	  response.29	  MAC-­‐1	  binding	  is	  responsible	  for	  platelet	  clearance	  seen	  in	  chilled	  platelet	  administration	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by	  leukocytes.136,137	  Factors	  XI	  and	  XII	  as	  well	  as	  kininogen	  bind	  to	  the	  complex	  when	  localized	  to	  lipid	  rafts	  after	  activation	  of	  the	  platelets	  by	  thrombin.26,27	  	  	  Perhaps	  the	  most	  interesting	  role	  of	  the	  GP	  Ib-­‐IX-­‐V	  complex	  involves	  its	  interaction	  with	  thrombin.	  	  It	  has	  been	  shown	  that	  thrombin	  binding	  to	  the	  complex	  induces	  adhesion,	  aggregation,	  and	  secretion.138	  While	  it	  was	  originally	  assumed	  that	  thrombin	  binding	  was	  responsible	  for	  the	  platelet	  response,	  it	  is	  now	  believed	  that	  GP	  Ib	  binds	  thrombin	  and	  presents	  it	  to	  the	  PAR1	  receptor	  to	  allow	  activation	  at	  low	  concentrations	  of	  thrombin.139	  This	  model	  implicates	  GP	  Ib	  as	  a	  catalytic	  cofactor,	  forming	  a	  ternary	  complex	  with	  PAR-­‐1	  and	  thrombin.140	  It	  has	  been	  shown	  that	  the	  interaction	  between	  GP	  Ib	  and	  thrombin	  occurs	  after	  cleavage	  of	  GP	  V	  from	  the	  receptor	  complex	  by	  the	  protease	  activity	  of	  activated	  thrombin.140	  This	  interaction	  mimics	  the	  action	  of	  the	  PAR3	  and	  PAR4	  interaction	  seen	  in	  murine	  platelets	  at	  low	  thrombin	  concentrations.	  
GP	  VI	  	  	   GP	  VI	  is	  the	  main	  collagen	  receptor	  found	  on	  platelets.	  It	  is	  a	  60,000	  Da	  glycoprotein	  that	  belongs	  to	  the	  immunoglobulin	  superfamily.141	  It	  has	  two	  extracellular	  immunoglobulin	  like	  domains,	  a	  mucin	  like	  core,	  a	  transmembrane	  domain,	  and	  short	  cytoplasmic	  tail	  that	  associates	  with	  FcRγ-­‐chain	  through	  a	  salt	  bridge	  (reviewed	  by	  Surin).142	  Once	  bound	  to	  collagen	  the	  initial	  step	  in	  activation	  involves	  the	  recruitment	  of	  Fyn	  and	  Lyn	  allows	  for	  the	  activation	  of	  the	  immunoreceptor	  tyrosine	  based	  motif	  on	  the	  FcRγ-­‐chain.143	  As	  depicted	  in	  Figure	  1.15	  this	  activation	  allows	  for	  the	  recruitment	  SLP76	  144,	  multiple	  Syk	  and	  Rho	  kinases	  (Gab2,	  Vav,	  Grb2,	  and	  Rho)145,	  and	  activation	  of	  the	  membrane	  bound	  linker	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Figure	   1.15:	   Signaling	   Events	   Following	   GP	   VI	   Ligand	   Activation.	   	   CVX;	  convulxin,	   CRP;	   collagen	   reactive	   protein,	   TXA2;	   thromboxane	  A2,	   cPLA2;	   cytosolic	  phospholipase	  A2,	  ABP;	  actin	  binding	  protein,	  PKC;	  protein	  kinase	  C,	  MLCK;	  myosin	  light	   chain	   kinase	   PLCγ2;	   phospholipase	   Cγ2,	   cGMP;	   cyclic	   guanosine	  monophosphate,	   DAG;	   diacylglycerol,	   IP3;	   inositol	   trisphosphate,	   PI3K;	  phospoinositide	  3-­‐kinase,	   ITAM;	   immunoreceptor	   tyrosine	  based	  motif	  LAT;	   linker	  of	   activated	   T-­‐cells,	   PKC;	   protein	   kinase	   C,	   DAG;	   diacylglycerol,	   PIP2;	  phosphatidylinositol	   4,5-­‐bisphosphate,	   PIP3;	   phosphatidylinositol	   (3,4,5)-­‐trisphosphate	  Adapted	  from	  Surin	  2008.	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for	  activation	  of	  T-­‐cells	  (LAT).	  	  This	  results	  in	  activation	  of	  PI3	  kinase,	  PLCγ,	  and	  generation	  of	  IP3	  and	  DAG.146	  This	  results	  in	  the	  final	  pathway	  of	  intracellular	  Ca++	  release,	  cPLA2	  activation147,	  and	  thromboxane	  A2	  generation.	  	  	  Combined	  signaling	  through	  the	  TxA2	  receptor	  and	  increased	  intracellular	  Ca++	  concentration	  allow	  for	  the	  activation	  of	  GP	  IIb/IIIa	  and	  exposure	  of	  pro-­‐coagulant	  membrane	  surfaces	  (Figure	  1.16),	  elucidating	  a	  complete	  activation	  of	  the	  platelet	  (Reviewed	  by	  Surin).142	  
G	  Protein	  Coupled	  Receptor	  Signaling	  Pathways	  	  	  	  	  	  	   A	  large	  portion	  of	  the	  platelet’s	  response	  to	  its	  environment	  is	  through	  G	  protein	  coupled	  receptors	  (GPCRs.)	  GPCRs	  are	  the	  largest	  family	  of	  proteins	  in	  the	  human	  genome.	  	  	  Activation	  of	  GPCRs	  can	  be	  accomplished	  through	  a	  variety	  of	  ligands	  including	  amines,	  lipids,	  peptides,	  ions,	  nucleotides,	  or	  proteases.148	  This	  agonist	  diversity	  allows	  GPCR	  signaling	  in	  platelets	  to	  respond	  to	  a	  variety	  of	  soluble	  ligands,	  and	  Figure	  1.17	  depicts	  the	  currently	  identified	  GCPRs	  in	  platelets	  as	  well	  as	  their	  physiological	  ligands.	  149	  GCPRs	  transduce	  their	  signals	  through	  heterotrimeric	  guanine	  nucleotide-­‐binding	  proteins	  (G	  proteins.)	  	  G	  proteins	  are	  composed	  of	  α,	  β,	  and	  γ	  subunits,	  and	  act	  in	  a	  molecular	  switching	  fashion.	  	  α subunits	  can	  be	  classified	  into	  four	  subfamilies:	  Gs,	  Gi,	  Gq,	  and	  G12/13.150–152	  as	  part	  of	  the	  activation	  process	  the	  G	  protein	  cycles	  through	  an	  inactive	  GDP	  bound	  state,	  and	  an	  active	  GTP	  bound	  state.	  	  151	  Upon	  ligand	  engagement	  a	  conformational	  change	  induced	  in	  the	  GPCR	  allows	  it	  to	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Figure	   1.16:	   Final	   Results	   of	   Collagen	   GP	   VI	   signaling.	   	   CVX;	   convulxin,	   CRP;	  collagen	   reactive	   protein,	   TxA2;	   thromboxane	   A2,	   PE;	   phosphatidylethanolamine,	  PS;	  phosphatidylserine.	  Adapted	  from	  Surin	  2008.142	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Figure	   1.17:	   	   Currently	   Identified	   G	   Protein	   Coupled	   Receptors	   and	   Their	  
Ligands.	   	   ADP;	   adenosine	   di-­‐phosphate,	   5-­‐HT;	   serotonin,	   LPA;	   lysophosphatidic	  acid,	   PAR;	   protease	   activated	   receptor,	   PGI2;	   prostacyclin,	   PGE3;	   prostaglandin	   E3.	  	  	  	  Adapted	  from	  Amisten	  2007.153	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facilitate	  a	  GDP-­‐GTP	  exchange	  reaction	  on	  the	  α	  subunit.	  	  Once	  bound	  to	  GTP	  the	  
α subunit	  disassociates	  from	  the	  βγ	  dimer,	  and	  then	  both	  continue	  to	  transmit	  their	  signals	  downstream.	  149–151,154	  	  	  	  	  	  	  	   The	  α	  subunit	  contains	  an	  intrinsic	  hydrolysis	  activity,	  but	  this	  activity	  is	  greatly	  increased	  by	  the	  binding	  of	  GTPase-­‐activating	  proteins	  (GAPs)	  such	  as	  regulator	  of	  GTPase-­‐activating	  signaling	  (RGS)	  proteins.	  	  GAPs	  bind	  to	  the	  switching	  regions	  of	  the	  α subunit,	  greatly	  increasing	  its	  hydrolysis	  activity.	  After	  hydrolysis	  the	  GDP	  bound	  α subunit	  re-­‐associates	  to	  the	  βγ subunit	  and	  can	  recouple	  to	  a	  receptor,	  allowing	  for	  another	  round	  of	  signaling.151	  Due	  to	  the	  fact	  that	  each	  receptor	  activation	  event	  results	  in	  activation	  of	  a	  βγ subunit,	  there	  is	  a	  level	  of	  commonality	  to	  the	  signaling	  response.	  	  Receptor	  activation	  also	  results	  in	  activation	  of	  one	  of	  four	  α subunit	  species,	  which	  vary	  between	  receptors.	  
149,151,154,155	  These	  individual	  species	  regulate	  a	  variety	  of	  platelet	  activation	  and	  inhibition	  responses	  through	  both	  distinct	  and	  cooperative	  pathways.	  
G	  Protein	  βγ  Subunits	  G	  Protein	  βγ Subunits	  (Gβγ)	  once	  activated	  move	  across	  the	  membrane	  to	  activate	  Phosphoinositide	  3-­‐kinase	  (PI3K.)155	  PI3K	  phosphorylates	  the	  membrane	  component	  phosphatidylinositol	  4,5-­‐bisphosphate	  (PIP2),	  generating	  phosphatidylinositol	  3,4,5-­‐triphosphate	  (PIP3).	  	  PIP3	  acts	  as	  a	  lipid	  second	  messenger	  that	  activates	  exchange	  factors	  for	  Rho	  family	  GTPases	  as	  well	  as	  protein	  kinase	  B	  (PKB/Akt).	  	  156	  Rho	  GTPases	  are	  highly	  involved	  in	  multiple	  pathways	  of	  platelet	  shape	  change,	  integrin	  inside	  out	  signaling,	  and	  secretion.	  	  157	  PKB	  has	  been	  the	  subject	  of	  some	  controversy.	  	  One	  downstream	  effector	  of	  activated	  PKB	  is	  Rap1.	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158	  It	  has	  been	  shown	  however	  that	  PKB	  can	  be	  activated	  independently	  of	  PKB	  in	  
vitro	  in	  platelets,	  suggesting	  that	  more	  than	  one	  pathway	  for	  PKB	  activation	  may	  be	  present.	  159	  It	  has	  been	  shown	  however	  that	  PKB	  activation	  in	  platelets	  is	  dependent	  on	  Gαi	  coupled	  signaling.160	  The	  role	  of	  PI3K	  in	  the	  activation	  of	  PKB	  as	  well	  as	  the	  observation	  that	  PKB	  activation	  is	  dependent	  on	  Gαi	  coupled	  signaling	  lends	  credit	  to	  the	  emerging	  idea	  that	  the	  main	  source	  of	  Gβγ signaling	  in	  platelets	  occurs	  through	  Gαi	  coupled	  receptors.	  154	  
G	  Protein	  αs	  Subunits	  G	  Protein	  αs	  Subunits	  (Gs)	  are	  the	  only	  inhibitory	  GCPR	  signaling	  molecules	  in	  platelets.	  	  They	  act	  by	  stimulating	  membrane	  bound	  adenylate	  cyclase	  (AC).149	  Stimulation	  of	  AC	  increases	  the	  intracellular	  level	  of	  cyclic	  AMP	  (cAMP),	  increasing	  the	  activity	  of	  protein	  kinase	  A	  (PKA).149,155	  	  	  	  	  	  	  	  	   PKA	  is	  involved	  in	  multiple	  inhibition	  pathways	  in	  platelets.	  	  PKA	  phosphorylates	  myosin	  light	  chain	  kinase	  (MLCK),	  impairing	  its	  ability	  to	  bind	  to	  the	  Ca2+-­‐Calmodulin	  complex.	  	  This	  phosphorylation	  inhibits	  cytoskeleton	  rearrangement	  needed	  to	  induce	  secretion	  and	  shape	  change	  responses.155	  PKA	  also	  phosphorylates	  the	  IP3	  receptor	  on	  the	  dense	  tubule	  system,	  lowering	  the	  intracellular	  Ca2+	  release	  response	  to	  the	  second	  messenger.	  149,155	  PKA	  is	  also	  responsible	  for	  VASP	  phosphorylation,	  which	  modulates	  the	  activity	  of	  GPIIb/IIIa.155	  	  
G	  Protein	  αi	  Subunits	  
	  	  	  	  	  	   G	  Protein	  αi	  Subunits	  (Gi)	  show	  the	  most	  diversity	  in	  reference	  to	  the	  individual	  receptors	  they	  are	  associated	  with.149	  The	  main	  physiological	  role	  of	  Gi	  signaling	  is	  inhibition	  of	  AC.151	  Inhibition	  of	  AC	  reduces	  the	  intracellular	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concentration	  of	  cAMP,	  lowering	  the	  activity	  of	  protein	  kinase	  A	  (PKA).	  	  155,161	  	  	  This	  pathway	  acts	  in	  direct	  inhibition	  of	  Gs	  signaling,	  and	  vice	  versa.	  	  As	  noted	  above,	  Gi	  signaling	  is	  also	  believed	  to	  be	  responsible	  for	  most	  of	  the	  Gβγ	  seen	  upon	  platelet	  stimulation,	  making	  it	  the	  main	  pathway	  that	  PKB	  and	  Rap1b	  signaling	  occurs.	  154	  	  	  	  	  	  	  	  	   There	  are	  two	  different	  isoforms	  of	  Gi	  found	  in	  platelets,	  Gi2	  and	  Gi3.154	  Mouse	  knockout	  studies	  have	  revealed	  a	  larger	  role	  of	  Gi2	  than	  Gi3	  in	  agonist	  induced	  activation.	  	  Gi2	  has	  been	  shown	  to	  preferentially	  interact	  with	  the	  ADP	  receptor	  P2Y12.	  Gi2	  knock	  out	  platelets	  showed	  reduced	  aggregation	  and	  loss	  of	  cAMP	  inhibition	  in	  vitro	  in	  response	  to	  both	  Thrombin	  and	  ADP.162,163	  	  	  	  	  	  	  	  	   Another	  Gi	  family	  member,	  G	  protein	  αz	  (Gz),	  is	  also	  expressed	  in	  platelets.	  	  It	  is	  coupled	  to	  the	  α2a	  receptor,	  and	  is	  responsible	  for	  the	  cells	  response	  to	  epinephrine.	  	  Gz	  follows	  the	  same	  activation	  pathway	  seen	  in	  Gi	  stimulation.	  	  Gz	  knockout	  studies	  produced	  platelets	  with	  no	  observable	  defects.158	  This	  is	  to	  be	  expected,	  as	  ADP	  autocrine	  and	  paracrine	  signaling	  occurs	  on	  a	  large	  scale	  after	  initial	  activation.	  
	  	  	  G	  Protein	  αq	  Subunits	  	  	  	  	  	  	   G	  Protein	  αq	  Subunits	  (Gq)	  have	  been	  extensively	  shown	  to	  target	  phospholipase	  Cβ	  (PLCβ)	  their	  main	  effector.	  	  Once	  the	  molecule	  is	  activated	  the	  membrane	  bound	  PLCβ moves	  to	  the	  membrane	  component	  PIP2	  generating	  IP3	  and	  DAG.	  164	  	  	  	  	  	  	  	  	  	  	  	  	  IP3	  activates	  the	  IP3R	  on	  the	  dense	  tubule	  system	  causing	  an	  intracellular	  Ca2+	  flux.	  	  This	  Ca2+	  flux	  facilitates	  the	  translocation	  of	  PKC	  to	  the	  membrane	  where	  it	  is	  tethered	  to	  phosphatidylserine	  (PS).165,166	  PKC	  then	  undergoes	  a	  conformational	  
	   55	  
change	  induced	  by	  DAG	  causing	  the	  expulsion	  of	  a	  pseudosubstrate	  domain	  from	  the	  substrate	  binding	  pocket.167	  Activated	  PKC	  can	  then	  move	  on	  to	  cause	  granule	  secretion	  through	  protein	  kinase	  D	  (PKD)	  and	  the	  exposure	  of	  the	  RGD	  binding	  domain	  of	  GPIIb/IIIa.155,168,169	  	  	  	  	  	  	  	   An	  additional	  effect	  of	  the	  elevated	  Ca2+	  and	  DAG	  allows	  for	  the	  formation	  of	  the	  guanine	  nucleotide	  exchange	  factor	  CalDAG-­‐GEF.	  	  CalDAG-­‐GEF	  has	  been	  implicated	  in	  activation	  of	  GPIIb/IIIa.168	  As	  expected,	  CalDAG-­‐GEF	  -­‐/-­‐	  platelets	  show	  a	  reduced	  aggregation	  response	  to	  all	  agonists.170	  	  	  	  	  	  	  	   Intracellular	  release	  of	  Ca2+	  also	  stimulates	  cytosolic	  phospholipase	  A2	  (cPLA2),	  allowing	  for	  the	  liberation	  of	  Arachadonic	  Acid	  (AA)	  from	  the	  platelet	  inner	  membrane.171	  AA	  moves	  through	  two	  separate	  enzyme	  pathways	  in	  the	  cytosol.	  	  AA	  is	  converted	  by	  cyclooxygenase-­‐1	  (COX-­‐1)	  to	  prostaglandin	  H2	  (PGH2).	  	  PGH2	  is	  then	  converted	  by	  thromboxane	  synthase	  to	  thromboxane	  A2.	  	  	  TxA2	  then	  diffuses	  out	  of	  the	  platelet	  and	  acts	  as	  an	  autocrine	  and	  paracrine	  stimulator	  of	  platelet	  activity.	  cPLA2	  -­‐/-­‐	  platelets	  show	  that	  95%	  or	  more	  of	  the	  TxA2	  generation	  is	  due	  to	  cPLA2	  activation.172	  	  	  	  	  	  	  	  	   AA	  is	  also	  converted	  to	  12-­‐hydroxyeicosatetraenoic	  acid	  (12-­‐HETE)	  in	  an	  oxidation	  reaction	  by	  12-­‐lipoxygenase	  (12-­‐LOX).	  	  12-­‐HETE	  has	  been	  demonstrated	  to	  be	  an	  autocrine	  moderator	  of	  platelet	  function,	  and	  interestingly	  knockout	  studies	  have	  shown	  that	  more	  than	  95%	  of	  12-­‐HETE	  is	  generated	  from	  cPLA2	  activation	  as	  well.172	  These	  two	  competing	  pathways	  do	  seem	  to	  have	  some	  pathway	  specificity,	  with	  evidence	  showing	  that	  thrombin	  activation	  of	  cPLA2	  to	  COX-­‐1	  is	  coupled	  to	  a	  separate	  signaling	  pathway	  than	  cPLA2	  to	  12-­‐LOX.173	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G	  Protein	  α12/13	  Subunits	  G	  Protein	  α12	  subunits	  (G12)	  consist	  of	  two	  separate	  α	  subunits,	  α12	  (G12)	  and	  α13	  (G13).	  	  Both	  subunits	  are	  expressed	  ubiquitously,	  and	  binding	  specificity	  to	  specific	  receptors	  is	  not	  strict	  among	  the	  two	  family	  members.151	  It	  should	  also	  be	  noted	  that	  most	  receptors	  that	  bind	  Gq	  also	  Bind	  G12	  and	  G13.	  	  In	  addition	  to	  receptor	  agonist	  related	  activation,	  there	  is	  also	  proof	  that	  PKC	  can	  phosphorylate	  G12	  family	  members.174	  This	  phosphorylation	  modification	  causes	  G12	  to	  lose	  its	  affinity	  to	  the	  βγ	  subunits,	  which	  provides	  feedback	  modulation	  of	  the	  G12	  and	  G13	  pathways	  after	  thrombin	  of	  TxA2	  stimulation.151	  G13	  has	  been	  shown	  to	  stimulate	  the	  RhoGEF	  activity	  p115RhoGEF,	  but	  G12	  is	  unable	  to	  activate	  this	  pathway.	  	  175,176	  Both	  subunits	  show	  an	  similar	  affinity	  to	  p115RhoGEF	  however.151	  	  This	  data	  taken	  together	  suggests	  a	  model	  where	  G12	  and	  G13	  compete	  for	  binding	  with	  p115RhoGEF	  with	  activation	  stemming	  from	  only	  G13	  signaling.	  	  In	  this	  context	  activation	  of	  receptors	  linked	  to	  heterogeneous	  mix	  of	  G12	  and	  G13	  lead	  to	  a	  balanced	  response	  of	  p115RhoGEF	  activity.	  	  Activation	  of	  PKC,	  through	  either	  integrin	  engagement	  or	  Gq	  activation,	  would	  then	  result	  in	  the	  phosphorylation	  of	  G12	  and	  its	  disassociation	  with	  the	  βγ	  subunit	  in	  its	  inactive	  form.	  	  Suppression	  of	  G12	  regulation	  of	  the	  G13	  signal	  would	  allow	  the	  preferential	  binding	  of	  G13	  to	  p115RhoGEF,	  promoting	  signal	  transduction.	  	  	  	  	  	  	  	   P115RhoGEF	  is	  a	  Ras	  homology	  (Rho)	  guanine	  nucleotide	  exchange	  factor	  that	  binds	  to	  G12	  and	  G13	  increasing	  their	  GAP	  activity,	  terminating	  their	  signaling	  potential.175	  Rho	  signaling	  is	  the	  main	  pathway	  initiated	  with	  G13	  signaling,	  leading	  to	  platelet	  shape	  change	  through	  ROCK.	  	  ROCK	  activation	  causes	  a	  decrease	  in	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MPase.	  	  This	  decrease	  in	  MPase	  coupled	  with	  the	  increase	  in	  MLCK	  activity	  associated	  with	  increased	  Ca2+	  levels	  allow	  for	  the	  modification	  of	  MLC	  and	  subsequent	  shape	  change	  associated	  with	  platelet	  activation.154	  In	  contrast	  G13	  -­‐/-­‐	  platelets	  show	  reduced	  aggregation	  and	  secretion	  with	  TxA2	  and	  thrombin,	  as	  well	  as	  inhibited	  shape	  change	  and	  RhoA	  activation	  in	  vitro.	  	  In	  vivo	  the	  mice	  show	  an	  increased	  bleeding	  time	  and	  they	  are	  protected	  against	  arterial	  thrombosis.177	  
Signaling	  Discussion	  
	   To	  draw	  general	  conclusions	  from	  GPCR	  signaling	  a	  more	  generalized	  picture	  of	  receptors	  and	  effectors	  is	  presented	  in	  Figure	  1.18.	  	  As	  witnessed	  in	  a	  combined	  depiction	  of	  integrated	  platelet	  signaling	  (Figure	  1.19)	  the	  platelet	  response	  is	  complicated	  and	  diverse.	  	  The	  cross	  talk	  that	  occurs	  between	  the	  pathways	  complicates	  any	  individual	  agonist	  responses	  when	  examining	  in-­‐vitro	  platelet	  function.	  	  His	  becomes	  even	  more	  complicated	  due	  to	  the	  interplay	  with	  inflammation	  and	  the	  endothelium.	  	  Care	  needs	  to	  be	  taken	  to	  ensure	  the	  proper	  conclusions	  are	  drawn	  from	  any	  isolated	  experiments,	  and	  distinction	  needs	  to	  be	  drawn	  when	  examining	  platelet	  function	  outside	  the	  vasculature	  compared	  to	  function	  inside	  the	  circulation.	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Figure	   1.18:	   Generalized	   Schematic	   of	   Platelet	   GCPR	   Signaling.	   PGI2;	  prostacyclin,	  TXA2;	  thromboxane	  A2,	  ADP;	  adenosine	  di-­‐phosphate,	  5-­‐HT;	  serotonin,	  AC;	   adenylyl	   cyclase,	   cAMP;	   cyclic	   adenosine	   monophosphate,	   PDE3;	  phosphodiesterase	   E3	   PAR;	   protease	   activated	   receptor,	   cPLA2;	   cytosolic	  phospholipase	   A2,	   PKC;	   protein	   kinase	   C,	   PKG;	   protein	   kinase	   G,	   NO;	   nitric	   oxide,	  NOS;	   nitric	   oxide	   synthase,	   PLCβ;	   phospholipase	   Cβ,	   cGMP;	   cyclic	   guanosine	  monophosphate,	   sGC;	   guanylate	   cyclase,	   DAG;	   diacylglycerol,	   IP3;	   inositol	  trisphosphate,	   PI3K;	   phospoinositide	   3-­‐kinase,	   RIAM;	   Rap1	   interacting	   adapter	  molecule.	  	  Adapted	  from	  Li	  2010.178	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Pathophysiology	  of	  Trauma	  Literature	  
Introduction	  
	   Currently	  there	  are	  a	  variety	  of	  conditions	  associated	  with	  coagulopathy	  following	  trauma.	  	  Understanding	  these	  conditions	  better	  may	  allow	  for	  new	  treatment	  strategies	  increasing	  survival	  in	  the	  trauma	  population.	  	  Recently	  The	  Scientific	  and	  Standardization	  Committee	  on	  DIC	  of	  the	  International	  Society	  on	  Thrombosis	  and	  Haemostasis	  (ISTH)	  has	  released	  a	  review	  indicating	  that	  a	  vast	  majority	  of	  these	  conditions	  could	  be	  considered	  one.179	  This	  idea	  would	  suggest	  that	  coagulopathy	  of	  trauma	  (COT),	  acute	  coagulopathy	  of	  trauma	  (ACoT),	  and	  early	  coagulopathy	  of	  trauma	  (ECoT)	  are	  all	  a	  component	  of	  disseminated	  intravascular	  coagulopathy	  (DIC).	  	  There	  is	  also	  emerging	  evidence	  of	  a	  separate	  disorder	  termed	  simply	  as	  hypercoagulability	  (HC).5	  For	  the	  purpose	  of	  this	  review	  DIC,	  ACoT,	  and	  ECoT	  will	  be	  considered	  generally	  the	  same	  condition	  of	  a	  consumption	  disorder	  at	  decreasing	  levels	  of	  severity.	  	  HC	  will	  also	  be	  discussed,	  and	  the	  traditional	  categorization	  of	  trauma-­‐induced	  coagulopathy	  (TIC)	  will	  encompass	  any	  condition	  induced	  by	  trauma	  that	  effects	  coagulation	  (hyper	  or	  hypo).	  
Disseminated	  Intravascular	  Coagulopathy	  (DIC)	  Disseminated	  Intravascular	  Coagulation	  (DIC)	  can	  be	  associated	  with	  trauma	  as	  well	  as	  septic	  infections.	  	  	  It	  is	  most	  commonly	  observed	  in	  severe	  sepsis,	  but	  can	  be	  observed	  in	  response	  to	  severe	  trauma	  as	  well.	  	  Septic	  induced	  DIC	  has	  been	  shown	  to	  involve	  activation	  of	  the	  innate	  immune	  response,	  which	  in	  turn	  is	  capable	  of	  initiating	  coagulation	  as	  well	  as	  inhibiting	  fibrinolysis.180–182	  Pathologically,	  sepsis	  related	  DIC	  results	  in	  systematic	  elevated	  thrombin	  generation	  combined	  with	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degradation	  and	  dysfunction	  in	  the	  anticoagulant	  and	  fibrinolytic	  pathways.	  	  The	  combined	  effects	  of	  this	  dysregulation	  can	  been	  associated	  with	  intravascular	  fibrin	  deposition	  and	  multiple	  organ	  dysfunction	  (MOD).182	  While	  initial	  effects	  of	  DIC	  are	  thromboembolic	  in	  nature,	  the	  consumption	  of	  protein	  coagulation	  factors	  and	  increased	  fibrinolytic	  activity	  often	  present	  as	  a	  hypocoagulability	  in	  testing.	  
Coagulopathy	  of	  Trauma	  (ACoT/ECoT)	  
	   Controversy	  surrounds	  the	  identification	  and	  characterization	  of	  ACoT	  and	  ECoT.	  	  Many	  different	  groups	  have	  used	  different	  diagnostic	  and	  qualification	  criteria	  leading	  to	  confusion.	  	  Current	  ISTH	  opinion	  is	  that	  these	  conditions	  are	  related	  closely	  to,	  if	  not	  part	  of	  the	  development	  of	  DIC.179	  These	  conditions	  are	  commonly	  characterized	  as	  an	  extension	  of	  plasma	  protein	  function	  testing	  (PT/PTT)	  due	  to	  consumption	  of	  factors.179,183,184	  Currently	  it	  is	  assumed	  that	  clotting	  factors	  are	  consumed	  at	  the	  site	  of	  injury	  during	  the	  body’s	  natural	  clotting	  response.	  	  Unfortunately	  it	  has	  yet	  to	  be	  proven	  if	  there	  is	  a	  true	  loss	  of	  factors,	  or	  if	  the	  functionality	  of	  the	  pathways	  are	  effected	  as	  well.	  	  	  Lending	  to	  the	  mechanistic	  mystery,	  these	  conditions	  are	  diagnosed	  in	  platelet	  poor	  plasma	  (PPP)	  removing	  a	  main	  component	  of	  the	  physiological	  response.	  	  A	  main	  difference	  between	  DIC	  and	  ACoT	  and	  ECoT	  is	  the	  lack	  of	  a	  fibrinolytic	  phenotype	  in	  the	  latter	  two.183,185	  	  
Hypercoagulability	  (HC)	  
	   Whole	  blood	  testing	  by	  thromboelastography	  (TEG)	  has	  been	  used	  recently	  in	  the	  treatment	  of	  trauma	  patients	  to	  better	  understand	  the	  complete	  coagulation	  profile	  of	  the	  blood.	  	  It	  has	  been	  able	  to	  identify	  hypercoagulable	  patients	  that	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traditional	  plasma	  based	  testing	  has	  not.5,186	  These	  patients	  present	  with	  TEG	  R	  times	  <	  3.7	  minutes,	  and	  other	  kinetic	  parameters	  may	  be	  quickened	  as	  well.185	  
Coagulation	  Monitoring	  
	   Over	  the	  years	  there	  have	  been	  numerous	  tests	  developed	  to	  monitor	  coagulation	  status.	  	  The	  original	  testing	  included	  simple	  observation	  tests	  such	  as	  bleeding	  time	  and	  plasma	  protein	  functionality	  tests.	  	  While	  these	  tests	  are	  imperfect,	  they	  are	  still	  used	  to	  this	  day	  in	  one	  form	  or	  another	  to	  assess	  bleeding	  status	  both	  in	  the	  research	  environment	  as	  well	  as	  clinically.	  	  To	  better	  understand	  the	  current	  state	  of	  coagulation	  testing	  the	  following	  currently	  accepted	  coagulation	  tests	  are	  examined	  in	  detail	  below.	  
Classical	  Coagulation	  Protein	  Testing	  	   Coagulation	  testing	  is	  a	  critical	  part	  of	  monitoring	  hemostasis.	  	  The	  established	  clinical	  plasma	  based	  clotting	  assays	  are	  used	  to	  determine	  both	  the	  functionality	  of	  the	  enzymatic	  pathways	  involved	  in	  clotting	  as	  well	  as	  the	  concentration	  and	  activity	  of	  the	  individual	  plasma	  proteins	  themselves.	  	  While	  extremely	  useful	  in	  identifying	  factor	  deficiencies	  such	  as	  Hemophilia,	  they	  offer	  little	  insight	  into	  actual	  cellular	  processes	  involved	  in	  clotting.	  	  Monitoring	  platelet	  aggregation	  allows	  for	  the	  examination	  of	  the	  platelet-­‐platelet	  interaction	  mediated	  by	  fibrinogen	  in	  both	  PRP	  as	  well	  as	  WB,	  but	  does	  so	  in	  a	  non-­‐clotting	  system.	  	  Adhesion	  studies	  allow	  for	  the	  monitoring	  of	  the	  ability	  platelets	  to	  adhere	  to	  an	  immobile	  surface	  through	  integrin	  interactions.	  	  Flow	  Cytometry	  allows	  for	  a	  thorough	  investigation	  into	  the	  signaling	  involved	  in	  the	  platelet	  hemostatic	  response	  on	  a	  cellular	  level.	  	  Thromboelastography	  allows	  for	  the	  examination	  of	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the	  entire	  whole	  blood	  system,	  integrating	  plasma,	  platelets,	  and	  the	  rest	  of	  the	  blood	  components	  to	  proceed	  down	  normal	  coagulation	  pathways.	  	  Taken	  together,	  these	  tools	  provide.	  	  
Plasma	  Based	  Clotting	  Assays	  Prothrombin	  Time	  (PT)	  is	  a	  test	  that	  was	  developed	  in	  1935	  by	  Dr.	  Armand	  Quick	  by	  using	  a	  rabbit	  brain	  extract	  to	  mimic	  tissue	  factor	  and	  recalcification	  of	  a	  citrated	  blood	  sample.9	  While	  the	  terminology	  and	  understanding	  of	  the	  extrinsic	  pathway	  has	  changed	  over	  the	  years,	  the	  method	  for	  assessing	  PT	  is	  relatively	  unchanged.	  	  PT	  tests	  the	  functionality	  of	  the	  extrinsic	  and	  common	  pathways	  together	  as	  a	  whole	  group.	  Both	  PT	  and	  PTT	  were	  covered	  in	  depth	  at	  the	  beginning	  of	  this	  chapter.	  Partial	  Thromboplastin	  Time	  (PTT)	  was	  developed	  in	  1953	  by	  a	  group	  of	  researchers,	  and	  was	  named	  as	  such	  due	  to	  the	  use	  of	  only	  a	  partial	  extract.9	  	  This	  assay	  was	  also	  modernized	  and	  optimized	  over	  the	  years,	  but	  also	  remains	  theoretically	  unchanged	  over	  the	  years.	  	  PTT	  is	  able	  to	  test	  the	  functionality	  of	  the	  intrinsic	  and	  common	  pathways	  as	  a	  group.	  	  Because	  of	  the	  inclusion	  of	  the	  common	  pathway	  in	  both	  tests,	  more	  testing	  would	  be	  needed	  if	  both	  tests	  produce	  an	  abnormal	  result.	  Fibrinogen	  concentration	  can	  be	  measured	  in	  two	  manners.	  	  The	  first	  method	  is	  mechanically	  by	  the	  method	  of	  Clauss.	  	  This	  method	  is	  most	  commonly	  used	  for	  clinical	  evaluation,	  as	  well	  as	  for	  research	  uses.	  	  It	  is	  a	  clot	  based	  quantitative	  assay	  that	  is	  able	  to	  determine	  functional	  fibrinogen	  levels.	  	  It	  involves	  the	  addition	  of	  purified	  thrombin	  to	  a	  diluted	  plasma	  sample.187	  Second,	  fibrinogen	  ELISA	  kits	  are	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commercially	  available,	  and	  can	  be	  used	  to	  determine	  if	  reduced	  functional	  results	  are	  due	  to	  actual	  consumption	  of	  fibrinogen,	  or	  if	  a	  state	  of	  dysfibrinogenemia	  exists.	  	  	  Coagulation	  factor	  and	  protein	  assays	  can	  be	  performed	  in	  a	  variety	  of	  manners.	  	  With	  small	  manipulations	  the	  same	  tests	  developed	  to	  monitor	  PT	  and	  PTT	  can	  be	  used	  to	  determine	  the	  functional	  concentration	  of	  the	  individual	  components	  of	  each	  system.	  	  Another	  technique	  involves	  the	  identification	  of	  the	  total	  molecule	  concentration	  by	  commercially	  available	  ELISA	  kits.	  	  The	  advantage	  to	  using	  both	  options	  is	  the	  ability	  to	  generate	  a	  functional	  to	  total	  concentration	  ratio	  of	  the	  components	  being	  tested.	  
Aggregation	  
Aggregometry	  
	   Aggregometry	  is	  commonly	  performed	  in	  two	  ways,	  by	  light	  transmission	  in	  PRP,	  or	  by	  impedance	  in	  whole	  blood	  (WB).	  	  Light	  transmission	  aggregometry	  (LTA)	  is	  the	  oldest	  method	  of	  measuring	  platelet	  aggregation,	  and	  relies	  on	  the	  formation	  of	  platelet-­‐platelet	  aggregates	  to	  deflect	  and	  absorb	  light	  passing	  through	  the	  plasma	  sample.	  	  LTA	  has	  considerable	  downfalls,	  including	  a	  high	  labor	  intensity	  factor,	  extended	  time	  requirements	  (20-­‐30	  minutes)	  to	  prepare	  plasma	  samples,	  and	  the	  lack	  of	  WBCs	  and	  RBCs	  that	  the	  platelets	  typically	  encounter	  in	  the	  circulation.188	  	   Whole	  blood	  aggregometry	  (WBA)	  is	  measured	  by	  impedance	  generated	  by	  platelets	  between	  two	  electrodes	  in	  a	  WB	  sample.	  	  Typically	  the	  sample	  is	  diluted	  1:1	  in	  saline,	  and	  spun	  at	  a	  low	  rate	  to	  ensure	  mixing	  and	  mimic	  a	  low	  shear	  environment.188	  The	  disadvantages	  of	  LTA	  are	  effectively	  nullified	  with	  WBA,	  as	  it	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requires	  no	  centrifugation,	  little	  labor	  intensity,	  and	  has	  all	  the	  normal	  components	  of	  the	  circulating	  blood.	  	  As	  a	  bonus	  it	  also	  requires	  less	  sample	  than	  LTA.	  	  Recent	  advances	  have	  automated	  this	  process	  even	  further	  with	  microplate	  aggregation	  and	  multiple	  probe	  aggregation	  further	  lowering	  the	  required	  sample	  volume	  and	  increasing	  throughput.189–191	  
Platelet	  Function	  Analyzer	  (PFA-­‐100®)	  	   The	  PFA-­‐100	  uses	  high	  shear	  conditions	  to	  measure	  the	  formation	  of	  a	  platelet	  plug,	  which	  in	  turn	  generates	  data	  on	  platelet	  adhesion	  and	  aggregation.	  	  The	  system	  uses	  disposable	  cartridges	  with	  internal	  membranes	  coated	  with	  collagen	  and	  either	  ADP	  (Coll/ADP)	  or	  epinephrine	  (Coll/EPI)	  to	  cause	  a	  contact	  activation	  of	  the	  blood.	  	  Blood	  is	  then	  passed	  through	  an	  aperture	  at	  high	  shear,	  and	  the	  amount	  of	  time	  required	  for	  the	  complete	  occlusion	  of	  this	  aperture	  is	  reported	  as	  the	  closure	  time	  (CT).192	  Normal	  human	  range	  for	  Coll/ADP	  and	  Coll/EPI	  are	  70-­‐125	  seconds	  and	  90-­‐200	  respectively.	  
Thromboelastography	  The	  TEG	  5000	  Thromboelastograph®	  Hemostasis	  Analyzer	  (Haemoscope	  Corp.,	  Niles,	  IN,	  USA)	  is	  used	  to	  measure	  viscoelastic	  properties	  of	  clotting	  in	  a	  whole	  blood	  (WB)	  system	  under	  low	  shear.	  	  The	  technology	  is	  well	  known	  and	  used	  in	  both	  the	  clinical	  and	  research	  setting.	  	  The	  assay	  is	  typically	  performed	  using	  recalcification	  with	  or	  without	  kaolin	  activation	  as	  per	  manufacturers	  instruction.193	  An	  explanation	  of	  the	  most	  commonly	  reported	  parameters	  can	  be	  found	  in	  Table	  1.5.	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Platelet	  Mapping®	  	  (Haemoscope	  Corp.,	  Niles,	  IN,	  USA)	  is	  a	  modified	  form	  of	  TEG,	  designed	  to	  isolate	  and	  determine	  platelet	  contributions	  to	  whole	  blood	  clotting.	  	  All	  required	  reagents	  were	  purchased	  in	  kit	  form	  directly	  from	  Haemoscope,	  and	  assays	  were	  performed	  according	  to	  manufacturer’s	  specifications.	  	  Briefly,	  platelet	  mapping	  involves	  comparing	  the	  kaolin-­‐activated	  MA	  (MAthrombin)	  obtained	  in	  citrated	  WB	  samples	  to	  testing	  performed	  on	  heparinized	  blood.	  	  The	  use	  of	  heparinized	  blood	  eliminates	  the	  thrombin	  contribution	  to	  the	  clotting	  process.	  	  In	  order	  to	  then	  determine	  the	  fibrin-­‐based	  contribution	  to	  the	  clot	  activator	  F	  (reptilase	  and	  FXIII)	  is	  added	  and	  MA	  is	  obtained	  (MAfibrin).	  	  In	  the	  final	  set	  of	  samples	  activator	  F	  and	  a	  platelet	  activator	  is	  added,	  which	  currently	  includes	  ADP	  and	  Arachadonic	  Acid	  (AA)	  when	  purchased	  as	  a	  kit.	  	  Literature	  searches	  also	  reveal	  published	  work	  using	  collagen	  by	  separate	  groups	  using	  standardized	  methods.194,195	  The	  resulting	  MA	  from	  the	  activated	  sample	  (MAactivator)	  is	  used	  to	  determine	  the	  activator	  inhibition	  activator	  related	  %aggregation	  (TEG-­‐MAactivator)	  is	  measured	  according	  to	  the	  following	  equation:196	  
TEG-­‐MAactivator	  (%)	  =	  [(MAactivator	  -­‐	  MAfibrin)/	  (MAthrombin	  -­‐	  MAfibrin)]	  x	  100	  The	  resulting	  aggregation	  level	  is	  compared	  to	  the	  thrombin-­‐activated	  sample	  and	  inhibition	  is	  calculated.	  	  Normal	  human	  range	  provided	  by	  the	  company	  is	  <70%	  for	  any	  individual	  activator.	  	  This	  assay	  was	  originally	  designed	  to	  monitor	  anticoagulant	  therapies,	  but	  recent	  work	  has	  begun	  to	  highlight	  other	  applications.196,198,199	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Table 1. Description of HAS, TEG and ROTEM parameters.
Abbreviation Name Explanation Reference range
TEG/ROTEM
r/CT Clotting time Initial clot formation time. It is the time interval between the addition of sample to
the cup and the production of a signal of at least 2 mm amplitude. It is interpreted
as a measure of the speed at which fibrin is produced and cross-linked
TEG: 3.0–8.0 min
ROTEM: 4–10.5 min
k/CFT Clot formation time The time from initial clot formation until an amplitude of 20 mm is reached. It






This is a reflection of the maximum structural integrity obtained by the clot. It is





FOT Force onset time The time that it takes for thrombin to be generated in whole blood 3.0–8.0 min
PCF Platelet contractile force Represents the force produced by platelets (at 20 min) during clot retraction and
therefore a measure of platelet function during clotting. It is dependent on
thrombin, platelet concentration and metabolic status
4.5–9.5 kdynes
CEM Clot elastic modulus Represents the strength of the clot after 20 min and it is measured simultaneously
with PCF. It is dependent on fibrin content, fibrin structure, red cell flexibility,
platelet concentration and PCF
14.0–35.0 kdynes cm2
Table	  1.5:	  Description	  of	  HAS,	  TEG,	  and	  ROTEM	  Parameters.	  
Adapted	  from	  Brophy	  2011.197	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ROTEM®	  	   The	  ROTEM	  analyzer	  (Pentapharm	  GmbH,	  Munich,	  Germany)	  is	  a	  modified	  form	  of	  thromboelastography	  which	  measures	  viscoelastic	  properties	  of	  whole	  blood	  (WB)	  clotting	  under	  low	  shear.200	  TEG	  and	  ROTEM	  parameters	  are	  relatable,	  and	  can	  be	  found	  in	  Table	  1.5.	  The	  ROTEM	  is	  also	  used	  to	  test	  the	  effectiveness	  of	  the	  intrinsic	  and	  extrinsic	  pathways	  individually	  through	  activation	  agonist	  changes.	  	  The	  commonly	  used	  tests	  in	  this	  lab	  include	  Na-­‐TEM	  (native	  WB	  clotting	  after	  recalcification),	  In-­‐TEM	  (intrinsically	  activated	  with	  thromboplastin-­‐phospholipid),	  and	  Ex-­‐TEM	  (extrinsically	  activated	  with	  rabbit	  brain	  thromboplastin).104	  
Hemodyne	  HAS®	  
	   The	  Hemodyne	  HAS	  (Hemodyne,	  Richmond,	  VA,	  USA)	  is	  a	  whole	  blood	  clotting	  assay	  used	  to	  measure	  platelet	  interactions	  in	  a	  clotting	  system.	  	  The	  basis	  of	  testing	  has	  been	  previously	  described	  in	  detail.201,202	  The	  HAS	  determines	  platelet	  contractile	  force	  (PCF),	  clot	  elastic	  modulus	  (CEM),	  and	  force	  onset	  time	  (FOT).	  	  PCF	  is	  a	  measurement	  of	  the	  forces	  generated	  by	  platelets	  during	  clot	  retraction.	  	  Normal	  range	  for	  health	  human	  subjects	  is	  4.5-­‐9.5	  kdyne.200	  CEM	  is	  used	  to	  express	  the	  clot	  stiffness	  that	  develops	  over	  a	  20	  minute	  time	  period.	  	  The	  normal	  range	  for	  humans	  is	  14-­‐35	  kdyne/cm.200	  FOT	  is	  a	  measure	  of	  the	  time	  it	  takes	  for	  the	  sample	  to	  start	  clotting	  after	  recalcification.	  	  Normal	  human	  range	  for	  FOT	  is	  3-­‐8	  minutes.	  	  A	  breakdown	  and	  further	  explanation	  of	  these	  parameters	  can	  be	  found	  in	  Table	  1.5.	  
Flow	  Cytometry	  
	   The	  Accuri	  C6	  flow	  cytometer	  (BD	  Biosciences,	  San	  Jose,	  CA,	  USA)	  was	  used	  for	  all	  flow	  experiments	  performed	  in	  this	  lab.	  	  The	  unit	  measures	  variables	  over	  a	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very	  large	  dynamic	  range,	  and	  is	  compact	  enough	  to	  fit	  on	  a	  benchtop.203	  It	  uses	  a	  pulse	  method	  to	  excite	  samples	  concurrently	  with	  both	  488	  nm	  and	  640	  nm	  lasers.	  	  The	  filter	  configuration	  for	  all	  measurements	  was	  530/30	  nm	  for	  FL1,	  585/40	  in	  FL2,	  670	  LP	  in	  FL3,	  and	  675/25	  in	  FL4.	  	  Quality	  control	  is	  performed	  daily	  with	  6	  and	  8	  bead	  validation	  as	  per	  manufacturer’s	  instruction.	  	  	  
Whole	  Blood	  Platelet	  Analysis	  
	   Platelets	  are	  commonly	  identified	  with	  the	  constitutive	  marker	  CD41.	  	  Other	  antibodies	  are	  used	  to	  identify	  various	  aspects	  of	  platelet	  activation.	  	  Commonly	  observed	  markers	  of	  platelet	  activation	  include:	  CD62-­‐P	  (P-­‐selectin),	  CD63	  antigen,	  PAC-­‐1	  (activated	  GPIIb/IIIa),	  increased	  intracellular	  ROS	  (reduced	  fluorescein	  and	  calcein	  derivatives),	  intracellular	  Ca++	  elevation	  (BAPTA	  derivatives),	  bound	  fibrinogen	  (streptavidin	  derivatives),	  and	  PS	  exposure	  (Annexin-­‐V).	  
Microparticles	  	   Platelet	  derived	  microparticles	  are	  small	  phospholipid	  microvesicles	  normally	  shed	  by	  activated	  cells,	  and	  are	  defined	  by	  both	  size	  as	  well	  as	  surface	  receptor	  staining.101	  The	  total	  circulating	  microparticles	  (cMPs)	  are	  determined	  using	  standardized	  sized	  polystyrene	  beads	  and	  FSC/SSC	  (0.01-­‐1.0	  μm).	  	  Size	  alone	  cannot	  be	  used	  as	  microparticles	  from	  endothelial	  cells,	  leukocytes,	  erythrocytes,	  and	  smooth	  muscle	  cells	  can	  all	  be	  found	  in	  the	  blood.	  	  A	  monoclonal	  antibody	  targeting	  a	  constitutive	  platelet	  marker	  (CD41)	  is	  used	  to	  identify	  platelet-­‐derived	  microparticles	  (pMPs)	  out	  of	  this	  population	  of	  cMPs.	  	  Other	  antibodies	  can	  be	  used	  to	  determine	  the	  origin	  of	  other	  cMPs	  (CD45=Leukocytes,	  CD31+	  /	  CD41-­‐	  =	  Endothelial	  cells)	  as	  well	  as	  surface	  expression	  of	  PS	  (Annexin-­‐V),	  TSP1	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(thrombospondin-­‐1),	  CD62P	  (P-­‐selectin),	  CD142	  (TF),	  and	  PAC-­‐1	  for	  functional	  characterization.104	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   Uncontrolled	  hemorrhage	  and	  resulting	  shock	  represent	  the	  major	  causes	  of	  preventable	  deaths	  on	  the	  battlefield.2,4	  Multiple	  avenues	  are	  being	  approached	  to	  increase	  protection	  for	  the	  warfighter,	  but	  severe	  traumatic	  injury	  will	  be	  a	  reality	  in	  battle	  for	  the	  foreseeable	  future.	  	  Improvements	  in	  the	  treatment	  of	  extremity	  bleeding	  have	  reduced	  its	  impact	  on	  mortality2,	  but	  the	  new	  generation	  of	  tourniquet	  technology	  will	  never	  be	  applicable	  to	  head	  and	  torso	  wounds.	  	  This	  makes	  arresting	  hemorrhage	  inside	  the	  parameters	  of	  trauma-­‐induced	  shock	  a	  complex	  undertaking.	  	  Development	  of	  ACoT	  and	  trauma	  induced	  DIC	  suggest	  a	  consumption	  disorder,	  as	  the	  loss	  of	  function	  of	  key	  plasma	  proteins	  complicates	  hemostasis.	  	  This	  intertwines	  the	  need	  for	  volume	  correction	  with	  the	  need	  to	  reverse	  coagulopathy	  when	  developing	  resuscitation	  methods.	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   Current	  US	  combat	  care	  protocols	  define	  three	  distinct	  stages	  in	  the	  treatment	  of	  casualties	  each	  with	  varying	  degrees	  of	  available	  intervention.	  	  Care	  under	  fire	  is	  the	  first	  stage	  of	  treatment,	  and	  occurs	  while	  still	  under	  direct	  fire	  from	  the	  enemy.	  	  Current	  military	  doctrine	  demands	  that	  the	  suppression	  of	  fire	  take	  precedence	  over	  rendering	  care,	  so	  the	  individual	  injured	  often	  performs	  this	  level	  of	  treatment	  (self	  aid).	  	  Management	  of	  bleeding	  is	  often	  the	  only	  aid	  rendered	  at	  this	  time.204	  	  Once	  immediate	  threats	  are	  subdued	  treatment	  moves	  into	  the	  tactical	  care	  stage.	  	  This	  stage	  often	  involves	  aid	  from	  fellow	  soldiers	  (buddy	  aid)	  as	  well	  as	  medics/corpsman	  embedded	  with	  combat	  units,	  and	  increases	  the	  options	  for	  treatment	  and	  intervention.	  	  During	  this	  time	  the	  possibility	  of	  further	  combat	  action	  is	  considered	  eminent.	  	  Treatment	  focuses	  on	  treating	  any	  remaining	  hemorrhage	  and	  limited	  breathing	  management.	  Fluid	  administration	  lines	  through	  intravenous	  access	  are	  possible	  during	  this	  stage	  if	  needed.	  	  All	  treatment	  is	  limited	  to	  what	  can	  be	  transported	  organically	  within	  the	  combat	  unit.204	  The	  final	  stage	  involves	  the	  evacuation	  to	  a	  forward	  medical	  support	  or	  surgical	  hospital,	  introducing	  a	  high	  level	  of	  care	  and	  access	  to	  blood	  components.	  	  While	  treatment	  at	  this	  stage	  may	  parallel	  treatment	  available	  in	  the	  civilian	  world,	  it	  can	  take	  hours	  to	  secure	  an	  area	  and	  evacuate	  the	  casualty.204	  Due	  to	  the	  need	  for	  both	  volume	  replacement	  as	  well	  as	  the	  reversal	  of	  coagulopathy,	  the	  ability	  to	  deliver	  whole	  blood	  (WB)	  or	  blood	  components	  during	  the	  tactical	  care	  stage	  could	  prove	  to	  be	  vital	  to	  the	  treatment	  of	  combat	  casualties.	  	  Issues	  with	  stability	  and	  shelf	  life	  with	  the	  transport	  of	  WB	  as	  well	  as	  the	  possibility	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for	  immunoreaction	  events	  and	  viral	  transmission	  related	  to	  blood	  product	  administration	  are	  complexities	  that	  have	  yet	  to	  have	  been	  solved.	  	  	  Fresh	  frozen	  plasma	  (FFP)	  offers	  both	  coagulation	  factor	  replacement	  as	  well	  as	  volume	  replacement	  due	  to	  high	  osmotic	  pressure.	  	  FFP	  lowers	  the	  space	  restrictions	  and	  increases	  shelf	  life	  to	  up	  to	  a	  year,	  but	  samples	  must	  be	  stored	  at	  	  	  	  	  	  -­‐18°	  C.205	  Freeze-­‐drying	  of	  plasma	  has	  been	  shown	  to	  create	  a	  lyophilized	  product	  that	  maintains	  coagulation	  activity.	  	  Treatment	  allowed	  the	  freeze	  dried	  plasma	  (FDP)	  to	  be	  stored	  at	  ambient	  temperature.205	  This	  process	  did	  reduce	  space	  requirements	  for	  storage	  even	  further,	  but	  the	  requirement	  to	  reconstitute	  at	  full	  volume	  and	  the	  lack	  of	  addressing	  the	  viral	  issue	  highlight	  the	  shortcomings	  of	  this	  process.206	  Recent	  development	  of	  a	  novel	  aseptic,	  hypertonic,	  hyperosmotic	  spray-­‐dried	  plasma	  (Entegrion	  Inc.,	  Research	  Triangle	  Park,	  NC,	  USA)	  addresses	  two	  key	  shortfalls	  of	  FDP.	  	  The	  spray	  dried	  plasma	  (SDP)	  process	  allows	  for	  both	  the	  destruction	  of	  viral	  contamination	  as	  well	  as	  reconstitution	  at	  one	  third	  of	  original	  volume.	  The	  increases	  in	  sterility	  combined	  with	  a	  possible	  2/3	  decrease	  in	  fluid	  volume	  are	  clear	  advantages	  over	  current	  choices.	  The	  goal	  of	  these	  experiments	  was	  to	  compare	  the	  effects	  of	  SDP	  to	  current	  treatments	  (WB,	  FFP)	  in	  swine	  model	  of	  traumatic	  shock	  and	  coagulopathy	  with	  focus	  on	  treatment	  of	  hypovolemia	  and	  coagulopathy.	  	  In	  order	  to	  accomplish	  this	  goal	  a	  model	  of	  trauma	  induced	  hypovolemic	  shock	  and	  coagulopathy	  that	  was	  repeatable	  was	  required.	  	  As	  part	  of	  the	  model	  development	  and	  verification	  process	  resuscitation	  protocols	  were	  evaluated	  as	  well.	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During	  the	  resuscitation	  protocol	  compatibility	  issues	  between	  the	  swine	  and	  the	  human	  SDP	  product	  were	  severe	  and	  caused	  the	  suspension	  of	  the	  study	  before	  the	  main	  goal	  could	  be	  met.	  	  Data	  generated	  during	  the	  model	  development	  did	  reveal	  a	  reproducible	  model	  of	  hypovolemic	  shock	  and	  trauma	  induced	  coagulopathy,	  but	  no	  treatment	  analysis	  could	  be	  made.	  	  An	  in-­‐vitro	  assay	  of	  the	  effects	  of	  SDP	  and	  FFP	  on	  human	  blood	  samples	  was	  used	  for	  a	  preliminary	  comparison	  of	  the	  two	  products	  while	  model	  species	  selection	  was	  evaluated.	  
2.2	  Materials	  and	  Methods	  
Materials	  
	   SDP	  was	  provided	  in	  powder	  form	  (Entegrion,	  Research	  Triangle	  Park,	  NC,	  USA)	  and	  reconstituted	  within	  1	  hour	  of	  intended	  use	  using	  provided	  buffer.	  	  The	  product	  is	  generated	  from	  pooled	  human	  plasma,	  which	  undergoes	  a	  proprietary	  treatment	  to	  produce	  a	  lyophilized	  product.	  	  Reconstituted	  it	  resembles	  pooled	  fresh	  citrated	  plasma	  in	  protein	  concentration	  and	  pH.	   	  
	   FFP	  was	  obtained	  from	  Virginia	  Blood	  Services	  (Richmond,	  VA,	  USA)	  and	  was	  all	  type	  A.	  	  All	  volunteer	  blood	  used	  from	  this	  study	  was	  type	  A	  to	  control	  for	  immunoreactions.	  	  	  Human	  type	  A	  blood	  was	  obtained	  from	  healthy	  volunteers	  via	  direct	  peripheral	  venipuncture	  by	  trained	  staff	  directly	  into	  standard	  vacutainers.	  	  All	  blood	  samples	  were	  performed	  one	  time	  only	  and	  drawn	  into	  a	  combination	  of	  sodium	  citrate,	  EDTA,	  and	  heparinized	  vacutainers	  with	  the	  total	  volume	  per	  sample	  point	  ≤ 25	  mL.	  	  Blood	  was	  obtained	  from	  excess	  controls	  drawn	  for	  the	  protocol	  “Defining	  Platelet	  Function	  During	  Polytrauma.”	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Large	  Animal	  Model	  
General	  Preparation/	  Instrumentation	  
	   The	  Virginia	  Commonwealth	  University	  Institutional	  Animal	  Care	  and	  Use	  Committee	  approved	  the	  experiments	  described	  in	  this	  section.	  	  Juvenile	  crossbred	  Yorkshire	  swine	  were	  used	  for	  all	  animal	  experiments.	  	  All	  animals	  were	  shipped	  to,	  inspected	  by,	  and	  quarantined	  within	  the	  VCU	  animal	  care	  facility.	  	  Animals	  were	  allowed	  to	  acclimate	  to	  their	  new	  environment	  for	  a	  minimum	  of	  72	  hours	  in	  order	  to	  limit	  stress	  influences	  on	  experimental	  outcome.	  	  During	  their	  entire	  stay	  in	  the	  animal	  care	  facility	  the	  swine	  were	  provided	  with	  food	  and	  water	  ad	  libitum.	  	   Immediately	  prior	  to	  the	  experiment	  the	  animals	  were	  sedated	  with	  intramuscular	  ketamine	  (20	  mg/kg)	  and	  xylazine	  (2	  mg/kg),	  then	  transported	  to	  the	  procedure	  room.	  	  Once	  in	  the	  procedure	  room	  anesthesia	  induction	  was	  achieved	  via	  inhalation	  with	  3-­‐5%	  isofluorane.	  	  After	  induction	  the	  animals	  were	  placed	  in	  the	  supine	  position	  and	  orally	  intubated.	  	  Anesthesia	  was	  maintained	  using	  1-­‐3%	  isofluorane	  in	  30%	  oxygen.	  	  Minute	  ventilation	  (Draeger	  Trilo,	  Telford,	  PA,	  USA)	  was	  adjusted	  to	  produce	  an	  end-­‐tidal	  CO2	  (etCO2)	  value	  of	  35-­‐40	  mmHg	  (Biopac	  Systems	  Inc.	  Goleta,	  CA,	  USA).	  	  Animals	  were	  placed	  on	  a	  warming	  blanket	  and	  kept	  at	  a	  core	  temperature	  between	  37-­‐38.5°C	  via	  readout	  from	  a	  rectal	  probe	  connected	  to	  the	  heating	  apparatus	  (Blanketrol	  II,	  Cincinnati	  Sub-­‐Zero	  Products,	  Cincinnati,	  OH,	  USA).	  	  	  	   During	  the	  preparation	  period	  and	  surgical	  instrumentation	  blood	  gases	  were	  monitored	  to	  ensure	  that	  the	  partial	  pressure	  of	  carbon	  dioxide	  (pCO2)	  was	  maintained	  at	  35	  ±	  5	  mmHg,	  and	  continuous	  oxygen	  consumption	  was	  monitored	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using	  indirect	  calorimetry	  (Biopac	  Systems	  Inc.	  Goleta,	  CA,	  USA).	  	  Oxygen	  debt	  was	  calculated	  from	  the	  same	  indirect	  calorimetric	  data.	  	   Continuous	  electrocardiograph	  (ECG)	  monitoring	  was	  performed	  using	  a	  standard	  3-­‐lead	  configuration	  (Biopac	  Systems	  Inc.	  Goleta,	  GA,	  USA).	  	  Mean	  arterial	  pressure	  (MAP)	  and	  arterial	  blood	  samples	  were	  performed	  via	  an	  arterial	  catheter	  placed	  surgically	  in	  the	  right	  carotid	  artery.	  	  Mixed	  venous	  hemoglobin	  saturation	  (ScvO2),	  central	  venous	  pressure	  (CVP),	  pulmonary	  artery	  pressure	  (PAP),	  and	  continuous	  cardiac	  output	  (CCO)	  were	  performed	  via	  an	  oximetric	  pulmonary	  artery	  catheter	  (Edward	  Lifesciences,	  Irvine,	  CA,	  USA)	  inserted	  into	  the	  pulmonary	  artery	  through	  the	  right	  internal	  jugular	  vein.	  	  This	  catheter	  was	  also	  used	  for	  mixed	  venous	  blood	  sampling.	  	  Blood	  samples	  for	  coagulation	  were	  drawn	  via	  catheter	  inserted	  into	  the	  left	  external	  jugular	  vein.	  	  This	  line	  was	  also	  used	  for	  fluid	  administration.	  The	  left	  femoral	  artery	  was	  exposed	  via	  a	  large	  surgical	  incision	  in	  the	  groin	  area	  and	  cannulated	  with	  a	  4.8	  mm	  internal	  diameter	  catheter	  used	  for	  the	  controlled	  arterial	  hemorrhage	  during	  the	  injury	  model.	  	   To	  ensure	  the	  highest	  level	  of	  accuracy	  in	  oxygen	  consumption	  monitoring	  the	  animals	  was	  given	  intravenous	  pancronium	  bromide	  (0.1	  mg/kg)	  every	  45	  minutes	  to	  induce	  and	  maintain	  paralysis.	  	  This	  is	  necessary	  as	  the	  animal’s	  physiological	  response	  to	  shock	  includes	  hyperventilation	  even	  under	  adequate	  surgical	  anesthesia,	  and	  this	  would	  skew	  oxygen	  consumption	  data	  via	  changes	  in	  minute	  volume.	  	  	  	   All	  animals	  were	  given	  a	  20-­‐minute	  stabilization	  period,	  during	  which	  blood	  gases,	  hemoglobin,	  and	  hematocrit	  were	  rechecked.	  	  At	  the	  end	  of	  this	  stabilization	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period	  baseline	  coagulation,	  blood	  chemistry,	  and	  hematology	  samples	  were	  drawn	  directly	  into	  appropriate	  vacutainers.	  	  After	  baseline	  samples	  animals	  were	  given	  an	  additional	  10	  minutes	  to	  stabilize	  prior	  to	  the	  injury	  protocol.	  
Injury	  Model	  	   The	  goal	  of	  injury	  design	  was	  to	  simulate	  a	  combination	  of	  injuries	  that	  may	  occur	  in	  the	  battlefield.	  	  Soft	  tissue	  injury	  and	  a	  long	  bone	  fracture	  were	  combined	  to	  the	  hemorrhage	  to	  create	  a	  dynamic	  injury.	  	  This	  type	  of	  additional	  injury	  has	  been	  shown	  to	  cause	  a	  significant	  adverse	  effect	  on	  oxygen	  transport	  when	  compared	  to	  hemorrhage	  alone.207,208	  Bilateral	  hind	  limb	  skeletal	  muscle	  injury	  was	  created	  by	  firing	  a	  7	  cm	  long,	  1	  cm	  diameter	  captive	  bolt	  device	  (Accles	  &	  Shelvoke,	  Ltd.,	  Birmingham,	  England)	  two	  times	  into	  each	  limb	  with	  care	  taken	  to	  avoid	  any	  major	  vasculature.	  	  The	  captive	  bolt	  device	  was	  also	  placed	  directly	  against	  the	  right	  femur	  and	  fired	  to	  generate	  a	  comminuted	  femur	  fracture.	  	  	  Animals	  were	  then	  subjected	  to	  a	  controlled	  hemorrhage	  until	  40%	  of	  their	  estimated	  total	  blood	  volume	  had	  been	  removed.	  	  The	  40%	  goal	  was	  chosen	  for	  reproducibility,	  injury	  severity	  (near	  fatal),	  and	  the	  fact	  that	  it	  was	  hypothesized	  that	  it	  would	  produce	  hemorrhagic	  shock	  severe	  enough	  to	  create	  a	  repeatable	  and	  measurable	  coagulopathy.	  	  Hemorrhage	  occurred	  at	  a	  rate	  of	  1%	  estimated	  blood	  volume	  per	  minute	  using	  a	  computerized	  pump	  (Masterflex	  pump	  and	  pump-­‐head,	  Cole	  Palmer,	  Vernon	  Hills,	  IL,	  USA)	  to	  a	  target	  MAP	  of	  30	  mmHg.	  	  Shed	  blood	  was	  collected	  in	  3-­‐bag	  blood	  collection	  sets	  (Terumo	  Products,	  Somerset,	  NJ,	  USA)	  to	  allow	  for	  subsequent	  use	  of	  whole	  blood	  as	  a	  resuscitation	  fluid	  to	  maintain	  MAP	  >	  30	  mmHg	  if	  needed.	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Indirect	  calorimetry	  was	  employed	  to	  monitor	  continuous	  oxygen	  consumption	  (VO2)	  at	  the	  airway	  in	  a	  breath-­‐by-­‐breath	  manner.	  	  Oxygen	  debt	  (OD)	  was	  calculated	  (200	  measurements	  per	  minute)	  and	  expressed	  in	  ml/kg.	  	  	  The	  calculation	  involved	  the	  cumulative	  difference	  between	  VO2	  during	  the	  injury	  period	  and	  the	  baseline	  VO2	  integrated	  the	  time	  before	  and	  after	  the	  injury	  and	  hemorrhage.	  	  	  During	  the	  injury	  period	  the	  animals	  were	  ventilated	  using	  room	  air	  and	  2%	  isofluorane,	  and	  the	  animal’s	  temperature	  was	  allowed	  to	  spontaneously	  drift	  by	  removal	  of	  the	  warming	  blanket.	  	  MAP	  was	  maintained	  at	  30	  mmHg	  using	  small	  aliquots	  of	  saline	  (or	  whole	  blood	  if	  absolutely	  required)	  until	  oxygen	  debt	  reached	  80	  mg/kg	  (D80).	  	  This	  level	  has	  been	  used	  extensively	  in	  this	  lab	  and	  is	  associated	  metabolic	  acidosis	  (lactate	  levels	  8-­‐12	  mmol/L	  and	  base	  excess	  levels	  -­‐10	  to	  -­‐15	  mEq/L),	  oxygen	  extraction	  ratios	  of	  80%	  or	  higher,	  and	  greater	  than	  50%	  mortality.207,208	  Once	  oxygen	  debt	  goals	  were	  reached	  blood	  samples	  were	  once	  again	  obtained	  for	  coagulation,	  blood	  gas,	  hematology,	  and	  blood	  chemistry	  analysis.	  	  	  
Physiological	  Monitoring	  
	   Systematic	  blood	  gas,	  metabolite,	  and	  electrolyte	  analysis	  was	  performed	  using	  the	  Stat	  Profile	  Critical	  Care	  Xpress	  Bedside	  Analyzer	  (Nova	  Biomedical	  Corp.,	  Waltham,	  MA,	  USA).	  	  Samples	  were	  obtained	  simultaneously	  from	  the	  arterial	  and	  venous	  sampling	  catheters	  described	  above	  at	  all	  time	  points	  during	  the	  experiments.	   	  	   Hematology	  analysis	  was	  performed	  using	  the	  VetScan	  HM2	  Hematology	  System	  Bedside	  Analyzer	  (Abaxis,	  Union	  City,	  CA,	  USA).	  	  Samples	  were	  obtained	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from	  the	  venous	  sampling	  catheter	  and	  drawn	  directly	  into	  standard	  EDTA	  anticoagulated	  vacutainers	  (BD	  Biosciences,	  San	  Jose,	  CA,	  USA).	  	   A	  combined	  blood	  chemistry	  panel	  was	  performed	  using	  the	  VetScan	  Chemistry	  System	  (Abaxis,	  Union	  City,	  CA,	  USA).	  	  Samples	  were	  obtained	  from	  the	  venous	  sampling	  catheter	  and	  drawn	  directly	  into	  standard	  Li-­‐Heparin	  vacutainers	  (BD	  Biosciences,	  San	  Jose,	  CA,	  USA).	  
Resuscitation	  	  After	  the	  end	  of	  the	  injury	  period	  after	  sampling	  animals	  were	  then	  utilized	  to	  test	  various	  resuscitation	  fluids	  as	  part	  of	  the	  approved	  protocol.	  	  This	  study	  was	  to	  test	  the	  effectiveness	  of	  a	  spray	  dried	  plasma	  product	  for	  treatment	  of	  the	  shock-­‐induced	  coagulopathy.	  	  It	  was	  compared	  to	  FFP,	  NS,	  and	  fresh	  whole	  blood	  (FWB)	  to	  determine	  both	  coagulation	  as	  well	  as	  resuscitation	  properties.	  	  	  Once	  this	  protocol	  had	  been	  completed,	  all	  surviving	  animals	  were	  euthanized	  via	  IV	  injection	  of	  Potassium	  Chloride	  while	  still	  under	  anesthesia.	  	  	  
In-­‐Vitro	  Model	  
Treatment	  Protocol	  Due	  to	  adverse	  reactions	  between	  the	  swine	  and	  the	  human	  plasma	  product	  testing	  was	  suspended	  prior	  to	  reaching	  a	  standardized	  administration	  protocol.	  	  An	  
in-­‐vitro	  experiment	  was	  designed	  to	  compare	  the	  coagulation	  effects	  of	  SDP	  to	  those	  of	  fresh	  frozen	  plasma	  (FFP)	  when	  added	  to	  whole	  human	  blood.	  	  Type	  A	  FFP	  was	  obtained	  from	  Virginia	  Blood	  Services,	  and	  type	  A	  whole	  blood	  was	  obtained	  by	  venipuncture	  from	  healthy	  volunteers.	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Samples	  were	  	  divided	  into	  3	  treatment	  groups	  receiving	  normal	  saline	  (NS),	  FFP,	  or	  SDP	  in	  a	  volume	  required	  to	  bring	  the	  treatment	  up	  to	  30%	  total	  concentration.	  	  This	  concentration	  was	  chosen	  to	  mimic	  the	  final	  conditions	  that	  were	  to	  be	  present	  in	  the	  animal	  prior	  to	  the	  decision	  to	  terminate	  the	  swine	  experiments.	  	  Samples	  were	  incubated	  at	  37° C	  for	  30	  minutes,	  inverted	  3	  times	  gently	  to	  avoid	  platelet	  activation	  prior	  to	  testing.	  
Coagulation	  Testing	  
	   All	  coagulation	  samples	  were	  drawn	  directly	  into	  Na-­‐Citrate	  1:9	  standard	  vacutainers	  (BD	  Biosciences,	  San	  Jose,	  CA,	  USA)	  from	  the	  venous	  sampling	  line.	  	  Samples	  were	  delivered	  to	  the	  lab	  within	  30	  minutes	  of	  draw,	  and	  all	  experiments	  were	  completed	  within	  2	  hours.	  Thromboelastography	  was	  performed	  on	  citrated	  whole	  blood	  samples	  using	  the	  TEG®	  5000	  Hemostasis	  Analyzer	  (Haemoscope	  Corp.,	  Niles,	  IL,	  USA)	  using	  kaolin	  and	  CaCl2	  as	  per	  manufacturer’s	  instructions.	  	  Use	  of	  this	  technique	  has	  been	  described	  by	  this	  lab	  before.193,209,210	  
	   Modified	  rotational	  thromboelastography	  was	  performed	  on	  the	  ROTEM®	  analyzer	  (Pentapharm	  GmbH,	  Munich,	  Germany).	  	  The	  standard	  Na-­‐TEM	  (simple	  recalcification),	  In-­‐TEM	  (intrinsically	  activated),	  and	  Ex-­‐TEM	  (extrinsically	  activated)	  tests	  were	  all	  completed	  according	  to	  manufacturer’s	  specifications.	  	  These	  tests	  have	  been	  described	  in	  detail	  by	  this	  lab	  before.197,200	  The	  plasma	  coagulation	  cascade	  pathway	  tests	  of	  Prothrombin	  Time	  (PT)	  and	  activated	  partial	  thromboplastin	  time	  (PTT)	  as	  well	  as	  functional	  fibrinogen	  concentration	  were	  all	  measured	  in	  platelet	  poor	  plasma	  using	  the	  Start-­‐4®	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coagulation	  analyzer	  (Diagnostica	  Stago,	  Asnières,	  France).	  	  All	  tests	  were	  performed	  according	  to	  the	  manufacturer’s	  recommendation.	  Samples	  were	  stained	  for	  flow	  cytometry	  with	  primary	  antibodies	  for	  CD62p-­‐PE,	  PAC-­‐1-­‐FITC,	  CD41-­‐PE-­‐Cy5	  and	  appropriate	  isotypic	  controls	  (BD	  Biosciences,	  San	  Jose,	  CA,	  USA).	  After	  a	  30-­‐minute	  incubation	  samples	  were	  fixed	  and	  analyzed	  with	  an	  Accuri	  C6	  cytometer	  (BD	  Biosciences,	  San	  Jose,	  CA,	  USA).	  A	  total	  of	  20,000	  cells	  were	  analyzed	  in	  each	  sample.	  	  	  Platelet	  aggregation	  was	  measured	  on	  the	  Chrono-­‐log	  Aggregometer	  (Chrono-­‐log	  Corp.,	  Havertown,	  PA,	  USA)	  on	  citrated	  whole	  blood	  as	  described	  by	  previous	  work	  in	  this	  lab.209	  Samples	  were	  activated	  using	  collagen	  (2μg/mL)	  or	  ADP	  (10	  μM	  final	  concentration)	  according	  to	  manufacturer’s	  recommendations.	  	  Aggregation	  was	  measured	  as	  impedance	  increases	  in	  whole	  blood	  after	  stimulation	  with	  agonist.	  Whole	  blood	  cell	  counts	  were	  performed	  on	  the	  ABX	  Micros	  60	  (Horiba	  Medical,	  Irvine,	  CA,	  USA).	  	  Tests	  were	  performed	  on	  EDTA	  anticoagulated	  whole	  blood	  drawn	  at	  the	  time	  of	  patient	  sampling	  according	  to	  manufacturer’s	  instruction.	  
Data	  Analysis	  Data	  distributions	  were	  checked	  using	  QQ	  plots,	  and	  descriptive	  statistics	  (counts,	  percentages,	  mean	  ±	  SD,	  median	  (IQR))	  were	  used	  to	  summarize	  data	  for	  all	  experiments.	  	  All	  parameters	  for	  in-­‐vitro	  studies	  were	  measured	  as	  fold	  change	  from	  control	  (NS	  treatment	  group).	  	  Different	  Treatment	  group	  parameters	  were	  compared	  using	  the	  student’s	  t-­‐test,	  analysis	  of	  variance	  (ANOVA),	  or	  the	  non-­‐
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parametric	  Kruskal-­‐Wallis	  test	  as	  appropriate.	  Multiple	  comparisons	  were	  made	  using	  either	  Tukey-­‐HSD	  method	  or	  Wilcoxon	  test	  as	  appropriate.	  	  All	  statistical	  analyses	  were	  performed	  using	  JMP	  statistical	  software,	  version	  10.0.0	  (SAS	  Institute,	  Cary,	  NC).	  	  The	  level	  of	  significance	  for	  all	  statistical	  tests	  was	  p<	  0.05.	  
Results	  
Large	  Animal	  Model	  
Observed	  Differences	  in	  Arterial	  and	  Venous	  Coagulation	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  During	  the	  model	  development	  phase	  of	  the	  experiments	  citrated	  whole	  blood	  was	  obtained	  in	  simultaneous	  samples	  at	  baseline	  from	  both	  the	  arterial	  and	  venous	  sampling	  catheters.	  	  Blood	  was	  drawn	  directly	  into	  standard	  Na-­‐Citrate	  vacutainers	  (BD	  Biosciences,	  San	  Jose,	  CA,	  USA)	  and	  subjected	  to	  plasma	  protein	  assays	  as	  well	  as	  mechanical	  whole	  blood	  coagulation	  assays.	  	  Samples	  showed	  no	  difference	  in	  PT,	  PTT,	  or	  functional	  fibrinogen	  measurements	  (data	  not	  shown).	  	  Venous	  blood	  showed	  significant	  quickening	  in	  TEG	  clotting	  kinetics	  (Table	  2.1),	  with	  R	  (mean	  decrease	  of	  27%)	  and	  k	  (mean	  decrease	  of	  23%)	  values	  both	  reflecting	  faster	  clotting.	  	  This	  significant	  kinetic	  increase	  was	  also	  apparent	  during	  HAS	  force	  onset	  time	  (FOT)	  analysis,	  with	  a	  mean	  decrease	  of	  32%.	  	  Maximum	  Amplitude	  (MA)	  also	  showed	  significant	  increases	  in	  venous	  blood	  suggesting	  a	  small	  increase	  in	  clot	  strength.	  	  As	  composition	  of	  protein	  components	  is	  constant	  between	  the	  samples,	  these	  differences	  appear	  to	  be	  platelet	  oriented.	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Table	  2.1:	  Mechanical	  Clotting	  Analysis	  of	  Matched	  Arterial	  and	  Venous	  Blood	  
Samples	  
	  
	  	   	  	   Unit	   Mean	  (STD	  DEV)	   p	  ≤	  0.05	  
	   	   	   	   	   	   	  
	   	   	   Arterial	   	   Venous	   	  Thromboelastography	   	   	   	   	   	  
	   	   n	   12	   	   12	   	  TEG	   	   	   	   	   	   	  
	   R	   min	   7.76	  (0.93)	   	   5.70	  (0.93)	   Y	  
	   K	   min	   1.68	  (0.23)	   	   1.29	  (0.22)	   Y	  
	   MA	   mm	   66.78	  (2.99)	   	   68.57	  (2.98)	   Y	  
	   	   	   	   	   	   	  Modified	  Thromboelastography	   	   	   	   	   	  
	   	   n	   12	   	   12	   	  HAS	   	   	   	   	   	   	  
	   FOT	   min	   5.58	  (0.85)	   	   3.77	  (0.83)	   Y	  
	   PCF	   kdyne	   8.96	  (2.06)	   	   9.15	  (2.06)	   N	  
	   CEM	   kdyne/cm
2	   25.44	  (5.88)	   	   27.96	  (5.68)	   N	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	  All	  data	  presented	  as	  mean	   (Standard	  Deviation).	   	  Bold	   type	   indicates	  parameters	  with	   significant	   differences.	   	   min;	   minute,	   TEG;	   Thromboelastograph,	   HAS;	  Hemostasis	   Analyzer	   System,	   R;	   R	   time,	   K;	   kinetic	   time,	   MA;	   maximal	   amplitude,	  FOT;	  force	  onset	  time,	  PCF;	  platelet	  contractile	  force,	  CEM;	  clot	  elastic	  modulus	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Verification	  of	  Clinically	  Relevant	  State	  of	  Hypovolemic	  Shock	  when	  Oxygen	  
Debt	  Reaches	  80	  mg/kg	  (D80)	  
	   In	  order	  to	  show	  a	  clinical	  relevance	  of	  the	  injury	  mechanism,	  a	  clear	  state	  of	  shock	  must	  be	  produced	  in	  response.	  	  To	  confirm	  the	  creation	  of	  a	  state	  of	  trauma-­‐induced	  shock	  a	  wide	  range	  of	  physiological	  parameters	  were	  monitored.	  	  To	  this	  end	  these	  parameters	  will	  be	  compared	  to	  accepted	  clinical	  definitions	  of	  shock	  states.	  Of	  the	  17	  animals	  used	  in	  this	  development	  study	  only	  1	  animal	  did	  not	  survive	  until	  D80,	  indicating	  that	  at	  the	  point	  of	  resuscitation	  the	  injury	  was	  severe,	  but	  not	  so	  severe	  it	  would	  overwhelm	  resuscitation	  efforts.	  Epidemiological	  studies	  have	  resulted	  in	  a	  better	  understanding	  of	  clinical	  states	  of	  hypovolemic	  shock.211	  Using	  this	  relatively	  new	  method	  of	  stratifying	  shock	  base	  excess	  (BE)	  is	  first	  converted	  to	  base	  deficit	  (BD).	  	  This	  is	  a	  simple	  transformation	  from	  a	  negative	  value	  to	  a	  positive	  value	  (BD=	  BE	  x	  -­‐1).	  	  Stratification	  then	  allows	  for	  characterization	  of	  four	  classes:	  no	  shock	  (BD≥	  2.0),	  mild	  shock	  (BD>	  2.0	  to	  6.0),	  moderate	  (BD>	  6.0	  to	  10.0),	  and	  severe	  (BD>	  10.0).211	  Using	  this	  classification	  arterial	  blood	  gas	  results	  show	  a	  state	  of	  moderate	  shock	  (mean	  6.54	  ±	  3.94)	  in	  the	  population	  at	  D80	  (Table	  2.2).	  	  This	  level	  is	  significantly	  higher	  than	  the	  mean	  baseline	  BD	  of	  -­‐5.76	  ±	  2.3.	  	  	  	   Lactic	  acidosis	  (serum	  lactate	  >	  5	  mg/dL)	  is	  also	  a	  common	  marker	  of	  metabolic	  dysfunction	  and	  systemic	  hypoxia	  and	  it	  has	  been	  shown	  that	  it	  can	  be	  viewed	  independently	  from	  BD.212	  Lactic	  acidosis	  has	  also	  been	  shown	  to	  cause	  increased	  INR	  values,	  and	  recombinant	  Factor	  VIIa	  (rFVIIa)	  has	  been	  shown	  to	  reverse	  this	  coagulopathy.213	  After	  the	  injury	  period	  the	  animals	  displayed	  a	  mean	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Table	  2.2:	  Blood	  Gas	  Parameters	  at	  Baseline	  and	  Compared	  to	  End	  of	  Hemorrhage	   	  	  
	  	   	  	   Unit	   Mean	  (STD	  DEV)	   p	  ≤	  .05	  
Arterial	  Blood	  Gas	   	   Baseline	   	   End	  of	  Injury	   	  
	   	   	   	   	   	   	  
	   pH	   	   7.43	  (0.07)	   	   7.32	  (0.06)	   Y	  
	   pCO2	   mmHg	   43	  (2)	   	   35.11	  (5.7)	   Y	  
	   pO2	   mmHg	   124	  (20)	   	   119.7	  (24.5)	   N	  
	   Hb	   g/dL	   9.9	  (0.61)	   	   8.32	  (1.31)	   Y	  
	   sO2	   %	   98.4	  (0.74)	   	   97.7	  (2.1)	   N	  
	   COHb	   %	   0.16	  (0.39)	   	   0.48	  (0.69)	   N	  
	   MethHb	   %	   0.51	  (0.2)	   	   0.62	  (0.62)	   N	  
	   K+	   mmol/L	   3.78	  (0.21)	   	   5.06	  (0.733)	   Y	  
	   Na+	   mmol/L	   137.9	  (2.8)	   	   135.6	  (3.2)	   Y	  
	   Ca++	   mEq/L	   1.2	   	   1.17	  (0.095)	   N	  
	   Cl-­‐	   mmol/L	   105.7	  (4)	   	   108.8	  (5.13)	   Y	  
	   Glucose	   mg/dL	   141.7	  (37.5)	   	   224.3	  (94.3)	   Y	  
	   Lactate	   mmol/L	   1.08	  (0.3)	   	   7.85	  (2.25)	   Y	  
	   ctO2	   Vol%	   13.7	  (0.83)	   	   11.5	  (1.7)	   Y	  
	   BE	   mEq/L	   5.76	  (2.3)	   	   -­‐6.54	  (3.94)	   Y	  
	   	   	   	   	   	   	  
Mixed	  Venous	  Blood	  Gas	   	   	   	   	   	  
	   	   	   	   	   	   	  
	   pH	   	   7.39	  (0.027)	   	   7.17	  (0.07)	   Y	  
	   pCO2	   mmHg	   54.6	  (3.93)	   	   65.4	  (3.7)	   Y	  
	   pO2	   mmHg	   42.1	  (3.74)	   	   21.96	  (20.8)	   Y	  
	   Hb	   g/dL	   9.96	  (0.82)	   	   8.89	  (1)	   Y	  
	   sO2	   %	   62.5	  (6.4)	   	   10.86	  (5.74)	   Y	  
	   COHb	   %	   0.011	  (0.45)	   	   0.194	  (0.18)	   N	  
	   MethHb	   %	   0.65	  (0.3)	   	   1.24	  (0.22)	   Y	  
	   K+	   mmol/L	   3.87	  (0.18)	   	   5.19	  (0.77)	   Y	  
	   Na+	   mmol/L	   138	  (3.9)	   	   136.3	  (4.1)	   N	  
	   Ca++	   mmol/dL	   1.21	  (0.076)	   	   1.22	  (0.08)	   N	  
	   Cl-­‐	   mmol/L	   103.56	  (3.8)	   	   105.5	  (4.4)	   N	  
	   Glucose	   mg/dL	   143.8	  (37)	   	   228.7	  (98.3)	   Y	  
	   Lactate	   mmol/L	   1.11	  (0.34)	   	   7.71	  (2.1)	   Y	  
	   ctO2	   Vol%	   8.73	  (1.3)	   	   1.31	  (0.55)	   Y	  
	   BE	   mEq/L	   7.62	  (2.6)	   	   -­‐3.85	  (4)	   Y	  	  	   	  	   	  	   	  	   	  	   	  	   	  	  All	   data	   presented	   as	  mean	   (Standard	   Deviation).	   	   Bold	   type	   indicates	   significant	  difference	   (p	   <	   0.05).	   	   pCO2;	   partial	   pressure	   CO2,	   pO2;	   partial	   pressure	   O2,	   Hb;	  hemoglobin,	   sO2;	   O2	   saturation,	   COHb;	   carboxyhemoglobin,	   MethHb;	  methemoglobin,	  ctO2;	  total	  blood	  O2	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arterial	  lactate	  level	  of	  7.85	  ±	  2.25	  mg/dL,	  placing	  them	  solidly	  within	  the	  clinical	  definition	  of	  lactic	  acidosis.	   	  	   Also	  of	  interest	  is	  the	  mean	  mixed	  venous	  sO2	  fell	  significantly	  by	  83%.	  	  This	  further	  indicates	  that	  the	  animals	  were	  under	  severe	  oxygen	  deficit	  conditions,	  and	  that	  a	  supply	  dependent	  shock	  condition	  was	  obtained.	  Hemodynamic	  parameters	  also	  reinforce	  the	  creation	  of	  a	  shock	  state.	  	  Continuous	  cardiac	  output	  (CCO)	  is	  routinely	  monitored	  as	  part	  of	  resuscitation	  protocols214,215,	  and	  quantifies	  the	  volume	  of	  blood	  that	  the	  heart	  moves	  over	  time.	  	  Mean	  CCO	  fell	  significantly	  66%	  after	  injury	  when	  compared	  to	  baseline	  measurements	  (Table	  2.3)	  Mean	  Arterial	  Pressure	  also	  fell	  dramatically	  and	  significantly	  from	  93.6	  ±	  15.6	  mmHg	  to	  37.8	  ±	  10.6	  mmHg	  at	  the	  end	  of	  the	  injury	  period.	  	  Reduced	  end	  tidal	  CO2	  (etCO2)	  has	  been	  correlated	  with	  poor	  outcome	  in	  trauma	  patients,	  and	  been	  suggested	  as	  a	  indicator	  of	  the	  need	  for	  aggressive	  resuscitation.216	  etCO2	  dropped	  significantly	  during	  the	  injury	  period,	  falling	  24%	  when	  compared	  to	  baseline	  values.	  	  Taken	  together	  these	  data	  confirm	  the	  state	  of	  a	  supply	  dependent	  condition	  of	  shock,	  and	  further	  characterize	  the	  severity	  of	  shock	  present	  in	  this	  model.	  Liver	  dysfunction	  has	  been	  characterized	  by	  many	  other	  groups	  during	  states	  of	  traumatic	  shock.217–219	  Using	  blood	  chemistry	  analysis	  (Table	  2.3)	  significant	  drops	  in	  albumin	  and	  alanine	  aminotransferase	  (30%	  and	  17%	  respectively)	  indicate	  that	  the	  injury	  did	  reduce	  liver	  function	  in	  these	  animals.	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Table	  2.3:	  Physiological	  Parameters	  at	  Baseline	  and	  Compared	  to	  End	  of	  
Hemorrhage	  
	  	   	  	   Unit	   Mean	  (STD	  DEV)	   p	  ≤	  0.05	  
	   	   	   Baseline	   	   End	  Hemorrhage	   	  
	   	   	   	   	   	   	  
	   	   n	   17	   	   16	   NA	  
	   	   	   	   	   	   	  
Hemodynamics	   	   	   	   	   	  
	   	   	   	   	   	   	  
	   etCO2	   mmHg	   44.6	  (2.6)	   	   34	  (6.3)	   Y	  
	   CCO	   L/min	   5.19	  (.97)	   	   1.77	  (0.63)	   Y	  
	   MAP	   mmHg	   93.6	  (15.6)	   	   37.8	  (10.6)	   Y	  
	   	   	   	   	   	   	  
	   	   	   	   	   	   	  
Hematology	   	   	   	   	   	  
	   	   	   	   	   	   	  
	   WBC	   10^9/L	   13.3	  (3.6)	   	   18.1	  (9.8)	   Y	  
	   LYM	   10^9/L	   9.8	  (2.6)	   	   10.8	  (2.8)	   Y	  
	   MON	   10^9/L	   0.28	  (0.25)	   	   0.24	  (0.28)	   N	  
	   GRA	   10^9/L	   3.3	  (2.2)	   	   7.1	  (8.3)	   N	  
	   	   	   	   	   	   	  
	   RBC	   10^12/L	   6.17	  (0.32)	   	   5.44	  (0.52)	   Y	  
	   HGB	   %	   9.72	  (0.71)	   	   8.55	  (1.06)	   Y	  
	   HCT	   %	   25	  (1.6)	   	   22.3	  (2.8)	   Y	  
	   	   	   	   	   	   	  
	   PLT	   10^9/L	   253.3	  (52)	   	   220.1	  (43.4)	   Y	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	  All	  data	  presented	  as	  mean	   (Standard	  Deviation).	  Bold	   type	   indicates	   significance.	  etCO2;	  end	  tidal	  CO2,	  CCO;	  continuous	  cardiac	  output,	  MAP;	  mean	  arterial	  pressure,	  WBC;	   white	   blood	   cells,	   LYM;	   lymphocytes,	   MON;	   monocytes,	   GRA;	   granulocytes,	  RBC;	  red	  blood	  cells,	  HGB;	  hemoglobin,	  HCT;	  hematocrit,	  PLT;	  platelets.	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Kidney	  function	  was	  also	  evaluated	  for	  changes	  occurring	  in	  response	  to	  the	  injury	  period.	  	  Blood	  urea	  nitrogen	  and	  creatinine	  are	  commonly	  used	  clinical	  markers	  of	  kidney	  function,	  and	  have	  been	  shown	  to	  be	  elevated	  in	  periods	  of	  kidney	  hypoperfusion.220,221	  These	  parameters	  both	  show	  significant	  elevation	  at	  D80,	  with	  an	  18%	  and	  47%	  respectively.	  	  To	  further	  strengthen	  this	  conclusion	  of	  organ	  dysfunction,	  total	  blood	  protein	  was	  found	  to	  drop	  significantly	  from	  5.73	  ±	  0.49	  g/dL	  to	  4.43	  ±	  0.66	  g/dL.	  	  This	  23%	  drop	  indicates	  a	  global	  decline	  in	  kidney	  and	  liver	  function.	  	  Taken	  together	  these	  results	  show	  an	  aspect	  of	  hypoxic	  and	  ischemic	  effects	  on	  both	  the	  liver	  and	  kidneys.	  	   Glucose	  measurements	  all	  indicate	  a	  hyperglycemic	  response	  to	  injury	  (Table	  2.2	  and	  Table	  2.4)	  that	  is	  consistent	  with	  traumatic	  shock.	  	  It	  has	  been	  shown	  that	  the	  development	  of	  hyperglycemia	  after	  injury	  correlates	  with	  a	  poor	  prognosis	  when	  compared	  to	  those	  with	  normal	  glucose	  metabolism.222	  	   Whole	  blood	  cell	  counts	  also	  reveal	  changes	  after	  the	  injury	  period.	  	  Mean	  white	  blood	  cell	  (WBC)	  counts	  rose	  significantly	  (44%)	  at	  D80	  when	  compared	  to	  baseline	  (Table	  2.3).	  	  Lymphocyte	  (LYM)	  counts	  also	  rose	  significantly	  (10%)	  when	  comparing	  these	  time	  points.	  	  Increased	  WBC	  counts	  are	  well	  recognized	  in	  trauma	  populations,	  and	  can	  be	  correlated	  with	  severity	  of	  injury.223,224	  Red	  blood	  cell	  (RBC)	  counts	  also	  reveal	  significant	  changes	  in	  response	  to	  the	  injury	  period.	  	  This	  agrees	  with	  prior	  findings	  in	  both	  human	  and	  swine	  trauma	  studies.208,209,225–228	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Table	  2.4:	  Blood	  Chemistry	  Values	  at	  Baseline	  and	  Compared	  to	  End	  of	  Hemorrhage	   	  	  
	  	   	  	   Unit	   Mean	  (STD	  DEV)	   p	  ≤	  0.05	  
	   	   	   Baseline	   	   End	  Hemorrhage	   	  
	   	   	   	   	   	   	  
	   	   n	   17	   	   16	   NA	  
	   	   	   	   	   	   	  
ALB	   	   g/dL	   3.3	  (0.4)	   	   2.3(0.6)	   Y	  
	   	   	   	   	   	   	  
ALP	   	   IU/L	   140	  (27)	   	   136	  (35)	   N	  
	   	   	   	   	   	   	  
ALT	   	   IU/L	   34	  (7.8)	   	   28.1	  (5.9)	   Y	  
	   	   	   	   	   	   	  
AMY	   	   IU/L	   1460	  (405)	   	   1140	  (330)	   Y	  
	   	   	   	   	   	   	  
TBIL	   	   mg/dL	   0.31	  (0.05)	   	   0.29	  (0.07)	   N	  
	   	   	   	   	   	   	  
BUN	   	   mg/dL	   9.1	  (2.7)	   	   10.7	  (2.5)	   Y	  
	   	   	   	   	   	   	  
Ca++	   	   mg/dL	   10.38	  (0.48)	   	   10.17	  (1.31)	   Y	  
	   	   	   	   	   	   	  
Phos	   	   mg/dL	   8.97	  (0.92)	   	   10.9	  (1.4)	   Y	  
	   	   	   	   	   	   	  
Cre	   	   mg/dL	   0.94	  (0.25)	   	   1.38	  (0.26)	   Y	  
	   	   	   	   	   	   	  
Glucose	   	   mg/dL	   139	  (38)	   	   220	  (96)	   Y	  
	   	   	   	   	   	   	  
Na+	   	   mmol/L	   133	  (2)	   	   133	  (2)	   N	  
	   	   	   	   	   	   	  
K+	   	   mmol/L	   4.89	  (0.8)	   	   5.64	  (1.02)	   Y	  
	   	   	   	   	   	   	  
TP	   	   g/dL	   5.73	  (0.49)	   	   4.43	  (0.66)	   Y	  
	   	   	   	   	   	   	  
GLOB	   	   g/dL	   2.6	  (0.87)	   	   1.99	  (0.66)	   Y	  
	  	   	  	   	   	  	   	  	   	  	   	  	  
	   	   	   	   	   	   	  All	   data	   presented	   as	   mean	   (Standard	   Deviation).	   	   Tests	   performed	   in	   Li-­‐Heparinized	   blood.	   	   Bold	   type	   indicates	   parameters	   with	   significant	   differences.	  	  ALB;	   Albumin,	   ALP;	   alkaline	   phosphatase,	   ALT;	   alanine	   aminotransferase,	   AMY;	  amylase,	   TBIL;	   bilirubin	   total,	   BUN;	   blood	   urea	   nitrogen,	   Cre;	   creatinine,	   TP;	   total	  protein,	  GLOB;	  globulin.	  
	   90	  
Observed	  Trauma	  Induced	  Coagulopathy	  in	  a	  Swine	  Model	  To	  determine	  the	  effects	  of	  the	  injury	  on	  coagulation	  a	  comparison	  was	  performed	  of	  blood	  drawn	  at	  baseline	  with	  blood	  drawn	  at	  D80.	  	  A	  summarization	  of	  the	  testing	  performed	  can	  be	  found	  in	  Table	  2.5.	  	  In	  response	  to	  shock	  a	  PT	  increase	  of	  13%	  (p	  <	  0.05)	  was	  found	  for	  the	  D80	  samples.	  	  Unexpectedly,	  both	  PTT	  and	  functional	  fibrinogen	  levels	  were	  decreased	  after	  injury,	  although	  they	  were	  not	  significantly	  different	  between	  the	  two	  groups.	  	  	  Platelet	  counts	  fell	  significantly	  during	  the	  injury	  period,	  dropping	  13%	  in	  response	  to	  the	  injury	  (Table	  2.3).	  	  This	  drop,	  while	  common	  among	  trauma	  populations229–231,	  did	  not	  reach	  levels	  to	  indicate	  a	  clinical	  state	  of	  thrombocytopenia.	   This	  drop	  does	  however	  need	  to	  be	  considered	  when	  evaluating	  tests	  of	  whole	  blood	  platelet	  function.	   	  TEG	  testing	  revealed	  significant	  increased	  clotting	  kinetics	  after	  injury	  as	  R	  decreases	  from	  5.68	  (±1.49)	  to	  4.16	  (±0.97)	  minutes	  (Table	  2.5).	  	  The	  kinetic	  time	  (K)	  also	  showed	  significant	  quickening,	  falling	  from	  1.32	  (±0.328)	  to	  1.03	  (±0.151)	  minutes.	  Significant	  decrease	  was	  seen	  in	  the	  angle	  (α)	  in	  the	  D80	  samples,	  falling	  from	  70.35	  (±4.39)	  to	  68.12	  (±5.32)	  degrees.	  	  The	  clot	  strength	  was	  significantly	  decreased	  as	  well,	  falling	  from	  68.12	  (±5.798)	  to	  66.94	  (±5.318)	  mm.	  	  	  	   ROTEM	  analysis	  was	  performed	  to	  judge	  the	  individual	  cascade	  pathways’	  contributions	  to	  the	  whole	  blood	  clotting	  process.	  	  There	  were	  significant	  differences	  found	  in	  kinetic	  parameters	  found	  in	  both	  In-­‐TEM	  and	  Ex-­‐TEM	  testing.	  	  Significant	  increases	  in	  median	  CFT	  were	  seen	  at	  12%	  and	  10%	  respectively.	  	  	  While	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Table	  2.5:	  Coagulation	  Values	  at	  Baseline	  and	  Compared	  to	  O2	  Debt=	  80	  mL/kg	   	  	  
	  	   	  	   Unit	   Mean	  (STD	  DEV)	   p	  ≤	  0.05	  
	   	   	   Baseline	   	   D80	   	  
Plasma	  Clotting	  Tests	   	   	   	   	   	  
	   	   n	   14	   	   11	   	  
	   	   	   	   	   	   	  
	   PT	   s	   12.9	  (0.85)	   	   14.6	  (1.74)	   Y	  
	   PTT	   s	   25.4	  (5.73)	   	   23.6	  (4.41)	   N	  
	   FIB	   mg/dL	   162	  (60.58)	   	   138.8	  (59.88)	   N	  
	   	   	   	   	   	   	  
Thromboelastography	   	   	   	   	   	  
	   	   n	   17	   	   16	   	  
	   	   	   	   	   	   	  
	   R	   min	   5.68	  (1.49)	   	   4.16	  (0.97)	   Y	  
	   K	   min	   1.32	  (.328)	   	   1.03	  (0.151)	   Y	  
	   Angle	   degrees	   70.35	  (4.39)	   	   68.12	  (5.32)	   Y	  
	   MA	   mm	   68.12	  (5.798)	   	   66.94	  (5.318)	   Y	  
	   	   	   	   	   	   	  
Modified	  Thromboelastography	   	   	   	   	  
	   	   n	   8	   	   8	   	  
	   	   	   	   	   	   	  
In-­‐TEM	   	   	   	   	   	   	  
	   CT	   s	   130.9	  (22.4)	   	   121.6	  (24.5)	   N	  
	   CFT	   s	   39.4	  (4.8)	   	   44.3	  (6.4)	   Y	  
	   Rα	   degrees	   82.2	  (1)	   	   81.1	  (1.3)	   Y	  
	   MCF	   mm	   67.4	  (4.7)	   	   65.5	  (4.3)	   Y	  
	   	   	   	   	   	   	  
Ex-­‐TEM	   	   	   	   	   	   	  
	   CT	   s	   51.2	  (10.7)	   	   48.3	  (9.7)	   N	  
	   CFT	   s	   45.1	  (4.8)	   	   49.6	  (7.6)	   Y	  
	   Rα	   degree	   81	  (1.1)	   	   80.2	  (1.6)	   Y	  
	   MCF	   mm	   70	  (4.6)	   	   68.9	  (4)	   N	  
	   	  	   	  	   	   	  	   	  	   	  	  All	   data	   presented	   as	  mean	   (Standard	   Deviation).	   	   Bold	   type	   indicates	   significant	  differences.	  PT;	  prothrombin	  time,	  PTT;	  activated	  partial	  thromboplastin	  time,	  FIB;	  Functional	  fibrinogen	  concentration,	  R;	  R	  time,	  K;	  k	  time,	  MA;	  maximum	  amplitude,	  CT;	  clotting	  time,	  CFT;	  clot	  formation	  time,	  MCF;	  maximum	  clot	  firmness.	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the	  parameters	  of	  Rα	  in	  both	  tests	  and	  MCF	  in	  In-­‐TEM	  did	  show	  significant	  differences,	  the	  magnitude	  of	  these	  differences	  is	  relatively	  small	  (<3%).	  	   This	  data	  viewed	  together	  does	  indicate	  that	  a	  mild	  coagulopathy	  has	  begun	  to	  develop	  at	  the	  end	  of	  the	  injury	  period.	  	  Kinetic	  increases	  seen	  in	  the	  TEG	  agree	  with	  current	  observations	  by	  various	  other	  groups.5,186	  The	  increases	  in	  PT	  indicate	  a	  dysfunction	  in	  the	  extrinsic	  system,	  and	  this	  parameter	  is	  the	  driving	  factor	  behind	  the	  clinical	  diagnosis	  of	  ACoT.	  	  Determination	  of	  ACoT	  in	  these	  samples	  is	  hindered	  by	  the	  lack	  of	  a	  standardized	  system	  of	  reporting	  these	  scores	  in	  swine.	  	  Due	  to	  this	  an	  INR	  is	  impossible	  to	  calculate	  at	  this	  time,	  however	  the	  dysfunction	  measured	  in	  the	  PT	  pathway	  was	  also	  observed	  in	  the	  In-­‐TEM	  and	  Ex-­‐Tem	  data.	  	  This	  leads	  to	  a	  more	  probable	  theory	  that	  the	  observed	  dysfunction	  is	  present	  in	  the	  final	  common	  pathway.	  	  Factor	  assays	  would	  be	  needed	  to	  clearly	  pinpoint	  the	  source.	  	  	  	   It	  is	  possible	  that	  a	  more	  comprehensive	  coagulation	  panel	  to	  include	  both	  platelet	  function	  testing	  as	  well	  as	  complete	  plasma	  proteomic	  analysis	  would	  be	  able	  to	  better	  define	  this	  mild	  coagulopathy	  seen	  in	  these	  animals.	  	  	  
SDP	  In-­‐Vitro	  Testing	  
Effects	  of	  Plasma	  Product	  Treatment	  on	  Whole	  Blood	  Coagulation	  and	  Platelet	  
Function	  There	  were	  a	  multitude	  of	  differences	  among	  the	  treatment	  groups,	  however	  the	  SDP	  and	  FFP	  treatments	  showed	  agreement	  in	  the	  11	  of	  the	  14	  (78.5%)	  differences	  when	  compared	  to	  the	  NS	  group	  (Table	  2.6).	  There	  were	  5	  direct	  significant	  (p<0.05)	  differences	  between	  the	  two	  treatment	  groups,	  and	  80%	  of	  these	  differences	  were	  observed	  during	  Na-­‐TEM	  testing.	  	  The	  other	  significant	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difference	  between	  the	  groups	  was	  PT.	  To	  further	  highlight	  the	  differences	  between	  the	  two	  groups	  there	  were	  also	  3	  indirect	  differences	  between	  the	  FFP	  and	  SDP	  groups.	  	  An	  indirect	  difference	  can	  be	  observed	  when	  an	  individual	  treatment	  group	  differs	  from	  control,	  but	  the	  other	  treatment	  group	  does	  not	  follow	  the	  same	  trend.	  	  The	  indirect	  differences	  observed	  in	  the	  clotting	  initiation	  times	  (R	  and	  CT)	  show	  a	  quicker	  response	  in	  SDP	  treated	  samples	  (45%	  and	  32%	  respectively)	  than	  control,	  but	  FFP	  was	  not	  significantly	  different	  than	  control.	  	  FFP	  treatment	  caused	  an	  increase	  in	  clot	  strength	  (15%)	  generated	  intrinsically	  (In-­‐TEM	  MCF),	  but	  this	  was	  not	  reflected	  in	  the	  SDP	  treatment	  group.	  	  Due	  to	  the	  small	  number	  of	  in-­‐vitro	  experiments,	  clinical	  relevance	  is	  not	  clear	  at	  this	  time.	  	  Platelet	  function	  was	  also	  assessed	  by	  flow	  cytometry.	  	  After	  treatment	  with	  SDP	  there	  was	  over	  a	  two-­‐fold	  increase	  in	  the	  number	  of	  platelets	  expressing	  PAC-­‐1	  (Figure	  2.1).	  	  	  A	  decrease	  in	  the	  cells	  expressing	  PAC-­‐1	  after	  FFP	  treatment	  appeared	  to	  be	  trending	  towards	  significance	  (p	  =	  0.0534).	  	  	  SDP	  treated	  platelet	  PAC-­‐1	  expression	  was	  significantly	  higher	  than	  FFP	  when	  compared	  directly.	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All	  data	  presented	  as	  mean	  fold	  change	  ±	  Standard	  Deviation,	  p	  ≤	  0.05	  was	  used	  to	  determine	   significance.	   	   ns;	   no	   significant	   differences	   between	   any	   groups,	   a;	  significant	   difference	   between	   FFP	   group	   and	   NS	   control	   group,	   b;	   significant	  difference	   between	   SDP	   group	   and	   NS	   control	   group,	   c;	   significant	   difference	  between	   FFP	   and	   SDP	   groups.	   PT;	   prothrombin	   time,	   PTT;	   activated	   partial	  thromboplastin	  time,	  FIB;	  Functional	  fibrinogen	  concentration,	  R;	  R	  time,	  K;	  k	  time,	  MA;	   maximum	   amplitude,	   CT;	   clotting	   time,	   CFT;	   clot	   formation	   time,	   MCF;	  maximum	  clot	  firmness	   	  
Table	  2.6:	  SDP	  In-­‐Vitro	  Coagulation	  Comparison	   	  	   	  	   	  	  
	  	   	  	   Unit	   Fold	  Change	  from	  control	   p	  ≤	  0.05	  








	   	   	   	   	   	   	  TEG	  
	   	   	   	   	   	  
	  
R	   min	   1.09	  ±	  0.089	   	   0.54	  ±	  0.089	   b,c	  
	  
K	   min	   0.74	  ±	  0.14	   	   0.54	  ±0.139	   a,	  b,	  c	  
	  
Angle	   degrees	   1.15	  ±	  0.236	   	   1.38	  ±	  0.289	   ns	  
	  
MA	   mm	   1.07	  ±	  0.084	   	   1.09	  ±	  0.084	   ns	  Na-­‐TEM	  
	   	   	   	   	   	  
	  
CT	   s	   1.17	  ±	  0.172	   	   0.68	  ±	  0.172	   b,c	  
	  
CFT	   s	   0.71	  ±	  0.035	   	   0.56	  ±	  0.025	   a,	  b,	  c	  
	  
Rα 	   degrees	   1.11	  ±	  0.0154	   	   1.18	  ±	  0.0153	   a,	  b,	  c	  
	  
MCF	   mm	   1.14	  ±	  0.041	   	   1.15	  ±	  0.043	   a,	  b	  In-­‐TEM	  
	   	   	   	   	   	  
	  
CT	   s	   1.02	  ±	  0.099	   	   0.97	  ±	  0.100	   ns	  
	  
CFT	   s	   0.70	  ±	  0.070	   	   0.72	  ±	  0.070	   a,	  b	  
	  
Rα 	   degrees	   1.09	  ±	  0.037	   	   1.10	  ±	  0.038	   a,	  b	  
	  
MCF	   mm	   1.15	  ±	  0.081	   	   1.13	  ±	  0.080	   a	  Ex-­‐TEM	  
	   	   	   	   	   	  
	  
CT	   s	   0.92	  ±	  0.095	   	   0.87	  ±	  0.095	   ns	  
	  
CFT	   s	   0.69	  ±	  0.037	   	   0.72	  ±	  0.034	   a,	  b	  
	  
Rα 	   degrees	   1.12	  ±	  0.019	   	   1.15	  ±	  0.020	   a,	  b	  
	  
MCF	   mm	   1.17	  ±	  0.047	   	   1.11	  ±	  0.042	   a,	  b	  
	   	   	   	   	   	   	  Aggregometry	  
	   	   	   	   	  
	  
Collagen	  	   Ohms	   0.94	  ±	  0.361	   	   1.07	  ±	  0.360	   ns	  
	  
ADP	   Ohms	   1.66	  ±	  0.870	   	   1.77	  ±	  0.870	   ns	  
	   	   	   	   	   	   	  Plasma	  
	   	   	   	   	   	  
	  
PT	   s	   0.73	  ±	  0.012	   	   0.85	  ±	  1.013	   a,	  b,	  c	  
	  
PTT	   s	   0.91	  ±	  0.076	   	   0.87	  ±	  0.076	   ns	  	  	   FIB	   mg/dL	   1.97	  ±	  0.150	   	  	   1.71	  ±	  0.149	   a,	  b	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2.4	  Discussion	  
Large	  Animal	  Model	  	   During	  the	  model	  development	  period	  arterial	  and	  venous	  samples	  were	  analyzed	  for	  coagulation	  differences.	  	  This	  kind	  of	  sampling	  is	  difficult	  in	  healthy	  human	  volunteers,	  as	  the	  discomfort	  and	  risk	  of	  arterial	  sampling	  often	  outweigh	  its	  benefit.	  	  In	  this	  case	  matched	  samples	  from	  12	  animals	  showed	  a	  clear	  separation	  of	  the	  two	  sources	  by	  kinetic	  measures.	  	  There	  were	  no	  differences	  in	  the	  function	  of	  the	  plasma	  cascade	  proteins,	  yet	  increases	  were	  seen	  in	  both	  kinetic	  measures	  and	  clot	  strength.	  	  These	  data	  as	  a	  whole	  suggest	  that	  the	  increases	  in	  the	  generation	  of	  thrombin	  and	  increases	  in	  strength	  are	  platelet	  driven,	  although	  platelet-­‐fibrin	  interactions	  measured	  via	  HAS	  analysis	  did	  not	  confirm	  these	  results.	  	  More	  tests	  would	  need	  to	  be	  performed	  to	  define	  exactly	  where	  this	  difference	  in	  function	  lies.	  	   Validation	  of	  both	  a	  state	  of	  shock,	  as	  well	  as	  the	  development	  of	  an	  endogenous	  coagulopathy	  in	  response	  to	  this	  shock	  was	  vital	  to	  moving	  forward	  to	  examine	  treatment	  differences	  between	  the	  products.	  	  A	  moderate	  state	  of	  hypovolemic	  shock	  was	  achieved	  in	  a	  relatively	  quick	  manner.	  	  Development	  of	  metabolic	  and	  respiratory	  acidosis,	  kidney	  and	  liver	  dysfunction,	  increased	  WBC	  counts,	  and	  hyperglycemia	  strengthen	  this	  assessment.	  	  Care	  must	  be	  used	  when	  determining	  injury	  severity	  in	  a	  model	  like	  this,	  as	  some	  biological	  markers	  and	  symptoms	  do	  not	  appear	  immediately.	  	  Reaching	  a	  point	  of	  “no	  return”	  where	  no	  matter	  resuscitation	  efforts	  the	  animal	  cannot	  survive.	  	  We	  have	  extensive	  experience	  in	  this	  model	  and	  the	  severity	  was	  set	  to	  a	  level	  found	  to	  be	  approximately	  50%	  lethal	  in	  past	  studies.207–209	  The	  loss	  of	  an	  animal	  before	  D80	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was	  reached	  strengthens	  the	  argument	  that	  the	  model	  was	  severe	  enough	  in	  this	  aspect.	  	   The	  data	  regarding	  coagulation	  did	  reflect	  the	  development	  of	  a	  moderate	  coagulopathy	  by	  D80.	  	  PT	  indicates	  a	  significant	  drop,	  as	  did	  ROTEM	  pathway	  assays.	  	  This	  indicates	  a	  probable	  issue	  in	  the	  common	  pathways,	  with	  labile	  factor	  being	  the	  most	  likely	  to	  drop	  in	  levels	  quickly.	  	  In	  order	  to	  determine	  this	  exactly	  a	  full	  panel	  of	  factor	  function	  tests	  and	  thrombin	  generation	  profiles	  in	  platelet	  poor	  plasma	  would	  be	  needed.	  	  The	  coagulopathy	  that	  was	  present	  did	  not	  follow	  simple	  hypocoagulability	  trends.	  	  Kinetic	  increases	  can	  be	  attributed	  to	  changes	  in	  platelet	  function	  and	  their	  ability	  to	  mediate	  thrombin	  generation.	  	  The	  magnitude	  of	  platelet	  function	  increase	  should	  be	  viewed	  in	  the	  context	  that	  it	  occurred	  after	  a	  10%	  decrease	  in	  the	  amount	  of	  circulating	  platelets.	  	  To	  completely	  define	  the	  contributions	  of	  platelet	  function	  a	  more	  targeted	  approach	  would	  need	  to	  be	  undertaken,	  but	  the	  current	  data	  suggests	  the	  presence	  of	  a	  more	  complex	  coagulopathy	  than	  originally	  anticipated.	  
In-­‐Vitro	  Model	  The	  problems	  associated	  with	  the	  transportation	  and	  storage	  of	  FFP	  on	  the	  battlefield	  has	  caused	  interest	  in	  the	  development	  of	  more	  shelf	  stable	  blood	  products.	  	  The	  spray-­‐dried	  plasma	  undergoes	  a	  form	  of	  lyophylization	  dramatically	  reducing	  volume	  and	  increasing	  shelf	  life.	  	  The	  theory	  is	  that	  it	  can	  be	  reconstituted	  upon	  need,	  fulfilling	  both	  a	  volumetric	  requirement	  due	  to	  osmotic	  pressure	  as	  well	  as	  supplying	  coagulation	  factors	  that	  may	  be	  lost	  in	  a	  patient	  due	  to	  consumption.	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Figure	   2.1:	   	  Platelet	   Activation	  Marker	   Analysis	   between	  Treatment	   Groups.	  	  Percentage	   of	   positive	   cells	   measured	   by	   flow	   cytometry	   and	   expressed	   as	   fold	  change.	   	   *	   p	   ≤	 0.05,	   PAC-­‐1;	   antibody	   identifying	   activated	   GP	   IIb/IIIa,	   CD62P;	   P-­‐selectin,	  	  	  	  	  FFP;	  fresh	  frozen	  plasma,	  SDP;	  spray	  dried	  plasma.	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shock,	  interspecies	  reactions	  between	  the	  human	  SDP	  and	  swine	  were	  considered	  a	  viable	  possibility.	  	  Due	  to	  these	  reasons	  the	  goal	  of	  testing	  the	  SDP	  to	  treat	  the	  coagulopathy	  were	  never	  fully	  realized.	  	  In	  an	  attempt	  to	  generate	  meaningful	  analysis	  this	  in-­‐vitro	  experiment	  was	  developed.	  	  	  	   Due	  to	  elevated	  levels	  of	  fibrinogen	  in	  all	  treatment	  groups,	  rises	  observed	  in	  clotting	  strength	  were	  expected	  when	  compared	  to	  control.	  	  The	  parameters	  of	  MCF	  and	  MA	  in	  normal	  recalcification	  assays	  showed	  no	  differences	  between	  the	  two	  treatment	  groups	  directly,	  suggesting	  that	  this	  strength	  increase	  is	  similar	  in	  response	  to	  both	  (Table2.6).	  	  Kinetic	  parameters	  show	  an	  increase	  in	  reaction	  speed	  and	  decrease	  in	  initiation	  time,	  as	  well	  as	  increased	  PAC-­‐1	  expression.	  	  This	  suggests	  platelet	  activation	  in	  response	  to	  SDP	  as	  compared	  to	  control.	  	  There	  were	  some	  signs	  of	  platelet	  activation	  in	  response	  to	  FFP	  as	  well,	  including	  increased	  CD62P	  expression	  (secretion)	  and	  faster	  kinetics	  than	  control	  samples.	  	  No	  clear	  distinction	  can	  be	  generalized	  from	  this	  data	  however,	  as	  the	  trends	  do	  not	  separate	  and	  define	  different	  populations	  in	  most	  direct	  and	  indirect	  comparisons	  (76%	  of	  parameters	  show	  no	  significant	  differences,	  and	  only	  86%	  of	  the	  parameters	  show	  no	  indirect	  differences).	  	  	  As	  a	  relatively	  small	  sample	  size	  perhaps	  the	  most	  reliable	  conclusions	  that	  can	  be	  drawn	  from	  this	  work	  is	  that	  FFP	  and	  SDP	  do	  have	  in-­‐vitro	  effects	  on	  platelet	  function	  when	  compared	  to	  NS	  treated	  samples.	  	  	  These	  effects	  can	  be	  viewed	  generally	  as	  increasing	  activity	  in	  the	  extrinsic	  pathway	  and	  increasing	  clotting	  kinetics	  mechanically,	  but	  more	  work	  must	  be	  done	  to	  specifically	  define	  these	  parameters	  in	  the	  context	  of	  platelet	  function.









	   It	  is	  well	  known	  that	  multisystem	  injury	  has	  an	  impact	  on	  hemostatic	  function	  and	  this	  impairment	  of	  the	  normal	  coagulation	  system	  impacts	  patient	  survival.	  	  During	  the	  current	  military	  conflicts	  uncontrolled	  truncal	  hemorrhage	  has	  been	  identified	  as	  the	  leading	  cause	  of	  potentially	  survivable	  death.2	  While	  combat	  operations	  very	  likely	  produce	  a	  higher	  incidence	  of	  traumatic	  injury	  than	  most	  individuals	  are	  faced	  with	  during	  civilian	  life,	  uncontrolled	  bleeding	  has	  also	  been	  identified	  as	  the	  second	  leading	  cause	  of	  death	  in	  civilian	  trauma.3	  As	  the	  amount	  and	  number	  of	  injuries	  increases	  in	  trauma	  coagulopathy	  presents	  earlier	  and	  is	  more	  common.	  232	  This	  earlier	  presentation	  of	  hemostatic	  dysfunction	  is	  found	  in	  almost	  40%	  of	  combat	  casualties	  that	  require	  blood	  product	  administration,	  and	  has	  been	  related	  to	  a	  six	  fold	  increase	  in	  mortality.4	  All	  these	  findings	  highlight	  a	  need	  for	  a	  better	  understanding	  of	  the	  mechanisms	  responsible	  for	  platelet	  dysfunction	  and	  coagulopathy	  in	  polytrauma	  victims.	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   The	  main	  objectives	  of	  this	  study	  were	  to	  clearly	  define	  platelet	  function	  in	  the	  polytrauma	  victim	  and	  to	  understand	  the	  impact	  of	  injury	  and	  treatment	  in	  this	  context.	  	  The	  hypothesis	  developed	  was	  that	  platelet	  function	  is	  altered	  during	  multisystem	  injury	  and	  has	  significant	  implications	  for	  hemostasis	  and	  damage	  control	  resuscitation	  and	  surgery.	  	  There	  were	  two	  specific	  aims	  that	  were	  pursued	  in	  order	  to	  verify	  this	  hypothesis.	  	  The	  first	  aim	  was	  to	  define	  platelet	  function	  over	  time	  in	  response	  to	  trauma	  using	  a	  comprehensive	  and	  multipronged	  panel	  of	  accepted	  and	  emerging	  coagulation	  tests.	  	  The	  second	  aim	  was	  to	  define	  the	  relationships	  between	  platelet	  function	  and	  injury	  severity,	  tissue	  hypoperfusion,	  hypothermia,	  acidosis,	  transfusion,	  traumatic	  brain	  injury,	  and	  clinical	  outcomes	  to	  include	  the	  need	  for	  immediate	  surgery	  and	  survival.	  
3.2	  Materials	  and	  Methods	  
Enrolment	  	  
	   All	  patients	  that	  presented	  over	  a	  24-­‐month	  period	  to	  the	  Virginia	  Commonwealth	  University	  Medical	  Center	  (VCUMC)	  Emergency	  Department	  meeting	  immediate	  trauma	  team	  activation	  criteria	  were	  screened	  for	  study	  inclusion.	  	  All	  patient	  participants	  and	  healthy	  volunteers	  were	  screened	  under	  the	  following	  criteria.	  Inclusion:	  
• Age	  ≥ 18 years	  
• Acutely	  injured	  patients	  meeting	  predetermined	  mechanistic,	  vital	  sign,	  and	  physical	  exam	  related	  criteria	  for	  immediate	  trauma	  team	  activation	  in	  the	  Emergency	  Department.	  
• Time	  of	  injury	  within	  3	  hours	  of	  initial	  sample	  procurement	  
• Healthy	  uninjured	  volunteer	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Exclusion	  Criteria:	  
• Pregnancy	  
• Documented	  do	  not	  resuscitate	  order	  
• Intentional	  self	  inflicted	  injury	  
• Recent	  (within	  two	  weeks)	  use	  of	  anticoagulants	  including	  heparins,	  aspirin,	  clopidogrel,	  prasugrel,	  or	  warfarin	  as	  confirmed	  by	  patient	  report	  or	  medical	  record.	  
• Prisoner	  
• Non-­‐English	  speaker	  
• Refusal	  to	  participate	  	  
Blood	  Sampling	  Protocol	  	   Blood	  samples	  were	  obtained	  via	  non-­‐heparinized	  peripheral	  catheters	  or	  direct	  peripheral	  veinipuncture	  directly	  into	  standard	  vacutainers	  by	  VCUMC	  trained	  staff.	  	  All	  blood	  samples	  were	  drawn	  into	  a	  combination	  of	  sodium	  citrate,	  EDTA,	  and	  heparinized	  vacutainers	  with	  the	  total	  volume	  per	  sample	  point	  ≤ 25	  mL.	  	  Healthy	  volunteers	  provided	  one	  sample	  only,	  while	  the	  trauma	  population	  was	  sampled	  serially	  at	  admission	  and	  then	  8,	  24,	  48,	  and	  72	  hours	  post	  admission.	  	  Precaution	  was	  taken	  to	  ensure	  that	  sample	  procurement	  was	  not	  a	  significant	  risk	  to	  the	  patient	  population,	  and	  samples	  were	  not	  obtained	  if	  the	  patient’s	  last	  clinical	  hemoglobin	  level	  was	  below	  7	  g/dL.	  	  	  
Patient	  Data	  Acquisition	  	  	   Demographic	  and	  descriptive	  data	  was	  collected	  from	  the	  patients’	  medical	  record.	  	  This	  data	  was	  needed	  to	  delineate	  groups	  according	  to	  injury	  severity,	  degree	  of	  tissue	  hypoperfusion,	  and	  presence	  and	  severity	  of	  head	  injury.	  	  This	  mined	  data	  was	  extensive	  and	  included:	  
• Age,	  sex,	  height,	  and	  weight	  
• Mechanism	  of	  injury	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• Vital	  signs	  (blood	  pressure,	  pulse,	  temperature,	  respiratory	  rate,	  and	  pulse	  oximetry	  data)	  
• Pre-­‐Admission	  use	  of	  aspirin,	  non-­‐steroidal	  anti-­‐inflammatory	  medications,	  warfarin,	  heparins,	  or	  other	  specific	  anti-­‐platelet	  drugs	  
• Major	  injuries	  as	  identified	  by	  physical	  examination,	  computed	  tomography,	  or	  during	  surgical	  intervention	  by	  anatomic	  distribution	  for	  calculation	  of	  the	  Injury	  Severity	  Score	  (ISS)	  
• Significant	  past	  medical	  history	  to	  include	  history	  of	  coronary	  artery	  disease,	  cerebrovascular	  accident,	  diabetes	  mellitus,	  coagulopathy,	  medication	  history,	  and	  medications	  used	  during	  current	  hospitalization	  
• Volume	  and	  type	  of	  blood	  products	  transfused	  and	  crystalloid	  resuscitation	  fluids	  administered	  
• Glascow	  Coma	  Scale	  and	  presence	  and	  type	  of	  intracranial	  injury	  
• Basic	  Metabolite	  and	  electrolyte	  profile	  	  
• Complete	  cell	  count	  with	  differential	  and	  platelet	  count	  
• Venous	  blood	  gas	  analysis	  with	  base	  excess	  
• Lactate	  concentration	  
• PT,	  PTT,	  INR	  
• Blood	  typing	  	  
• Serum	  alcohol	  level	  
• Serum	  Toxicology	  screen	  for	  drugs	  of	  abuse	  Data	  was	  also	  collected	  from	  medical	  records	  regarding	  the	  subsequent	  time	  points	  including	  new	  medications	  and	  interventions	  as	  well	  as	  any	  clinical	  tests	  performed	  within	  two	  hours	  of	  the	  follow	  up	  time	  points.	  	  	  
Coagulation	  Testing	  High	  shear	  platelet	  adhesion	  and	  aggregation	  was	  quantified	  using	  the	  PFA-­‐100	  (Siemens	  Healthcare	  Diagnostics,	  Tarrytown,	  NY,	  USA).	  	  This	  technology	  has	  been	  described	  before192,	  but	  briefly	  uses	  two	  disposable	  cartridges	  to	  test	  platelet	  response	  to	  collagen	  and	  ADP	  (Coll/ADP)	  or	  collagen	  and	  epinephrine	  (Coll/EPI).	  	  The	  amount	  of	  time	  needed	  for	  the	  blood	  to	  form	  a	  plug	  and	  completely	  occlude	  the	  cartridge	  aperture	  is	  expressed	  as	  the	  closure	  time	  (CT),	  and	  was	  recorded	  for	  each	  patient.	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Platelet	  aggregation	  was	  measured	  on	  the	  Chrono-­‐log	  Aggregometer	  (Chrono-­‐log	  Corp.,	  Havertown,	  PA,	  USA)	  on	  citrated	  whole	  blood	  as	  described	  previously	  by	  this	  lab.209	  Samples	  were	  activated	  using	  collagen	  (2μg/mL)	  or	  ADP	  (10	  μM	  final	  concentration)	  according	  to	  manufacturer’s	  recommendations.	  	  Aggregation	  was	  measured	  as	  impedance	  increases	  in	  whole	  blood	  after	  stimulation	  with	  agonist.	  Kinetics	  of	  thrombin	  generation	  were	  assessed	  in	  platelet	  poor	  plasma	  (PPP),	  as	  described	  by	  Hemker233,	  by	  measuring	  the	  cleavage	  of	  a	  fluorogenic	  substrate	  	  using	  the	  Calibrated	  Automated	  Thrombogram®	  (CAT®;	  Thrombinoscope	  BV,	  Masstricht,	  The	  Netherlands).	  A	  Fluoroscan	  Ascentâ	  fluorometer	  (Thermolab	  Systems	  OY,	  Helsinki,	  Finland)	  was	  used	  to	  measure	  the	  resultant	  fluorescence.	  Thromboelastography	  was	  performed	  on	  citrated	  whole	  blood	  samples	  using	  the	  TEG®	  5000	  Hemostasis	  Analyzer	  (Haemoscope	  Corp.,	  Niles,	  IL,	  USA)	  using	  kaolin	  and	  CaCl2	  as	  per	  manufacturer’s	  instructions.	  	  Use	  of	  this	  technique	  has	  been	  described	  by	  this	  lab	  in	  previous	  work.193,209,210	  
	   Further	  mechanical	  whole	  blood	  coagulation	  analysis	  was	  performed	  on	  whole	  blood	  using	  the	  Hemodyne	  Hemostasis	  Analysis	  System	  (HAS	  Hemodyne	  Inc.,	  Richmond,	  VA,	  USA)	  using	  citrated	  whole	  blood.	  	  In	  depth	  assay	  procedures	  have	  been	  described	  by	  this	  lab	  before.209	  Parameters	  for	  both	  the	  TEG	  and	  the	  HAS	  have	  been	  reviewed	  in	  depth	  in	  prior	  work	  by	  this	  lab.	  193	  The	  Platelet	  Mapping®	  assay	  (Haemoscope	  Corp.,	  Niles,	  IL,	  USA)	  utilizes	  modified	  TEG	  based	  thromboelastography	  to	  determine	  functionality	  of	  the	  arachidonic	  acid	  (AA)	  and	  ADP	  response	  pathways	  in	  platelets.	  	  The	  assay	  was	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described	  in	  depth	  earlier	  in	  this	  work.	  	  Multiple	  groups	  have	  recently	  demonstrated	  significant	  correlation	  between	  platelet	  mapping	  response	  and	  optical	  platelet	  aggregometry,	  suggesting	  further	  diagnostic	  value	  to	  this	  assay.194,234	  Briefly	  involves	  isolating	  the	  platelet	  contribution	  to	  the	  whole	  blood	  clotting	  process.	  	  Heparinized	  samples	  are	  used	  to	  eliminate	  thrombin	  response,	  and	  then	  reptilase,	  Factor	  XIII	  (FXIII),	  and	  either	  ADP,	  AA,	  or	  collagen	  are	  added	  to	  initiate	  these	  respective	  pathways.	  	  The	  resulting	  MA	  is	  compared	  to	  a	  matched	  citrated	  sample	  activated	  by	  kaolin	  and	  recalcification	  (full	  MA	  potential)	  after	  subtracting	  the	  fibrin	  contributions	  measured	  by	  a	  sample	  with	  only	  reptilase	  and	  FXIII.	  	  The	  data	  is	  expressed	  at	  %	  inhibition	  of	  the	  individual	  agonist	  pathways	  examined.	  ELISA	  was	  used	  to	  quantify	  additional	  plasma	  proteins	  related	  to	  coagulation.	  	  Citrated	  whole	  blood	  was	  centrifuged	  to	  produce	  platelet	  poor	  plasma	  as	  per	  laboratory	  protocol.	  Plasma	  was	  then	  aliquoted	  and	  frozen	  at	  -­‐80°	  C.	  	  All	  ELISA	  assays	  were	  commercially	  obtained	  as	  kits	  and	  performed	  to	  manufacturer’s	  instructions	  on	  freshly	  thawed	  samples.	  	  Thrombin-­‐Antithrombin	  (TAT)	  complex	  was	  measured	  using	  the	  Enzygnost®	  TAT	  micro	  kit	  (Siemens	  Healthcare	  Diagnostics,	  Tarrytown,	  NY,	  USA).	  	  D-­‐dimer	  concentrations	  were	  determined	  using	  the	  TECHNOZYM®	  D-­‐Dimer	  ELISA	  Kit	  (Technoclone	  GH,	  Vienna,	  Austria).	  The	  plasma	  coagulation	  cascade	  pathway	  tests	  of	  Prothrombin	  Time	  (PT)	  and	  activated	  partial	  thromboplastin	  time	  (PTT)	  as	  well	  as	  functional	  fibrinogen	  concentration	  were	  all	  measured	  in	  platelet	  poor	  plasma	  using	  the	  Start-­‐4®	  coagulation	  analyzer	  (Diagnostica	  Stago,	  Asnières,	  France).	  	  All	  tests	  were	  performed	  according	  to	  the	  manufacturer’s	  recommendation.	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Whole	  blood	  cell	  counts	  were	  performed	  on	  the	  ABX	  Micros	  60	  (Horiba	  Medical,	  Irvine,	  CA,	  USA).	  	  Tests	  were	  performed	  on	  EDTA	  anticoagulated	  whole	  blood	  drawn	  at	  the	  time	  of	  patient	  sampling	  according	  to	  manufacturer’s	  instruction.	  Samples	  were	  stained	  for	  flow	  cytometry	  with	  primary	  antibodies	  for	  CD62p-­‐PE,	  PAC-­‐1-­‐FITC,	  CD41-­‐PE-­‐Cy5	  and	  appropriate	  isotypic	  controls	  (BD	  Biosciences,	  San	  Jose,	  CA,	  USA).	  After	  a	  30-­‐minute	  incubation	  samples	  were	  fixed	  and	  analyzed	  with	  an	  Accuri	  C6	  cytometer	  (BD	  Biosciences,	  San	  Jose,	  CA,	  USA).	  A	  total	  of	  20,000	  platelets	  were	  analyzed	  in	  each	  sample.	  	  	  
Clinical	  Interpretation	  
	   Point	  of	  care	  tests	  performed	  at	  VCUMS	  at	  time	  of	  admission	  were	  used	  to	  determine	  the	  variables	  of	  systolic	  blood	  pressure	  (BPS),	  diastolic	  blood	  pressure	  (BPD),	  temperature,	  base	  excess	  (BE),	  respiratory	  rate	  (RESP	  RATE),	  O2	  saturation	  (sO2),	  pulse,	  lactate,	  Glasgow	  Coma	  Scale	  (GCS),	  injury	  severity	  score	  (ISS),	  and	  Traumatic	  Brain	  Injury	  (TBI).	  	  Emergency	  response	  fluid	  administration	  data	  was	  also	  obtained	  from	  the	  patient	  records	  at	  VCUMS.	  ACoT	  was	  defined	  by	  accepted	  guidelines	  adopted	  by	  the	  American	  Society	  of	  Anesthesiologists	  and	  summarized	  by	  Yuan.235	  Briefly	  patients	  presenting	  with	  an	  International	  Normalized	  Ratio	  (INR)	  ≥	  1.5	  were	  classified	  as	  presenting	  with	  ACoT.	  Early	  coagulopathy	  of	  trauma	  (ECoT)	  was	  defined	  as	  an	  INR	  	  >	  1.2	  but	  <	  1.5,	  as	  defined	  by	  past	  work	  by	  other	  labs.185	  	  	   Hypercoagulability	  was	  defined	  by	  an	  TEG	  R-­‐time	  of	  <3.7	  minutes,	  and	  was	  based	  on	  recent	  work	  performed	  by	  Shreiber.5	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DIC	  classification	  was	  based	  on	  currently	  accepted	  guidelines	  developed	  by	  the	  International	  Society	  for	  Thrombosis	  and	  Hemostasis	  (ISTH).230,236	  Briefly	  the	  parameters	  of	  platelet	  count,	  plasma	  D-­‐Dimer	  levels,	  fibrinogen	  concentration,	  and	  prothrombin	  time	  are	  assigned	  values	  based	  on	  standardized	  levels.	  	  These	  scores	  are	  tabulated,	  with	  any	  score	  over	  the	  cutoff	  level	  considered	  overt	  DIC.	  	  Further	  explanation	  of	  this	  calculation	  can	  be	  found	  in	  Table	  3.1.	  	  	  Hypothermia	  classification	  was	  based	  on	  currently	  accepted	  definitions229,	  with	  a	  temperature	  of	  <	  35°	  C	  at	  admission	  considered	  a	  state	  of	  hypothermia.	  	   Hypovolemic	  Shock	  classifications	  were	  based	  on	  the	  work	  of	  Mutschler	  utilizing	  Base	  Deficit	  (BD)	  at	  the	  time	  of	  admission	  to	  the	  Emergency	  Department.211	  Briefly	  shock	  is	  stratified	  into	  four	  categories;	  no	  shock	  (BD	  ≤	  2.0	  mmol/L),	  mild	  	  (BD	  >	  2.0	  to	  6.0	  mmol/L),	  moderate	  (BD	  >	  6	  to	  10.0	  mmol/L),	  and	  severe	  (BD	  >	  10.0	  mmol/L).	  
Data	  Analysis	  	  	  	  	  	  	   Data	  distributions	  were	  checked	  using	  QQ	  plots,	  and	  descriptive	  statistics	  (counts,	  percentages,	  mean	  ±	  SD,	  median	  (IQR))	  were	  used	  to	  summarize	  patients'	  data	  for	  each	  set	  of	  categorical	  groups.	  Different	  groups’	  parameters	  were	  compared	  using	  the	  analysis	  of	  variance	  (ANOVA)	  or	  the	  non-­‐parametric	  Kruskal-­‐Wallis	  test	  as	  appropriate.	  Multiple	  comparisons	  were	  made	  using	  either	  Tukey-­‐HSD	  method	  or	  Wilcoxon	  test	  as	  appropriate.	  Pearson’s	  Chi-­‐square	  test	  was	  used	  for	  categorical	  variables.	  All	  statistical	  analyses	  were	  performed	  using	  JMP	  statistical	  software,	  version	  10.0.0	  (SAS	  Institute,	  Cary,	  NC).	  	  The	  level	  of	  significance	  for	  all	  statistical	  tests	  was	  p<	  0.05.	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  3.3	  Results	  
Demography	  Across	  the	  course	  of	  the	  study	  there	  were	  105	  patients	  enrolled	  for	  which	  ISS	  score	  was	  available.	  	  Table	  3.2	  summarizes	  the	  intake	  data	  on	  all	  patients	  used	  for	  this	  analysis.	  	  There	  were	  more	  men	  enrolled	  by	  a	  4:1	  ratio	  when	  compared	  to	  women.	  	  The	  majority	  of	  patients	  had	  blunt	  injuries	  (73%),	  22%	  presented	  with	  blunt	  and	  penetrating	  injuries,	  and	  6%	  of	  the	  patients	  suffered	  from	  penetrating	  injuries	  alone.	  	  The	  median	  ISS	  score	  was	  18	  (IQR	  10	  to	  29)	  indicating	  a	  diverse	  trauma	  severity	  population.	  	  	  	  TBI	  was	  indicated	  in	  26%	  of	  the	  patient	  population.	  	  	  	  Hypovolemic	  shock	  was	  indicated	  in	  56%,	  and	  the	  majority	  of	  the	  shock	  cases	  were	  mild	  (57%).	  	  	  Coagulopathy	  was	  observed	  in	  varying	  degrees.	  	  One	  third	  of	  the	  subjects	  presented	  with	  hypofibrinogenemia,	  21%	  with	  ACoT,	  and	  17%	  with	  ECoT.	  6%	  of	  the	  patients	  showed	  overt	  signs	  of	  DIC.	  	  Pre-­‐hospital	  saline	  was	  administered	  to	  85%	  of	  the	  subjects,	  and	  14%	  received	  blood	  products	  prior	  to	  admission.	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Table	  3.1:	  Definition	  of	  Overt	  DIC	   	  	   	  	  
	  Criterion	   	  	   	  	   	  	   	  	   Points	  
	  
	   	   	   	   	   	   	  (1)	  Baseline	  Platelet	  Count	  
	   	   	   	  
	  
≥	  100	  000	  µL^-­‐1	  









<	  50	  000	  µL^-­‐1	  
	   	  
2	  points	  
	  
	   	   	   	   	   	   	  
(2)	  Baseline	  D-­‐Dimer	  
	   	   	   	  
	  
≤	  390	  ng/mL	  









>	  4	  000	  ng/mL	  
	   	  
3	  points	  
	  
	   	   	   	   	   	   	  (3)	  INR	  
	   	   	   	   	   	  
	  
≤	  1.4	  




>	  1.4	  to	  ≤	  2.3	  





	   	   	  
2	  points	  
	  
	   	   	   	   	   	   	  
(4)	  Fibrinogen	  Level	  
	   	   	   	   	  
	  
≥	  100	  mg/dL	  




<	  100	  mg/	  dL	  
	   	  
1	  point	  
	  
	   	   	   	   	   	   	  
Sum:	  1	  +	  2	  +	  3	  +	  4	   	  	   	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  ≥	  5	  points:	  Overt	  DIC	  
	  DIC;	   disseminated	   intravascular	   coagulation,	   INR;	   International	   Normalized	   Ratio.	  	  Adapted	  from	  Kienast	  et.	  al.	  (2006).237	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Table	  3.2:	  Demography,	  Injury	  Severity,	  Pathophysiology,	  and	  Treatment	  Parameters	  Upon	  Admission	  
of	  105	  Trauma	  Patients	  Investigated	  
	  	   	  	   	  Units	   	  	  	  	  	  	  	  	  Patients	  
	   	   	   	  
n	  
	   	  
	  	  	  	  	  	  	  	  	  105	  
	   	   	   	  Age	  
	  
	  	  	  	  	  	  	  	  YRS	   35	  (24,	  52.5)	  
	   	   	   	  Sex	   MALE	   	  	  	  	  	  	  %	  (n)	   82	  (86)	  
	   FEMALE	   	  	  	  	  	  	  	  %	  (n)	   18	  (19)	  
	   	   	   	  Race	   W	   	  	  	  	  	  	  %	  (n)	   56	  (59)	  
	   NW	   	  	  	  	  	  	  	  %	  (n)	   47	  (49)	  
	   	   	   	  Injury	  Type	   B	  	   	  	  	  	  	  	  %	  (n)	   73	  (76)	  
	   P	  	   	  	  	  	  	  	  	  %	  (n)	   22	  (23)	  
	   B/P	   	  	  	  	  	  	  	  %	  (n)	   6	  (6)	  
	   	   	   	  ISS	  
	  
	  	  	  	  SCORE	   18	  (10,	  29)	  
	   	   	   	  GCS	  
	  
	  	  	  	  	  SCORE	   15	  (4.5,	  15)	  
	  
	  
	   	  
TBI	  
	  
%	  (n)	   25	  (26)	  
	   	   	   	  Hypothermia	  
	  
%	  (n)	   3	  (3)	  
	   	   	   	  Shock	   Total	   %	  (n)	   56	  (59)	  
	   Mild	   %	  (n)	   32	  (33)	  
	   Moderate	   %	  (n)	   12	  (13)	  
	   Severe	   %	  (n)	   12	  (13)	  
	   	   	   	  Hypofibrinogenemia	  
	  
%	  (n)	   33	  (35)	  
	   	   	   	  ACoT	  
	  
%	  (n)	   21	  (22)	  
	   	   	   	  DIC	  
	  
%	  (n)	   6	  (6)	  
	   	   	   	  Blood	  Products	  (PH)	  
	  
%	  (n)	   14	  (15)	  
	   	   	   	  Saline	  (PH)	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  %	  (n)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  85	  (89)	  
	  	   	  	   	  	   	  	  
	   	   	   	  All	  data	  presented	  as	  mean	  (IQR)	  or	  %	  (n).	  	  ISS;	  Injury	  Severity	  Score,	  GCS;	  Glasgow	  Coma	  Scale,	  TBI;	  Traumatic	  Brain	  Injury,	  ACoT;	  Advanced	  Coagulopathy	  of	  Trauma,	  DIC;	  Disseminated	  Intravascular	  Coagulation,	  	  PH;	  Pre-­‐Hospital,	  W;	  White,	  NW;	  Non-­‐White,	  B;	  Blunt,	  P;	  Penetrating,	  B/P;	  Blunt	  and	  Penetrating.	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a	  Patients.	  	  Generated	  by	  Two	  Ways	  Hierarchical	  Cluster	  Analysis.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  The	  variables	  are	  clustered	  in	  at	  least	  4	  main	  groups	  as	  well	  as	  the	  patients	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Classification	  of	  Patient	  Population	  by	  Injury	  Severity	  The	  patient	  data	  from	  VCUMS	  were	  combined	  with	  the	  platelet	  function	  and	  coagulation	  assay	  data	  for	  analysis.	  The	  combination	  of	  physiological	  and	  clinical	  parameters	  with	  laboratorial	  coagulation	  tests	  has	  the	  potential	  to	  result	  in	  a	  better	  characterization	  of	  the	  patient	  state	  and	  lead	  to	  better	  treatment	  decisions	  and	  improved	  outcome.	  Using	  this	  database	  an	  exploratory	  analysis	  with	  hierarchical	  two	  ways	  clustering	  using	  40	  different	  variables	  was	  performed.	  This	  statistical	  method	  was	  adapted	  from	  previous	  work	  by	  Cohen	  et.	  al.238	  Figure	  3.1	  shows	  the	  heat	  map	  and	  dendrogram	  resulting	  from	  this	  analysis	  suggesting	  the	  existence	  of	  at	  least	  4	  clusters	  of	  patients	  with	  different	  combination	  of	  measurements	  values.	  	  Only	  half	  of	  the	  patients	  from	  the	  study,	  with	  no	  missing	  data,	  could	  be	  used	  for	  this	  analysis,	  limiting	  the	  use	  of	  these	  grouping	  techniques.	  Nonetheless,	  the	  heat	  map	  suggests	  that	  the	  Injury	  Severity	  Score	  (ISS)	  could	  be	  used	  as	  a	  method	  of	  grouping	  the	  trauma	  patients	  and	  helps	  to	  understand	  the	  pattern	  of	  physiological	  response.	  	  	  ISS	  is	  clustered	  with	  the	  clinical	  parameters	  pulse,	  lactate,	  volume	  of	  IV	  normal	  saline	  and	  white	  blood	  cells	  count	  as	  well	  as	  the	  laboratory	  variables	  PT,	  PTT,	  %	  of	  ADP	  inhibition,	  D-­‐dimer	  and	  TAT	  complexes,	  indicating	  association	  of	  parameters	  not	  usually	  used	  for	  triage	  in	  the	  ER.	  Although	  these	  parameters	  look	  to	  be	  the	  best	  predictors	  of	  cluster	  allocation	  the	  complex	  relationship	  of	  variables	  supports	  a	  physiologic	  response	  to	  trauma	  that	  is	  more	  subtle	  and	  intricate.	  	  	  In	  response	  to	  the	  clustering	  results	  patients	  were	  stratified	  into	  4	  different	  groups	  based	  on	  their	  ISS	  score	  as	  described	  before	  by	  Copes	  in	  1988239	  and	  further	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adapted	  by	  Bolorundo.231	  The	  groups	  were:	  mild	  injury	  (ISS	 ≤	  8),	  moderate	  injury	  (ISS	  9	  -­‐	  15),	  severe	  injury	  (ISS	  16	  -­‐	  25)	  and	  profound	  injury	  (ISS	  >	  25).	  Using	  the	  four-­‐group	  stratification	  admission	  variables	  were	  once	  again	  tabulated	  in	  Table	  3.3.	  	  From	  this	  analysis	  the	  emergence	  of	  trends	  begins	  to	  appear.	  	  	  There	  appears	  to	  be	  an	  increase	  in	  the	  both	  the	  number	  of	  cases	  as	  well	  as	  the	  severity	  of	  hypovolemic	  shock	  as	  the	  level	  of	  Injury	  severity	  increases	  (Table	  3.3).	  	  TBI	  also	  trends	  upwards	  as	  shock	  level	  increases.	  ACoT	  and	  hypofibrinogenemia	  also	  appear	  to	  trend	  higher	  as	  injury	  severity	  increases,	  but	  the	  simple	  appearance	  of	  hypofibrinogenemia	  did	  not	  indicate	  ACoT.	  	  This	  suggests	  consumption	  of	  additional	  factors	  other	  than	  fibrinogen	  in	  the	  development	  of	  coagulopathy.	  	  Both	  DIC	  and	  hypothermia	  were	  relatively	  rare.	  	  3	  cases	  of	  hypothermia	  were	  seen	  between	  the	  severe	  and	  profound	  categories	  combined,	  and	  the	  6	  cases	  of	  DIC	  were	  only	  present	  in	  the	  profound	  category.	  To	  explore	  these	  qualitatively	  observed	  trends	  further	  data	  was	  examined	  for	  correlation	  between	  ISS	  categories	  and	  presentation	  of	  clinical	  disorders.	  	  These	  results	  can	  be	  found	  in	  Table	  3.	  	  Strong	  positive	  correlation	  was	  found	  between	  ISS	  severity	  and	  GCS	  (p<0.0002),	  hypofibrinogenemia	  (p<0.0001),	  and	  ACoT	  (p<0.0001).	  Hypovolemic	  shock	  occurrence	  also	  strongly	  correlated	  with	  ISS	  category	  positively	  (p<0.0001),	  but	  sample	  size	  was	  insufficient	  (n=22)	  to	  determine	  if	  individual	  shock	  severity	  categories	  showed	  significant	  correlation	  with	  shock	  severity	  levels	  using	  the	  Pearson’s	  Chi-­‐square	  test.	  	  	  
	   113	  
Table	  3.3:	  Demography,	  Pathophysiology,	  and	  Treatment	  Parameters	  Upon	  Admission	  
Based	  on	  ISS	  Classification	  of	  105	  Trauma	  Patients	  
	  
	  	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	   Unit	   ISS	  Classification	   Correlation	  
	   	   	  
Mild	   Moderate	   Severe	   Profound	  
	   	  ISS	  Score	  
	   	  
1	  to	  8	   9	  to	  15	   16	  to	  24	   ≥	  25	  
	  
	   	   	   	   	   	   	   	  n	  
	   	  
17	   27	   25	   36	   NA	  
	  
	   	   	   	   	   	   	  Age	  
	  
YRS	   27	  (21,	  52.5)	   39	  (27,	  52)	   39	  (25,	  53)	   31	  (23,	  53)	   NA	  
	  
	   	  
	   	   	  
	   	  Sex	   MALE	   %	  (n)	   14	  (82)	   24	  (89)	   21	  (84)	   27	  (75)	   NA	  
	   FEMALE	   %	  (n)	   3	  (18)	   3	  (11)	   4	  (16)	   9	  (25)	  
	  
	  
	   	  
	   	   	  
	   	  Race	   W	   %	  (n)	   10	  (59)	   12	  (44)	   14	  (56)	   23	  (64)	   NA	  
	   NW	   %	  (n)	   7	  (41)	   15	  (56)	   11	  (44)	   13	  (36)	  
	  
	  
	   	  
	   	   	  
	   	  Injury	  Type	   B	  	   %	  (n)	   11	  (65)	   18	  (67)	   18	  (72)	   29	  (81)	   NA	  
	   P	  	   %	  (n)	   5	  (29)	   8	  (30)	   5	  (20)	   5	  (14)	  
	  
	   B/P	   %	  (n)	   1	  (6)	   1	  (4)	   2	  (8)	   2	  (6)	  
	  
	  
	   	  
	   	   	  
	   	  GCS	  
	  
SCORE	   15	  (14.5,	  15)	   15	  (14,	  15)	   14	  (8,	  5)	   8.5	  (3,	  15)	   Negative	  (a)	  
	  
	   	   	   	   	   	   	  TBI	  
	  
%	  (n)	   0	  (0)	   4	  (15)	   7	  (28)	   15	  (42)	   Positive	  (a)	  
	  
	   	   	   	   	   	   	  Hypothermia	  
	  
%	  (n)	   0	  (0)	   0	  (0)	   1	  (4)	   2	  (6)	  
	   	  
	  
	   	   	   	   	   	   	  Shock	   Total	   %	  (n)	   4	  (23)	   10	  (37)	   17	  (68)	   28	  (78)	   Positive	  (b)	  
	   Mild	   %	  (n)	   3	  (16)	   8	  (30)	   7	  (28)	   15	  (42)	  
	  
	   Moderate	   %	  (n)	   0	  (0)	   1	  (4)	   8	  (32)	   4	  (11)	  
	  
	   Severe	   %	  (n)	   1	  (6)	   1	  (4)	   2	  (8)	   9	  (25)	  
	  
	  
	   	   	   	   	   	   	  Hypofibrinogenemia	  
	  
%	  (n)	   1	  (6)	   3	  (11)	   8	  (32)	   23	  (64)	   Positive	  (b)	  
	  
	   	   	   	   	   	   	  ACoT	  
	  
%	  (n)	   0	  (0)	   1	  (4)	   6	  (24)	   17	  (47)	   Positive	  (b)	  
	  
	   	   	   	   	   	   	  DIC	  
	  
%	  (n)	   0	  (0)	   0	  (0)	   0	  (0)	   6	  (17)	   Positive	  (b)	  
	  
	   	   	   	   	   	   	  Blood	  Products	  (PH)	  
	  
%	  (n)	   0	  (0)	   2	  (7)	   4	  (16)	   9	  (36)	   NS	  
	  
	   	   	   	   	   	   	  Saline	  (PH)	  
	  
%	  (n)	   16	  (94)	   18	  (67)	   21	  (84)	   31	  (86)	   NS	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  All	  data	  presented	  as	  %	  (n)	  or	  median	  (IQR).	   	  Bold	  text	   indicates	  significance	  (p	  ≤	  0.05).	  	  a;	  p	  ≤	  0.05,	  b;	  p	  ≤	  0.0001,	  ISS;	  Injury	  Severity	  Score,	  GCS;	  Glasgow	  Coma	  Scale,	  TBI;	   Traumatic	   Brain	   Injury,	   ACoT;	   Advanced	   Coagulopathy	   of	   Trauma,	   DIC;	  Disseminated	   Intravascular	   Coagulation,	   PH;	   Pre-­‐Hospital,	   W;	   White,	   NW;	   Non-­‐White,	  B;	  Blunt,	  P;	  Penetrating,	  B/P;	  Blunt	  and	  Penetrating.	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   Table	  3.4	  shows	  a	  cumulative	  tabulation	  of	  all	  variables	  that	  were	  found	  to	  be	  outside	  normal	  ranges.	  	  White	  blood	  cell	  counts	  were	  elevated	  in	  the	  severe	  (13.8	  (11.05,	  18.7)	  10^9	  cells/L)	  and	  profound	  (13.95	  (11.025,	  19.125)	  10^9	  cells/L)	  categories.	  	  Red	  blood	  cells	  were	  lower	  than	  normal	  values	  in	  the	  moderate	  (4.3	  (3.7,	  4.89)	  10^12	  cells/L),	  severe	  (3.8	  (3.5,	  4.4)	  10^12	  cells/L),	  and	  profound	  (3.85	  (3.1,	  4.275)	  10^12	  cells/L)	  categories.	  	  High	  shear	  adhesion	  and	  aggregation	  was	  higher	  in	  response	  to	  collagen	  and	  ADP	  in	  both	  the	  moderate	  (62	  (53,	  84)	  seconds)	  and	  severe	  (61	  (51.5,	  77.5)	  seconds)	  groups,	  while	  in	  response	  to	  collagen	  and	  epinephrine	  only	  the	  severe	  group	  (89	  (81.5,	  130.5)	  seconds)	  was	  outside	  normal	  ranges.	  	  Inhibition	  of	  the	  ADP	  pathway	  was	  elevated	  in	  mild	  (75.7	  (42.1,	  82.3)%),	  severe	  (85.9	  (61.675,	  98.425)%),	  and	  profound	  (97	  (79.75,	  99.75)%)	  injury	  groups.	  Prothrombin	  time	  is	  elevated	  in	  only	  the	  profound	  group	  (17.4	  (15,	  20.5)	  seconds),	  and	  D-­‐dimer	  levels	  are	  higher	  in	  the	  moderate	  (1065.05	  (302.4,	  3684.45)	  ng/mL),	  severe	  (1986.15	  (363.975,	  4252.95)	  ng/mL),	  and	  profound	  (3448.	  75	  (778.525,	  4897.925)	  ng/mL)	  categories.	  
Coagulation	  Based	  Classification	  	   	  While	  ISS	  is	  still	  the	  gold	  standard	  in	  trauma	  evaluation,	  this	  method	  may	  not	  identify	  subtle	  differences	  in	  platelet	  function	  when	  measured	  across	  a	  global	  population.	  	  Two	  other	  standards	  were	  chosen	  to	  separate	  the	  population	  based	  on	  observed	  coagulopathies	  in	  an	  attempt	  to	  better	  define	  possible	  changes.	  ACoT	  is	  a	  recognized	  and	  relatively	  severe	  consumption	  disorder,	  but	  recent	  work	  suggests	  the	  development	  of	  an	  early	  coagulopathy	  as	  well	  (ECoT).	  	  Using	  these	  new	  parameters	  data	  was	  again	  analyzed	  (Table	  3.5).
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Table	  3.5:	  Demography,	  Pathophysiology,	  and	  Treatment	  Parameters	  Upon	  Admission	  Based	  on	  
Consumption	  Coagulopathy	  	  
	  	   	  	   Unit	   Coagulopathy	  Classification	  
	   	   	  
Normal	   ECoT	   ACoT	  
	   	   	  
INR	  <	  1.2	   INR	  1.2	  to	  <	  1.5	   INR	  ≥	  1.5	  
	   	   	   	   	   	  n	  
	   	  
61	   18	   24	  
	  
	   	   	   	   	  ISS	  Score	  
	   	  
14	  (9,22)	   20.5	  (11.25,	  29.25)	   33.5	  (22,42.5)	  
	  
	   	   	   	   	  Age	  
	  
YRS	   37	  (23.5,	  53)	   47	  (26.5,	  61.5)	   29.5	  (23.25,	  44.5)	  
	  
	   	  
	   	   	  
Sex	   MALE	   %	  (n)	   90	  (55)	   72	  (13)	   71	  (17)	  
	   FEMALE	   %	  (n)	   10	  (6)	   28	  (5)	   29	  (7)	  
	  
	   	  
	   	   	  
Race	   W	   %	  (n)	   52	  (32)	   44	  (8)	   21	  (5)	  
	   NW	   %	  (n)	   48	  (29)	   56	  (10)	   79	  (19)	  
	  
	   	  
	   	   	  
Injury	  Type	   B	  	   %	  (n)	   72	  (44)	   78	  (14)	   71	  (17)	  
	   P	  	   %	  (n)	   7	  (4)	   0	  (0)	   4	  (1)	  
	   B/P	   %	  (n)	   21	  (13)	   22	  (4)	   25	  (6)	  
	  
	   	  
	   	   	  
GCS	   	   SCORE	   15	  (13,	  15)	   12.5	  (3,	  15)	   9	  (3,	  15)	  
	  
	   	   	   	   	  TBI	  
	  
%	  (n)	   21	  (13)	   33	  (6)	   33	  (8)	  
	  
	   	   	   	   	  Hypothermia	  
	  
%	  (n)	   0	  (0)	   14	  (2)	   8	  (1)	  
	  
	   	   	   	   	  Shock	   Total	   %	  (n)	   58	  (35)	   39	  (7)	   13	  (3)	  
	   Mild	   %	  (n)	   30	  (18)	   33	  (6)	   38	  (9)	  
	   Moderate	   %	  (n)	   7	  (4)	   22	  (4)	   21	  (5)	  
	   Severe	   %	  (n)	   5	  (3)	   6	  (1)	   29	  (7)	  
	  
	   	   	   	   	  Hypofibrinogenemia	  
	  
%	  (n)	   10	  (6)	   33	  (6)	   88	  (21)	  
	  
	   	   	   	   	  
	  
	   	   	   	   	  Blood	  Products	  (PH)	  
	  
%	  (n)	   5	  (3)	   18	  (3)	   36	  (8)	  
	  
	   	   	   	   	  Saline	  (PH)	  
	  
%	  (n)	   82	  (50)	   72	  (13)	   88	  (21)	  
	  	   	  	   	  	   	  	   	  	   	  	  All	  data	  presented	  as	  mean	  (IQR)	  or	  %	  (n).	  	  ISS;	  Injury	  Severity	  Score,	  GCS;	  Glasgow	  Coma	  Scale,	  TBI;	  Traumatic	   Brain	   Injury,	   ACoT;	   Advanced	   Coagulopathy	   of	   Trauma,	   ECoT;	   Early	   Coagulopathy	   of	  Trauma,	  DIC;	  Disseminated	  Intravascular	  Coagulation,	  PH;	  Pre-­‐Hospital,	  W;	  White,	  NW;	  Non-­‐White,	  B;	  Blunt,	  P;	  Penetrating,	  B/P;	  Blunt	  and	  Penetrating.	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   Recent	  work	  by	  many	  groups	  has	  also	  indicated	  a	  state	  of	  hypercoagulability	  (HC)	  measured	  by	  thromboelastography5,186,	  so	  the	  classification	  developed	  by	  Schreiber5	  for	  HC	  (TEG	  R	  <	  3.7)	  was	  also	  used.	  This	  particular	  coagulopathy	  is	  not	  expected	  to	  be	  consumption	  driven.	  	  The	  data	  from	  this	  analysis	  can	  be	  found	  in	  Table	  3.6.	  	   These	  two	  tables	  then	  can	  be	  compared	  to	  the	  data	  generated	  to	  the	  ISS	  stratification	  to	  see	  if	  similarities	  exist.	  	  The	  consumption	  disorder	  grouping	  shows	  that	  68%	  of	  the	  patients	  for	  whom	  a	  reportable	  INR	  and	  R	  time	  were	  found	  (103)	  developed	  some	  level	  of	  coagulopathy.	  	  ISS	  scores	  appear	  to	  rise	  as	  level	  of	  coagulopathy	  increases,	  agreeing	  with	  the	  observation	  that	  ISS	  categorical	  values	  were	  correlated	  with	  development	  of	  ACoT	  (Table	  3.3).	  	  Other	  parameters	  were	  observed	  to	  have	  similar	  responses	  to	  the	  ISS	  table	  as	  well.	  	  Increased	  shock	  appears	  to	  lead	  to	  increased	  coagulopathy,	  and	  intuitively	  functional	  fibrinogen	  concentration	  falls	  as	  consumptive	  coagulopathy	  persists.	  	  When	  looking	  at	  the	  hypercoagulability	  data	  there	  appears	  to	  be	  a	  disconnect	  between	  ISS	  score	  and	  development	  of	  this	  disorder.	  30%	  of	  the	  patients	  showed	  signs	  of	  HC.	  Median	  ISS	  was	  20	  (9,30)	  in	  the	  HC+	  group	  compared	  to	  the	  HC-­‐.	  	  Interestingly	  of	  the	  18	  females	  used	  for	  this	  examination	  only	  2	  (11%)	  developed	  HC.	  	  This	  is	  in	  stark	  contrast	  to	  the	  52%	  (29	  out	  of	  56)	  of	  the	  men	  whom	  developed	  this	  pathology.	  	  When	  comparing	  this	  same	  female	  population	  66%	  (12	  out	  of	  18)	  developed	  some	  sort	  of	  consumptive	  coagulopathy,	  and	  7	  reached	  the	  level	  of	  ACoT	  (29%).	  	  30	  men	  (55%)	  developed	  either	  ECoT	  or	  ACoT	  matching	  the	  HC	  data	  well.	  	  36%	  of	  ACoT	  and	  18%	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of	  ECoT	  subjects	  received	  pre-­‐hospital	  blood	  products,	  where	  only	  23%	  of	  HC	  received	  them.	  	  	   To	  investigate	  apparent	  trends	  in	  the	  two	  competing	  data	  tables	  Chi-­‐squared	  correlations	  were	  analyzed	  between	  the	  two	  types	  of	  coagulopathy	  and	  hypovolemic	  shock,	  ISS	  categories,	  and	  hypofibrinogenemia.	  	  The	  parameters	  of	  ECoT	  and	  ACoT	  were	  both	  considered	  as	  consumption	  coagulopathy	  (INR	  driven)	  and	  were	  compared	  to	  HC	  (R	  driven)	  coagulopathy	  (Table	  3.7).	  Individuals	  that	  presented	  with	  both	  ACoT	  and	  HC	  were	  excluded	  from	  this	  analysis	  in	  order	  to	  examine	  the	  individual	  disorders	  separately.	  	  Chi-­‐squared	  analysis	  revealed	  a	  positive	  association	  when	  comparing	  ACoT	  with	  ISS	  (p<	  0.0001)	  and	  hypovolemic	  shock	  (p<	  0.05)	  as	  well	  as	  a	  negative	  correlation	  with	  hypofibrinogenemia.	  (p	  <	  0.0001).	  	  HC	  does	  not	  appear	  to	  correlate	  with	  shock	  (p=0.3586),	  ISS	  categories	  (p=0.9831),	  or	  hypofibrinogenemia	  (p=0.5947)	  	   To	  better	  define	  the	  relationships	  seen	  in	  the	  categorical	  correlations	  a	  set	  of	  constant	  variable	  continuous	  correlations	  were	  performed	  focusing	  on	  the	  parameters	  that	  drive	  the	  two	  examined	  coagulopathy	  categories.	  	  INR	  and	  R	  time	  were	  selected,	  as	  they	  are	  the	  defining	  parameter	  for	  ACoT/ECoT	  and	  HC	  classifications	  respectively.	  	  They	  were	  compared	  to	  BD	  (defining	  parameter	  for	  hypovolemic	  shock),	  Fibrinogen,	  and	  ISS	  (Table	  3.8).	  	  INR	  showed	  strong	  positive	  correlation	  with	  BD	  (p<0.05,	  r=0.54)	  and	  ISS	  (p<0.0001,	  r=0.447),	  and	  a	  strong	  negative	  correlation	  with	  fibrinogen.	  	  In	  support	  of	  the	  categorical	  Chi-­‐squared	  testing,	  HC	  does	  not	  appear	  to	  be	  correlated	  with	  BD	  (p=0.98),	  ISS	  (p=0.5436),	  or	  fibrinogen	  (p=0.318).
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Table	  3.6:	  Demography,	  Pathophysiology,	  and	  Treatment	  Parameters	  Upon	  Admission	  Based	  
on	  Hypercoagulability	  
	  	   	  	   Unit	   TEG	  Classification	  
	   	   	  
HC	   Normal	  
	   	   	  
R	  <	  3.7	   R>=3.7	  
	   	   	   	   	  n	  
	   	  
31	   72	  
	  
	   	   	   	  ISS	  Score	  
	   	  
20	  (9,	  30)	   17.5	  (12,	  29)	  
	  
	   	   	   	  Age	  
	  
YRS	   40	  (27,	  53)	   33	  (23,	  52.75)	  
	  
	   	  
	   	  
Sex	   MALE	   %	  (n)	   94	  (29)	   22	  (16)	  
	   FEMALE	   %	  (n)	   6	  (2)	   78	  (56)	  
	  
	   	  
	   	  
Race	   W	   %	  (n)	   52	  (16)	   42	  (30)	  
	   NW	   %	  (n)	   48	  (15)	   58	  (42)	  
	  
	   	  
	   	  
Injury	  Type	   B	  	   %	  (n)	   58	  (18)	   79	  (57)	  
	   P	  	   %	  (n)	   29	  (9)	   19	  (14)	  
	   B/P	   %	  (n)	   13	  (4)	   1	  (1)	  
	  
	   	  
	   	  
GCS	  
	  
SCORE	   14	  (9,	  15)	   15	  (3,	  15)	  
	  
	   	   	   	  TBI	  
	  
%	  (n)	   23	  (7)	   28	  (20)	  
	  
	   	   	   	  Hypothermia	  
	  
%	  (n)	   0	  (0)	   6	  (3)	  
	  
	   	   	   	  Shock	   Total	   %	  (n)	   61	  (19)	   55	  (40)	  
	   Mild	   %	  (n)	   32	  (10)	   32	  (23)	  
	   Moderate	   %	  (n)	   19	  (6)	   10	  (7)	  
	   Severe	   %	  (n)	   10	  (3)	   13	  (9)	  
	  
	   	   	   	  Hypofibrinogenemia	  
	  
%	  (n)	   27	  (8)	   36	  (26)	  
	  
	   	   	   	  ACoT	  
	  
%	  (n)	   23	  (7)	   24	  (17)	  
	  
	   	   	   	  Blood	  Products	  (PH)	  
	  
%	  (n)	   23	  (7)	   10	  (7)	  
	  
	   	   	   	  Saline	  (PH)	  
	  
%	  (n)	   80	  (25)	   82	  (59)	  
	  	   	  	   	  	   	  	   	  	  All	  data	  presented	  as	  mean	  (IQR)	  or	  %	  (n).	  	  ISS;	  Injury	  Severity	  Score,	  GCS;	  Glasgow	  Coma	  Scale,	  TBI;	  Traumatic	  Brain	  Injury,	  ACoT;	  Advanced	  Coagulopathy	  of	  Trauma,	  DIC;	  Disseminated	  Intravascular	  Coagulation,	  PH;	  Pre-­‐Hospital,	  W;	  White,	  NW;	  Non-­‐White,	  B;	  Blunt,	  P;	  Penetrating,	  B/P;	  Blunt	  and	  Penetrating.	  






Table	  3.7:	  Correlation	  Comparison	  of	  Coagulopathy	  Categories	  
	   	  	  	   	  	   	  	   Category	   	  	  
	   	  
ACoT	   HC	  
	   	  
correlation	   p	  value	   correlation	   p	  value	  
	   	  
	   	   	   	  
Shock	  
	  
positive	   <	  0.05	   none	  	   0.3586	  
	   	  
	   	   	   	  
ISS	  Category	   positive	   <	  0.0001	   none	   0.9831	  
	   	  
	   	   	   	  
Hypofibrinogenemia	   negative	   <	  0.0001	   none	  	   0.5947	  
	  	   	  	   	  	   	  	   	  	   	  	  HC;	  hypercoagulability,	  ISS;	  International	  Normalized	  Ratio.	  	  	  	  	  	  	  	  	  	  
Table	  3.8:	  Correlation	  Comparison	  of	  Coagulopathy	  "Driving	  Factors"	  
	  	  	   	  	   	  	   Driving	  Parameter	   	  	  
	   	  
INR	   R	  
	   	  
correlation	  (p	  value)	   r	  value	   correlation	  (p	  value)	   r	  value	  






positive	  (<	  0.05)	   0.54	   none	  (0.98)	   NA	  






positive	  (<	  0.0001)	   0.447	   none	  (0.543)	   NA	  




FIB	   	  	   negative	  (<	  0.0001)	   -­‐0.5034	   none	  (0.318)	   NA	  INR;	  International	  Normalized	  Ratio,	  R;	  R	  time,	  BD;	  Base	  Deficit,	  ISS,	  injury	  severity	  score,	  FIB;	  functional	  fibrinogen	  concentration.	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   The	  correlations	  suggest	  two	  non-­‐related	  disorders,	  but	  do	  not	  define	  individual	  parameters.	  	  In	  order	  to	  define	  the	  two	  groups	  by	  their	  platelet	  function	  components	  coagulation	  data	  was	  compiled	  and	  analyzed	  for	  differences.	  	  Mean	  platelet	  counts	  were	  not	  significantly	  different	  between	  HC	  (188.9	  ±	  74.80)	  and	  the	  ECoT/ACoT	  group	  (213.9	  	  ±	  63.80).	  	  	  PFA	  testing	  demonstrated	  no	  significant	  differences	  between	  the	  two	  classification	  groups	  in	  high	  shear	  conditions.	  	  Interestingly	  in	  the	  HC	  group	  collagen	  and	  ADP	  activation	  resulted	  in	  a	  median	  CT	  relatively	  close	  to	  the	  lower	  limit	  (60	  s)	  of	  normal	  for	  this	  test	  (61	  (53,67)	  s)	  (Table	  3.9).	  	  	  Whole	  blood	  aggregometry	  revealed	  a	  higher	  response	  to	  collagen	  in	  the	  HC	  group	  (13.98	  	  ±	  4.412	  Ohms)	  than	  in	  the	  ACoT	  group	  (9.79	  	  ±	  4.687	  Ohms).	  	  ADP	  stimulation	  generated	  a	  stronger	  response	  in	  HC	  platelets	  (10.28	  	  ±	  4.487	  Ohms)	  than	  in	  ACoT	  (6.29	  	  ±	  3.016	  Ohms)	  as	  well.	  	  	  Flow	  cytometry	  analysis	  showed	  no	  significant	  differences	  between	  the	  two	  groups,	  and	  fell	  within	  the	  normal	  reportable	  ranges	  for	  this	  lab.	  Care	  must	  be	  exercised	  when	  drawing	  any	  conclusions	  from	  the	  mechanical	  testing	  in	  this	  particular	  situation.	  	  A	  strong	  case	  for	  bias	  can	  be	  made	  due	  to	  two	  separate	  and	  compelling	  reasons.	  	  Kinetics	  appear	  increased	  in	  both	  HAS	  (FOT)	  and	  TEG	  (R,	  K,	  Angle)	  analysis.	  HC	  classification	  criteria	  is	  defined	  by	  a	  decreased	  R	  time,	  so	  significant	  mathematical	  bias	  is	  imparted	  on	  the	  mean/median	  of	  this	  group	  as	  well	  as	  K	  and	  Angle	  which	  are	  directly	  related	  to	  the	  same	  kinetic	  processes	  (thrombin	  generation).	  	  FOT	  is	  a	  comparable	  measure	  to	  R	  time,	  and	  must	  also	  be	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Table	  3.9:	  Comparison	  of	  Platelet	  Function	  Tests	  between	  Coagulopathy	  Groups	  
	  	  	   	  	   Unit	   Coagulation	  Status	   p	  value	  
	   	   	  
HC	   ACoT	  
	  
	   	  
n	   24	   17	  
	  Aggregation	  
	  
	   	  
	  High	  Shear	  
	  
	   	  
	  
	  
COLL/ADP	   s	   61	  (53,	  67)	   67	  (53,	  80)	   0.1997	  
	  
COLL/EPI	   s	   92	  (77,	  121)	   123	  (97.25,	  153)	   0.1879	  
	   	   	  
	   	  
	  Low	  Shear	  
	  
	   	  
	  
	  
COLL	   Ohms	   13.98	  (4.412)	   9.79	  (4.687)	   0.0068	  
	  
ADP	   Ohms	   10.28	  (4.487)	   6.29	  (3.016)	   0.0015	  
	   	   	  
	   	  
	  Flow	  Cytometry	  
	  
	   	  
	  
	  
CD62P	  	   %	   3.8	  (2,	  15.5)	   2.6	  (1.15,	  6.15)	   0.1264	  
	  
PAC-­‐1	   %	   4.9	  (0.9,	  17.5)	   1.55	  (0.35,	  8.725)	   0.0896	  
	   	   	  
	   	  
	  Mechanical	  Testing	  
	  
	   	  
	  HAS	  	  	  
	  
	   	  
	  
	  
FOT	   min	   2.76	  (0.898)	   4.21	  (1.300)	   0.0005	  
	  
PCF	   kdynes	   8.61	  (1.825)	   5.13	  (2.279)	   <	  0.0001	  
	  
CEM	   kdyne/cm2	   33.27	  (7.348)	   23.39	  (11.499)	   0.0095	  
TEG	  
	  
	   	  
	  
	  
R	   min	   3.12	  (0.378)	   5.10	  (0.996)	   <	  0.0001	  
	  
K	   min	   1.25	  (0.297)	   2.06	  (1.187)	   <	  0.0001	  
	  
Angle	   degrees	   72.38	  (3.879)	   62.01	  (10.000)	   0.0006	  
	  
MA	   mm	   62.64	  (4.500)	   54.15	  (8.332)	   0.0009	  
Platelet	  Mapping	  
	  
	   	  
	  
	  
ADP	  Inhibition	   %	   71.92	  (25.113)	   85.80	  (26.041)	   0.1168	  
	  
AA	  Inhibition	   %	   48.10	  (25.404)	   46.01	  (27.865)	   0.8224	  All	  data	  presented	  as	  mean	  (SD)	  or	  median	  (IQR).	  	  Bold	  type	  indicates	  significant	  differences.	  HC;	  hypercoagulability,	  ACoT;	  Acute	  Coagulopathy	  of	  Trauma,	  COLL;	  collagen,	  ADP;	  adenosine	  di-­‐phosphate,	  EPI;	  epinephrine,	  FOT;	  force	  onset	  time,	  PCF;	  platelet	  contractile	  force,	  CEM;	  clot	  elastic	  modulus,	  	  R;	  R	  time,	  K;	  K	  time,	  MA;	  maximum	  amplitude.
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viewed	  with	  equal	  skepticism.	  	  This	  same	  logical	  argument	  can	  be	  used	  to	  rule	  out	  strength	  measurements	  as	  well.	  	  Consumption	  and	  dysfunction	  in	  the	  plasma	  cascade	  is	  the	  driving	  factor	  behind	  elevations	  of	  INR,	  which	  are	  used	  to	  define	  ACoT.	  	  	  Platelet	  mapping	  showed	  no	  significant	  differences	  between	  the	  groups.	  	  AA	  inhibition	  was	  normal	  in	  both	  the	  HC	  group	  (48.10	  	  ±	  25.404	  %)	  and	  ACoT	  group	  (46.01	  	  ±	  27.865	  %).	  	  ADP	  inhibition	  was	  slightly	  higher	  than	  normal	  (<	  70%)	  in	  the	  HC	  group	  (71.92	  	  ±	  25.113	  %)	  and	  ACoT	  patients	  fell	  squarely	  in	  the	  above	  normal	  range	  (85.80	  	  ±	  26.041).	  
3.4	  Discussion	  Current	  practice	  in	  trauma	  care	  is	  to	  classify	  individuals	  based	  on	  ISS.	  	  ISS	  does	  strongly	  correlate	  with	  development	  of	  ACoT	  but	  this	  does	  not	  tell	  the	  whole	  story	  behind	  coagulation	  changes	  in	  this	  patient	  population.	  	  The	  development	  of	  a	  more	  targeted	  method	  of	  evaluation	  of	  the	  coagulopathy	  induced	  by	  traumatic	  injury	  may	  possibly	  lead	  to	  improved	  treatment	  parameters	  as	  well	  as	  better	  outcomes	  compared	  to	  current	  practice.	  	  	  	   If	  broken	  into	  4	  severity	  classifications	  ISS	  does	  correlate	  strongly	  with	  the	  physical	  appearance	  of	  TBI	  and	  lower	  GCS.	  	  The	  Coagulation	  disorders	  hypofibrinogenemia	  and	  ACoT	  also	  appear	  to	  be	  strongly	  associated	  with	  the	  ISS	  stratification	  proposed.	  	  If	  one	  were	  to	  examine	  only	  the	  commonly	  used	  clinical	  coagulation	  tests	  (PT,	  PTT,	  [Fibrinogen])	  this	  classification	  system	  does	  appear	  to	  be	  effective.	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   If	  the	  clustering	  analysis	  is	  revisited	  however	  it	  suggests	  a	  complex	  interplay	  between	  traumatic	  injury	  and	  the	  systematic	  physiological	  coagulation	  response.	  	  An	  alternate	  approach	  was	  then	  employed	  in	  which	  patients	  were	  classified	  according	  to	  coagulation	  disorders,	  in	  an	  attempt	  to	  identify	  more	  subtle	  changes.	  	  INR	  driven	  consumption	  coagulopathy	  analysis	  data	  does	  show	  strong	  association	  with	  ISS,	  and	  when	  classified	  by	  severity	  this	  stratification	  resembles	  ISS	  stratification	  in	  its	  association	  with	  shock	  and	  hypofibrinogenemia.	  	  	  Using	  mechanical	  kinetic	  testing	  to	  identify	  a	  hypercoagulable	  population	  a	  competing	  classification	  system	  was	  developed	  based	  on	  TEG	  R	  time.	  	  This	  population	  has	  been	  reported	  by	  many	  groups	  in	  recent	  years,	  and	  as	  been	  consistently	  apparent	  in	  our	  recent	  animal	  shock	  studies.	  	  This	  classification	  system	  does	  not	  show	  correlation	  with	  development	  or	  severity	  of	  shock,	  and	  appears	  to	  effect	  women	  at	  a	  lower	  rate	  than	  men	  in	  this	  population.	  	  	  The	  driving	  forces	  behind	  the	  classification	  systems	  were	  examined	  to	  determine	  if	  the	  stratification	  of	  variables	  introduced	  bias	  into	  these	  associations	  as	  well.	  	  When	  looking	  at	  continuous	  variable	  correlations	  the	  associations	  between	  INR	  (driving	  force	  behind	  ACoT	  diagnosis)	  and	  BD,	  ISS,	  and	  functional	  fibrinogen	  concentration	  maintain	  the	  relationships	  observed	  during	  categorical	  analysis.	  	  On	  the	  other	  hand	  R	  time	  (driving	  force	  behind	  HC	  diagnosis)	  shows	  no	  significant	  correlation	  with	  these	  same	  variables,	  further	  strengthening	  the	  theory	  that	  these	  two	  populations	  are	  distinct.	  Direct	  comparison	  of	  the	  ACoT+	  population	  with	  the	  HC+	  population	  shows	  distinct	  differences	  in	  platelet	  aggregation	  response,	  and	  suggests	  the	  possibility	  of	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two	  separate	  conditions.	  	  Categorical	  data	  supports	  the	  distinction	  when	  looking	  at	  the	  incidence	  of	  ACoT	  within	  the	  HC	  grouping.	  	  The	  rate	  of	  occurrence	  of	  ACoT	  in	  the	  HC+	  population	  (23%)	  is	  comparable	  to	  the	  rate	  in	  the	  HC-­‐	  population	  (24%),	  suggesting	  that	  while	  separate	  in	  many	  ways,	  HC	  and	  consumption	  coagulopathy	  are	  not	  mutually	  exclusive.	  Interestingly	  female	  patients	  were	  found	  to	  develop	  HC	  at	  a	  much	  lower	  rate	  than	  men	  (11%	  to	  52%	  respectively)	  suggesting	  a	  sex	  related	  component	  to	  this	  disorder.	  All	  the	  data	  presented	  in	  this	  analysis	  suggest	  a	  disconnect	  between	  current	  clinical	  treatment	  classification	  and	  the	  full	  extent	  of	  trauma	  induced	  coagulopathy.	  	  A	  more	  focused	  approach	  to	  delineate	  treatment	  based	  on	  in	  depth	  platelet	  function	  and	  coagulation	  evaluation.	  	  	  The	  analysis	  of	  the	  data	  obtained	  during	  this	  study	  is	  in	  the	  very	  early	  stages,	  and	  only	  admission	  variables	  have	  been	  analyzed	  at	  this	  point.	  	  As	  more	  in	  depth	  examination	  of	  the	  data	  occurs	  it	  is	  hoped	  that	  a	  better	  picture	  of	  not	  only	  the	  presentation	  of	  coagulopathy	  becomes	  apparent,	  but	  also	  the	  progression	  and	  resolution	  of	  these	  conditions	  over	  time	  lead	  to	  better	  strategies	  for	  care	  in	  the	  severely	  injured.	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   Oxidative	  stress	  has	  been	  shown	  extensively	  to	  be	  a	  component	  of	  a	  variety	  of	  disease	  states	  as	  well	  as	  ischemic	  and	  hypoxic	  injury.	  	  It	  is	  also	  well	  known	  that	  many	  disease	  states	  such	  as	  cardiovascular	  disease,	  sepsis,	  diabetes,	  and	  traumatic	  shock	  all	  involve	  the	  development	  of	  a	  coagulopathy	  to	  some	  extent.	  	  Due	  to	  this	  the	  examination	  of	  the	  effects	  the	  exposure	  of	  platelets	  to	  oxidative	  stress	  warrants	  investigation.	  	  In	  this	  set	  of	  experiments	  a	  novel	  model	  of	  ROS	  exposure	  on	  platelets	  in	  whole	  blood	  was	  developed	  in	  order	  to	  elucidate	  the	  effects	  that	  oxidative	  stress	  has	  on	  platelet	  function	  and	  coagulation.	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Reactive	  Oxygen	  Species	  In	  Vitro	  Exposure	  Model	  	   While	  many	  groups	  have	  examined	  the	  effects	  of	  various	  reactive	  oxygen	  species	  on	  platelets,	  the	  artificial	  environments	  employed	  in	  these	  experiments	  introduces	  considerable	  variation.	  	  The	  use	  of	  washed	  platelet	  models	  have	  been	  shown	  to	  introduce	  considerable	  activation	  in	  the	  process	  due	  to	  repeated	  washes	  and	  the	  high	  forces	  associated	  with	  multiple	  high	  speed	  centrifugation	  steps.	  	  The	  washing	  process	  decreases	  aggregation	  in	  response	  to	  collagen	  as	  well	  as	  increases	  basal	  CD62P	  expression	  in	  both	  basal	  and	  collagen	  activated	  platelets	  (Figure	  4.1	  and	  Figure	  4.2	  respectively).240	  The	  use	  of	  platelet	  poor	  plasma	  as	  a	  buffer	  has	  also	  been	  attempted	  in	  order	  to	  avoid	  the	  activation	  associated	  with	  the	  washed	  platelet	  model.	  	  Unfortunately	  the	  results	  have	  been	  divergent,	  and	  little	  consensus	  has	  been	  reached.241	  These	  inconsistencies	  may	  be	  attributed	  to	  increases	  in	  protein	  concentration	  and	  subsequent	  buffering	  ability	  increases	  associated	  with	  PPP	  composition.	  To	  best	  mimic	  the	  physiological	  environment	  that	  platelets	  encounter	  during	  in	  vivo	  ROS	  exposure	  the	  use	  of	  whole	  blood	  in	  required.	  The	  use	  of	  hydrogen	  peroxide	  (H2O2)	  as	  a	  ROS	  for	  cellular	  exposure	  is	  possibly	  the	  easiest	  method	  to	  explore	  their	  effects.	  	  It	  is	  relatively	  cheap	  and	  available	  as	  a	  reagent.	  	  It	  also	  passes	  freely	  through	  cell	  membranes	  allowing	  diffusion	  driven	  intracellular	  exposure.	  	  It	  does	  not	  however	  mimic	  natural	  exposure	  conditions,	  which	  involve	  superoxide	  generation	  (O2-­‐)	  and	  its	  subsequent	  enzymatic	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Figure	  4.1:	   	  Differential	  Aggregation	  Responses	  in	  Washed	  Platelets.	   	  Adapted	  from	  Schoenfeld	  et	  al.	  (2004)240	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and	  spontaneous	  conversion	  to	  other	  species	  including	  H2O2	  as	  well	  as	  various	  reactive	  nitrogen	  species	  (RNS).241	  To	  better	  mimic	  a	  pathological	  state	  the	  use	  of	  xanthine	  and	  xanthine	  oxidase	  was	  utilized	  to	  generate	  O2-­‐.	  	  	  Hypoxanthine	  is	  generated	  in	  ischemia,	  cardiovascular	  disease,	  and	  traumatic	  shock.242,243	  Hypoxanthine	  is	  converted	  first	  to	  xanthine	  (X)	  and	  then	  to	  uric	  acid	  by	  xanthine	  oxidase	  (XO),	  generating	  an	  O2-­‐	  at	  each	  step.	  	  This	  X/XO	  system	  utilizes	  the	  final	  step	  in	  this	  process,	  and	  has	  been	  shown	  to	  generate	  oxidative	  stress	  in	  washed	  platelet	  models	  in	  a	  consistent	  and	  dose	  dependent	  manner.244	  	   Using	  Handin’s	  work	  an	  in	  vitro	  model	  of	  ROS	  exposure	  on	  platelets	  in	  whole	  blood	  has	  been	  developed.	  75	  µU/mL	  of	  XO	  combined	  with	  .15	  mM	  X	  has	  been	  shown	  to	  generate	  approximately	  19.2	  nmol	  O2-­‐	  /	  mL/	  min.	  244	  While	  this	  set	  of	  experiments	  was	  performed	  using	  washed	  platelets,	  the	  generation	  of	  superoxide	  via	  the	  X/XO	  system	  is	  known	  to	  occur	  in	  whole	  blood.	  	  This	  level	  of	  exposure	  has	  been	  shown	  by	  past	  work	  to	  cause	  increased	  platelet	  sensitivity	  to	  thrombin	  without	  causing	  complete	  platelet	  activation.244	  
4.2	  Materials	  and	  Methods	  
Blood	  Sampling	  	   All	  blood	  samples	  used	  to	  develop	  this	  model	  were	  surplus	  from	  healthy	  volunteers	  that	  enrolled	  in	  a	  separate	  approved	  study:	  “Defining	  Platelet	  Function	  
in	  Polytrauma”.	  	  This	  data	  was	  intended	  to	  serve	  as	  a	  feasibility	  test	  for	  a	  grant	  proposal.	  	  	  All	  blood	  was	  drawn	  via	  direct	  veinipuncture	  into	  standard	  sodium	  citrate	  vacutainers	  by	  trained	  staff	  in	  accordance	  to	  guidelines	  approved	  by	  the	  VCU	  IRB.	  	  All	  experiments	  were	  begun	  within	  30	  minutes	  of	  sample	  acquisition.	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Treatment	  Protocol	  	   Blood	  samples	  were	  aliquoted	  into	  two	  treatment	  groups.	  	  A	  superoxide	  generation	  system	  was	  created	  in	  the	  test	  group	  by	  addition	  of	  75	  µU/mL	  xanthine	  oxide	  (XO)	  in	  phosphate	  buffered	  saline	  (PBS).	  A	  vehicle	  control	  was	  used,	  with	  matching	  amounts	  of	  PBS	  added	  based	  on	  blood	  volume	  to	  match	  the	  spiking	  volume	  of	  the	  treatment	  group.	  	  In	  order	  to	  assure	  adequate	  supply	  of	  substrate	  both	  samples	  were	  given	  a	  dose	  of	  xanthine	  to	  bring	  their	  exogenous	  xanthine	  concentration	  to	  0.15	  mM.	  	  Immediately	  following	  addition	  of	  XO	  or	  vehicle	  the	  samples	  were	  gently	  inverted	  three	  times	  to	  ensure	  mixing	  and	  then	  incubated	  for	  30	  minutes	  at	  37°C.	  	  After	  incubation	  analysis	  was	  performed	  immediately	  to	  analyze	  the	  effects	  of	  ROS	  exposure	  on	  the	  plasma	  coagulation	  cascade,	  platelet	  function,	  and	  whole	  blood	  clotting.	  	  	  
Coagulation	  Testing	  Thromboelastography	  was	  performed	  on	  citrated	  whole	  blood	  samples	  using	  the	  TEG®	  5000	  Hemostasis	  Analyzer	  (Haemoscope	  Corp.,	  Niles,	  IL,	  USA)	  using	  kaolin	  and	  CaCl2	  as	  per	  manufacturer’s	  instructions.	  	  Use	  of	  this	  technique	  has	  been	  described	  by	  this	  lab	  before.193,209,210	  The	  plasma	  coagulation	  cascade	  pathway	  tests	  of	  Prothrombin	  Time	  (PT)	  and	  activated	  partial	  thromboplastin	  time	  (PTT)	  as	  well	  as	  functional	  fibrinogen	  concentration	  were	  all	  measured	  in	  platelet	  poor	  plasma	  using	  the	  Start-­‐4®	  coagulation	  analyzer	  (Diagnostica	  Stago,	  Asnières,	  France).	  	  All	  tests	  were	  performed	  according	  to	  the	  manufacturer’s	  recommendation.	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Flow	  Cytometry	  Samples	  were	  stained	  for	  flow	  cytometry	  with	  primary	  antibodies	  for	  CD62p-­‐PE,	  PAC-­‐1-­‐FITC,	  CD41-­‐PE-­‐Cy5	  and	  appropriate	  isotypic	  controls	  (BD	  Biosciences,	  San	  Jose,	  CA,	  USA).	  After	  a	  30-­‐minute	  incubation	  samples	  were	  fixed	  and	  analyzed	  with	  an	  Accuri	  C6	  cytometer	  (BD	  Biosciences,	  San	  Jose,	  CA,	  USA).	  A	  total	  of	  20,000	  cells	  were	  analyzed	  in	  each	  sample.	  	  	  Intracellular	  ROS	  detection	  was	  performed	  using	  Invitrogen	  CM-­‐H2DCFA	  (Life	  Technologies,	  Grand	  Island,	  NY,	  USA)	  For	  this	  measurement	  citrated	  PRP	  was	  prepared	  by	  centrifuging	  citrated	  whole	  blood	  at	  130g	  for	  10	  minutes.	  	  PRP	  was	  incubated	  with	  monoclonal	  antibodies	  directed	  against	  CD41a	  and	  CM-­‐H2DCFA,	  for	  15	  minutes	  at	  37°C,	  and	  then	  immediately	  analyzed.	  	  Platelets	  were	  identified	  using	  CD41a	  and	  levels	  of	  ROS	  quantified	  by	  mean	  fluorescent	  intensity	  in	  the	  FL1	  channel.	  	  Platelet	  aggregates	  were	  defined	  by	  shifts	  in	  FSC/SSC	  described	  in	  prior	  work	  by	  prior	  groups.245–247	  Agonist	  stimulation	  was	  performed	  with	  ADP	  (10mM)	  or	  convulxin	  (500	  ng/mL).	  
Data	  Analysis	  Data	  was	  analyzed	  using	  a	  paired	  student’s	  t-­‐test	  and	  matched	  pairs	  analysis.	  	  Each	  individual	  sample	  was	  reported	  as	  relative	  fold	  change	  from	  baseline.	  	  	  All	  statistical	  analyses	  were	  performed	  using	  JMP	  statistical	  software,	  version	  10.0.0	  (SAS	  Institute,	  Cary,	  NC).	  	  The	  level	  of	  significance	  for	  all	  statistical	  tests	  was	  p<	  0.05.	  
4.3	  Results	  
ROS	  Exposure	  Increases	  Intracellular	  ROS	  Levels	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Figure	   4.3:	   	   Increased	   Intracellular	   ROS	   Levels	   in	   Platelets	   After	   X/XO	  
Treatment.	   	   Cellular	   Staining	   performed	   via	   CM-­‐H2DCFA	   and	   flow	   cytometry.	  	  Results	  expressed	  in	  relative	  fold	  change	  of	  mean	  fluorescent	  intensity.	  	  n=3,	  20,000	  platelets	  analyzed	  per	  run.	  	  *;	  p	 ≤	  0.05,	  X;	  xanthine,	  XO;	  xanthine	  oxidase.	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The	  X/XO	  system	  generates	  extracellular	  O2-­‐	  in	  the	  blood	  sample.	  	  To	  ensure	  that	  this	  extracellular	  superoxide	  flux	  is	  capable	  of	  generating	  the	  internal	  ROS	  elevation	  required	  for	  examining	  ROS	  effects	  on	  intracellular	  signaling	  pathways	  cells	  were	  quantified	  for	  intracellular	  ROS	  levels	  via	  flow	  cytometry.	  	  Treatment	  of	  whole	  blood	  with	  the	  X/XO	  system	  at	  the	  75	  µU/mL	  XO	  level	  significantly	  increased	  the	  level	  of	  intracellular	  ROS	  in	  platelets	  (p<	  .05)	  as	  measured	  by	  CM-­‐H2DCFA	  staining	  for	  flow	  cytometry	  (Figure	  4.3).	  This	  shows	  the	  X/XO	  system	  is	  a	  valid	  option	  for	  increasing	  platelet	  ROS	  levels	  in	  a	  whole	  blood	  model.	  	  
Reactive	  Oxygen	  Species	  Exposure	  Does	  Not	  Effect	  Coagulation	  Protein	  
Pathways	  
	   While	  platelets	  are	  the	  main	  driving	  factor	  in	  coagulation	  and	  hemostasis,	  the	  proper	  function	  of	  the	  plasma	  protein	  enzymatic	  cascades	  are	  paramount	  for	  the	  conversion	  of	  fibrinogen	  to	  fibrin,	  and	  hence	  a	  stable	  clot.	  	  Due	  to	  the	  use	  of	  a	  global	  coagulation-­‐monitoring	  tool	  (TEG)	  to	  evaluate	  whole	  blood	  clotting,	  the	  proper	  function	  of	  the	  clotting	  cascades	  must	  be	  evaluated.	  	  Immediately	  after	  incubation	  with	  the	  X/XO	  system	  plasma	  was	  analyzed	  for	  PT,	  PTT,	  and	  functional	  fibrinogen	  concentration.	  	  There	  was	  no	  significant	  difference	  in	  either	  the	  intrinsic	  or	  extrinsic	  pathways,	  and	  fibrinogen	  levels	  were	  normal	  in	  all	  samples	  both	  pre	  and	  post	  ROS	  exposure	  (Figure	  4.4)	  
Reactive	  Oxygen	  Species	  Exposure	  Increases	  Clotting	  Kinetics	  
	   Clotting	  kinetic	  properties	  of	  whole	  blood	  are	  an	  important	  measure	  of	  the	  ability	  of	  the	  whole	  coagulation	  system	  to	  progress	  at	  a	  normal	  rate.	  	  While	  this	  measure	  does	  not	  often	  delineate	  an	  exact	  point	  at	  which	  the	  analyzed	  sample	  may	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Figure	  4.5:	  Decrease	  in	  Relative	  R	  Time	  After	  ROS	  Exposure.	  Results	  expressed	  in	  fold	  change	  compared	  to	  vehicle	  control.	  	  n=3.	  	  *;	  p	  ≤	  0.05,	  XO;	  xanthine	  oxidase.	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have	  a	  deviation,	  it	  allows	  for	  the	  monitoring	  of	  the	  systems	  normal	  progression	  on	  a	  global	  level.	  	  This	  data	  demonstrated	  a	  significant	  (p<	  .05)	  drop	  in	  the	  relative	  R	  	  values	  of	  the	  sample	  after	  ROS	  treatment	  when	  compared	  to	  a	  matched	  vehicle	  sample	  (Figure	  4.5).	  	  While	  other	  measures	  of	  clotting	  kinetics	  such	  as	  k	  and	  angle	  displayed	  no	  change	  (data	  not	  shown)	  this	  decrease	  in	  kinetics	  suggests	  an	  increase	  in	  the	  platelet’s	  ability	  to	  mediate	  thrombin	  generation.	  	  	  	  	  
Reactive	  Oxygen	  Species	  Exposure	  Increases	  Clot	  Strength	  
	   The	  measure	  of	  clot	  strength	  in	  whole	  blood	  is	  a	  combination	  of	  functional	  fibrinogen	  concentration	  as	  well	  as	  the	  platelet’s	  ability	  to	  aggregate	  and	  attach	  to	  the	  fibrin	  network	  and	  contract.193	  As	  shown	  earlier	  there	  was	  no	  change	  in	  functional	  fibrinogen	  concentration	  between	  the	  ROS	  treatment	  group	  and	  the	  vehicle	  control	  group.	  	  It	  is	  then	  logical	  to	  attribute	  changes	  in	  the	  measures	  of	  clot	  strength	  to	  platelet	  function	  when	  comparing	  the	  groups.	  	  Analysis	  of	  both	  the	  (MA)	  as	  well	  as	  G	  TEG	  values	  both	  indicate	  a	  significant	  (p<	  .05)	  increase	  in	  clot	  strength	  in	  the	  ROS	  exposed	  platelets	  when	  compared	  to	  the	  control	  group	  (Figure	  4.6).	  	  This	  data	  suggests	  an	  increase	  in	  platelet	  function,	  as	  functional	  fibrinogen	  can	  be	  viewed	  as	  constant	  between	  the	  samples.	  	  
Reactive	  Oxygen	  Species	  Exposure	  Effects	  on	  Basal	  Platelet	  Activation	  	   Two	  measures	  of	  platelet	  activation	  were	  examined	  by	  flow	  cytometry.	  	  CD62P	  surface	  expression	  is	  widely	  used	  to	  identify	  platelet	  secretion.	  	  CD62P	  is	  an	  integral	  part	  of	  the	  α-­‐granule	  membrane,	  and	  is	  exposed	  after	  the	  granules	  are	  secreted.	  	  Aggregation	  is	  examined	  in	  two	  separate	  ways.	  	  The	  PAC-­‐1	  antibody	  binds	  to	  the	  activated	  fibrinogen	  receptor,	  GPIIb/IIIa.	  	  Once	  activated,	  GP	  IIb/IIIa	  binds	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fibrinogen,	  aggregating	  with	  other	  activated	  platelets	  bound	  through	  the	  same	  mechanism.	  	  Measuring	  both	  PAC-­‐1	  binding	  as	  well	  as	  the	  formation	  of	  platelet	  aggregates	  using	  changes	  in	  forward	  scatter	  and	  side	  scatter	  gives	  a	  thorough	  picture	  of	  the	  functionality	  of	  the	  platelet	  aggregation	  process.	  	  After	  treatment	  with	  75	  µU/mL	  XO	  for	  30	  minutes	  there	  was	  a	  slight	  significant	  (p<	  .05)	  decrease	  in	  basal	  CD62P	  expression	  (Figure	  4.7).	  	  It	  should	  be	  noted	  that	  while	  a	  significant	  decrease	  in	  relative	  expression	  was	  noted,	  the	  levels	  in	  both	  treated	  and	  untreated	  samples	  were	  well	  within	  the	  expected	  range.	  	  All	  other	  basal	  markers	  showed	  no	  differences	  in	  response	  to	  the	  ROS	  treatment.	  
Reactive	  Oxygen	  Species	  Exposure	  Causes	  Differential	  Effects	  on	  Platelet	  
Aggregation	  After	  ROS	  exposure	  there	  was	  a	  significant	  (p<	  .05)	  decrease	  in	  the	  relative	  %	  of	  platelets	  that	  stained	  positive	  for	  PAC-­‐1	  in	  response	  to	  ADP	  stimulation	  (Figure	  4.8).	  	  The	  relative	  %	  of	  PAC-­‐1	  +	  platelets	  after	  stimulation	  with	  the	  collagen	  mimetic	  convulxin	  (CVX)	  remained	  the	  same.	  	  Not	  surprisingly	  the	  relative	  mean	  fluorescent	  intensity	  (MFI)	  of	  PAC-­‐1	  was	  significantly	  (p<	  .05)	  decreased	  in	  the	  ADP	  stimulated	  platelets,	  which	  is	  consistent	  with	  the	  lower	  percentage	  of	  cells	  that	  were	  able	  to	  bind	  the	  antibody	  (Figure	  4.9).	  	  Interestingly	  the	  relative	  PAC-­‐1	  MFI	  rises	  significantly	  (p<	  .05)	  in	  CVX	  stimulated	  platelets	  after	  ROS	  exposure.	  	  This	  suggests	  that	  while	  the	  ROS	  treatment	  does	  not	  increase	  the	  number	  of	  platelets	  that	  can	  be	  activated	  by	  collagen,	  these	  platelets	  that	  are	  activated	  are	  expressing	  more	  activated	  GPIIb/IIIa	  per	  cell	  than	  the	  untreated	  platelets.	  	  	  It	  therefore	  can	  be	  argued	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Figure	   4.8:	   	   Differential	   Agonist	   Induced	   PAC-­‐1	   Expression	   After	   ROS	  
Exposure.	  Results	  expressed	  in	  fold	  change	  of	  positively	  stained	  cells	  compared	  to	  vehicle	  control.	  	  n=3.	  	  *;	  p	  ≤	  0.05,	  XO;	  xanthine	  oxidase,	  CVX;	  convulxin.	  	  	  	  
	  
Figure	  4.9:	  	  Differential	  Agonist	  Induced	  Absolute	  PAC-­‐1	  Expression	  After	  ROS	  















































	   139	  
	  
























	   140	  
that	  the	  treated	  platelets	  can	  become	  more	  fully	  activated	  by	  CVX	  after	  ROS	  exposure.	  When	  examining	  the	  formation	  of	  platelet	  aggregates	  the	  data	  agrees	  with	  the	  PAC-­‐1	  binding	  data.	  	  Relative	  ADP	  induced	  platelet	  aggregate	  formation	  significantly	  decreased	  (p<	  .05)	  in	  ROS	  treated	  platelets	  compared	  to	  vehicle	  control	  samples.	  	  After	  CVX	  stimulation	  there	  was	  a	  significant	  increase	  in	  relative	  platelet	  aggregate	  formation	  (p<	  .05)	  when	  compared	  to	  the	  control	  group	  (Figure	  4.10)	  
4.4	  Discussion	  
	   The	  major	  proof	  of	  concept	  for	  the	  model	  was	  the	  demonstrated	  rise	  in	  intracellular	  ROS	  levels.	  	  The	  main	  goal	  was	  to	  develop	  a	  system	  to	  determine	  the	  effects	  ROS	  exposure	  has	  on	  platelet	  activity,	  and	  in	  order	  to	  reach	  this	  goal	  the	  rise	  in	  ROS	  internally	  had	  to	  be	  observed.	  	  	  	   The	  lack	  in	  differences	  seen	  in	  the	  functional	  plasma	  clotting	  pathways	  indicates	  that	  the	  effects	  of	  the	  model	  are	  unable	  to	  influence	  them	  at	  these	  levels.	  	  This	  data	  becomes	  more	  interesting	  when	  examining	  the	  TEG	  data	  together.	  	  The	  decrease	  in	  R	  time	  suggests	  a	  quickening	  in	  kinetics	  of	  the	  entire	  whole	  blood	  clotting	  reaction.	  	  By	  excluding	  the	  plasma	  pathways	  this	  kinetic	  quickening	  may	  be	  considered	  more	  platelet	  driven.	  	  The	  increases	  in	  clot	  strength	  observed	  after	  treatment	  when	  compared	  to	  a	  fixed	  fibrinogen	  level	  and	  identical	  platelet	  counts	  begin	  to	  implicate	  platelets	  as	  well.	  Clot	  strength	  measurements	  on	  the	  TEG	  are	  the	  sum	  of	  effects	  of	  the	  fibrinogen/fibrin	  concentration,	  platelet	  count,	  and	  platelet	  function.197	  When	  fibrinogen	  and	  platelet	  counts	  are	  removed	  from	  the	  equation	  the	  main	  driver	  of	  MA	  becomes	  platelet	  function.	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When	  examining	  platelet	  function	  on	  the	  cellular	  level,	  basally	  there	  are	  little	  difference	  between	  the	  two	  groups.	  	  CD62	  expression	  was	  significantly	  reduced	  in	  the	  platelets	  exposed	  to	  ROS,	  but	  the	  absolute	  value	  of	  these	  measurements	  did	  not	  indicate	  widespread	  activation	  in	  any	  sample	  before	  activation.	  Activation	  response	  was	  observed	  to	  be	  differential	  according	  to	  the	  individual	  agonist	  used.	  	  ADP	  was	  used	  as	  a	  GPCR	  agonist,	  and	  CVX	  as	  an	  integrin	  agonist.	  	  ADP	  response	  was	  lower	  across	  the	  board	  in	  the	  treatment	  groups	  when	  compared	  to	  vehicle,	  displaying	  dysfunction	  in	  one	  or	  more	  of	  the	  autocrine	  signaling	  pathways.	  	  CVX	  response	  on	  the	  other	  hand	  increased	  aggregate	  formation	  dramatically,	  and	  while	  it	  did	  not	  change	  the	  %	  of	  cells	  expressing	  PAC-­‐1,	  MFI	  was	  significantly	  increased	  suggesting	  that	  more	  individual	  receptors	  on	  each	  cell	  were	  becoming	  activated.	  	   It	  appears	  that	  ROS	  exposure	  does	  cause	  significant	  differences	  in	  coagulation.	  	  Using	  a	  combined	  classical,	  mechanical,	  and	  flow	  cytometric	  analysis	  the	  changes	  appear	  to	  be	  increased	  activity	  in	  platelets	  of	  the	  treatment	  group.	  	  These	  become	  more	  apparent	  in	  response	  to	  the	  collagen	  mimetic	  CVX,	  yet	  while	  at	  the	  same	  time	  there	  seems	  to	  be	  a	  concurrent	  decrease	  in	  the	  activity	  of	  the	  ADP	  pathway.	  	  It	  should	  be	  understood	  that	  the	  agonist	  responses	  can	  be	  specific	  to	  the	  agonist	  itself	  or	  multiple	  layers	  of	  control	  asserted	  downstream.	  	  	  It	  cannot	  then	  be	  determined	  if	  there	  is	  an	  actual	  ADP	  response	  issue,	  an	  autocrine	  signaling	  dysfunction,	  or	  a	  problem	  related	  to	  the	  GCPR	  response	  in	  general	  compared	  to	  integrin	  response	  (PLCβ	  and	  PLCγ2	  for	  example).	  	  Regardless	  of	  this	  uncertainty	  the	  conclusion	  that	  there	  is	  a	  measurable	  coagulopathy	  in	  the	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ROS	  treatment	  group	  is	  solid.	  	  More	  testing	  needs	  to	  be	  done	  however	  to	  fully	  define	  the	  precise	  location	  and	  magnitude	  of	  the	  changes	  occurring.	  	  	  	   	  









	   When	  considering	  all	  data	  presented	  in	  this	  volume	  of	  work	  certain	  conclusions	  can	  be	  drawn	  about	  the	  pathology	  and	  development	  of	  trauma	  induced	  coagulopathy.	  	  	  While	  the	  animal,	  human,	  and	  in-­‐vitro	  experiments	  shared	  certain	  goals	  (defining	  coagulopathy	  under	  conditions	  of	  trauma,	  shock,	  and	  oxidative	  stress),	  they	  were	  designed	  discretely	  without	  the	  expectation	  of	  any	  unified	  conclusions.	  	  Evaluation	  of	  the	  main	  conclusions	  drawn	  from	  these	  studies	  appear	  to	  converge	  around	  the	  idea	  that	  there	  are	  two	  competing	  forces	  in	  trauma	  related	  coagulation	  changes,	  and	  that	  these	  changes	  may	  possibly	  be	  unrelated.	  	  Animal	  studies	  suggest	  than	  in	  response	  to	  moderate	  hypovolemic	  shock	  there	  are	  significant	  and	  complicated	  conditions	  that	  arise.	  	  While	  decreased	  plasma	  clotting	  factor	  activity	  suggests	  the	  beginning	  of	  a	  consumption	  related	  disorder,	  mechanical	  testing	  indicates	  increased	  kinetic	  and	  strength	  properties.	  	  This	  
	   144	  
disconnection	  between	  variables	  in	  a	  relatively	  controlled	  setting	  of	  traumatic	  shock	  suggests	  that	  while	  plasma	  clotting	  function	  decreases,	  platelet	  activity	  increases.	  The	  data	  collected	  from	  the	  human	  polytrauma	  study	  suggests	  that	  injury	  severity	  is	  highly	  correlated	  with	  both	  the	  development	  of	  hypovolemic	  shock	  as	  well	  as	  the	  development	  of	  consumption	  based	  coagulopathies	  (ACoT/ECoT).	  	  Additionally	  there	  was	  the	  development	  of	  a	  hypercoagulopathy	  after	  trauma	  in	  a	  significant	  population	  that	  was	  platelet	  function	  related,	  and	  appeared	  at	  a	  much	  higher	  rate	  in	  men	  than	  women.	  	  These	  two	  conditions	  were	  not	  mutually	  exclusive,	  but	  the	  incidence	  of	  ACoT	  in	  the	  HC+	  population	  seemed	  to	  remain	  consistent	  between	  HC+	  and	  HC-­‐	  groups	  (23%	  and	  24%	  respectively).	  	  HC	  was	  not	  correlated	  to	  injury	  severity,	  shock,	  or	  hypofibrinogenemia	  suggesting	  that	  it	  is	  a	  separate	  response.	  	  This	  data	  again	  highlights	  a	  disconnect	  between	  platelet	  function	  (increased)	  and	  factor	  function	  (decreased).	  
In-­‐Vitro	  experiments	  were	  designed	  to	  recreate	  the	  oxidative	  stress	  seen	  during	  trauma	  and	  subsequent	  blood	  loss.	  	  The	  X/XO	  system	  utilizes	  the	  same	  ROS	  generating	  machinery	  involved	  in	  endogenous	  hypoxia	  and	  ischemic	  injury.	  	  After	  exposure	  to	  X/XO	  generated	  O2-­‐	  resulted	  in	  increased	  intracellular	  ROS	  levels	  and	  increased	  platelet	  function.	  	  This	  becomes	  of	  increased	  interest	  due	  to	  the	  fact	  that	  none	  of	  the	  plasma	  protein	  pathways	  were	  affected.	  	  Taken	  together	  this	  data	  shows	  the	  development	  of	  a	  hypercoagulable	  state	  in	  absence	  of	  a	  consumption	  disorder.	  	  Increased	  response	  to	  collagen	  pathway	  stimulation	  while	  maintaining	  an	  abover	  normal	  level	  of	  inhibition	  in	  the	  ADP	  pathway	  suggests	  differential	  effects	  in	  the	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response	  of	  platelets	  to	  ROS	  exposure	  that	  needs	  to	  be	  investigated	  more	  completely.	  All	  three	  experiments	  were	  able	  to	  identify	  what	  appears	  to	  be	  two	  distinct	  and	  competing	  forces	  involved	  in	  the	  coagulation	  response	  to	  trauma.	  	  Consumption	  disorders	  have	  been	  characterized	  for	  decades,	  and	  current	  treatment	  protocols	  revolve	  around	  INR	  for	  plasma	  administration.	  	  This	  is	  expected,	  as	  this	  disorder	  appears	  more	  apparent	  in	  the	  clinical	  setting	  as	  it	  involves	  current	  standard	  test	  panels	  (PT,	  PTT,	  [Fibrinogen])	  and	  correlates	  well	  with	  injury	  severity	  and	  the	  development	  of	  hypovolemic	  shock.	  	  On	  the	  other	  hand	  HC	  classifications	  currently	  require	  the	  use	  of	  TEG	  testing,	  which	  is	  not	  commonplace	  in	  the	  clinical	  setting	  in	  regards	  to	  trauma.	  	  If	  that	  fact	  is	  combined	  with	  the	  data	  showing	  that	  this	  condition	  does	  not	  correlate	  with	  shock,	  ISS,	  or	  INR	  it	  is	  easy	  to	  understand	  why	  this	  pathology	  is	  commonly	  not	  recognized.	  The	  relationship	  of	  sex	  with	  HC	  poses	  more	  questions,	  as	  it	  is	  known	  that	  estrogen	  has	  a	  protective	  effect	  in	  the	  context	  of	  hypoxia	  and	  oxidative	  stress.248–250	  Taken	  together	  with	  data	  generated	  in	  the	  in-­‐vitro	  X/XO	  experiments	  this	  suggests	  that	  ROS	  may	  be	  one	  of	  the	  driving	  factors	  behind	  the	  development	  of	  HC.	  	  A	  much	  more	  in	  depth	  look	  at	  this	  is	  required	  before	  any	  solid	  conclusion	  can	  be	  drawn	  however.	  	  	  Regardless	  of	  the	  causes	  of	  HC,	  it	  does	  appear	  that	  there	  are	  two	  different	  types	  of	  coagulopathies	  present	  in	  the	  response	  of	  trauma.	  	  There	  is	  a	  plasma	  related	  loss	  of	  function	  and	  a	  platelet	  related	  increase	  in	  function.	  	  These	  two	  conditions	  are	  not	  mutually	  exclusive,	  but	  do	  appear	  to	  involve	  different	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parameters.	  	  It	  could	  be	  argued	  that	  early	  increases	  in	  platelet	  function	  cause	  coagulation	  and	  thus	  consumption,	  but	  the	  lack	  of	  a	  significant	  drop	  in	  platelets	  when	  comparing	  the	  two	  groups	  makes	  this	  argument	  unlikely.	  	  It	  is	  also	  possible	  that	  the	  increase	  in	  platelet	  function	  is	  an	  effort	  to	  maintain	  homeostasis	  triggered	  in	  the	  body	  due	  to	  loss	  of	  coagulation	  factors.	  	  This	  however	  is	  not	  supported	  by	  the	  fact	  that	  only	  24%	  of	  the	  HC+	  population	  presented	  with	  ACoT.	  	  	  A	  more	  likely	  scenario	  is	  that	  oxidative	  stress	  has	  an	  effect	  on	  platelet	  function,	  and	  this	  effect	  is	  not	  demonstrated	  in	  non-­‐cellular	  pathways	  such	  as	  the	  enzymatic	  plasma	  coagulation	  pathways.	  	  There	  are	  a	  wide	  variety	  of	  effects	  that	  oxidative	  stress	  can	  have	  on	  cellular	  signaling	  and	  lipid	  storage	  pools,	  highlighting	  the	  need	  to	  investigate	  this	  phenomena	  more	  completely.	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